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 Drug abuse and addiction are considered to be a result, at least in part, of the 
rewarding effects produced by increasing dopamine levels.  5-HT3 serotonin receptors have 
been shown to indirectly affect dopamine levels. Therefore, the effect of the 5-HT3 
receptor partial agonist, MD-354, on the actions of psychomotor stimulants was analyzed 
in mouse locomotor activity assays to determine whether MD-354 is working through a 5-
HT3 receptor agonist or antagonist mode of action. Studies with (+)amphetamine and 
xxii 
(+)methamphetamine in combination with MD-354 indicated MD-354 is either devoid of 
action or is behaving similar to the 5-HT3 receptor antagonist, ondansetron.  This effect 
could be occurring centrally; however peripheral effects can not be discounted.   In 
combination with cocaine, MD-354 behaved similar to the 5-HT3 receptor agonist, SR 
57227A, known to act both centrally and peripherally.  This difference between central and 
peripheral effects could account for the different modes of action observed with MD-354.  
  Studies also involved synthesis of potentially brain-penetrant carbamate analogs of 
MD-354, and QSAR to assist in validating a 5-HT3 receptor agonist pharmacophore. 
 
 1 
 
 
 
 
I.  Introduction 
 
 Drug abuse and addiction are growing problems in today’s society, where 
prevention is the only real treatment.  There are various drugs available, both prescription 
drugs and illegal drugs, that are abused due to their positive (i.e., rewarding) effects.  
Some common effects that lead to abuse include feelings of euphoria and stress relief.1 
However, repetitive use, tolerance, and dependence (whether psychic or physical) lead to 
abuse, addiction, and the unfortunate withdrawal that follows when an addict no longer 
has access to the drug of abuse.   
 Some of the most commonly abused psychomotor stimulants on the market are 
the Schedule II drugs amphetamine, usually in the form of prescription medications, 
methamphetamine, which is more commonly found on the street in an impure form, or in 
prescription medications, and cocaine, most commonly a street drug.  All three drugs 
have been shown to have an effect on the monoamines dopamine (involved with 
cognition, memory, and reward), norepinephrine (involved with memory, mood, and 
arousal), and serotonin (involved with mood, appetite, anxiety, reward, and aggression).2 
 DOM is a phenylalkylamine hallucinogen that produces euphoric and stimulant 
effects at low doses, but more hallucinogenic effects at higher doses.3 DOM is 
structurally similar to amphetamine and could possibly behave in a similar manner even 
though it is not classified as a psychomotor stimulant. 
2 
The phenylalkylamine psychomotor stimulant amphetamine, and its more potent analog 
methamphetamine, increase synaptic dopamine levels through several different methods: 
blocking dopamine reuptake and releasing dopamine from vesicles in the presynaptic 
terminal.4,5  Cocaine, a non-phenylalkylamine stimulant, works by blocking reuptake of 
dopamine into the presynaptic terminal.2 The positive reinforcing effects of cocaine are 
due to increased synaptic dopamine levels, known as the “dopamine hypothesis”.6  The 
positive subjective effects, such as the “high” observed with stimulants could be due to 
differences in levels of norepinephrine, known as the “noradrenergic hypothesis”.7 
 Serotonin has also been shown to play a role in the rewarding effect of 
psychomotor stimulants.  Although there are numerous 5-HT receptor populations and 
subpopulations, the receptor population of interest when describing drugs of abuse is the 
5-HT3 receptor.  Of the seven 5-HT receptor families, 5-HT3 receptors are the only 
serotonin receptor population that is a ligand-gated ion channel (LGIC) receptor as 
opposed to the others that are G-protein coupled receptors (GPCR).8  Activation of 
serotonin systems, more commonly 5-HT3 receptor systems, have been shown to 
modulate dopamine release.  Grant reviewed that 5-HT3 receptor agonists may indirectly 
increase dopamine levels whereas 5-HT3 receptor antagonists indirectly decrease 
dopamine levels.9  This could be due, in part, to the location of serotonin receptors in 
different regions of the brain relative to dopamine receptors, more specifically location in 
the mesolimbic dopaminergic pathway.9  Further support from Tecott et al.  indicated that 
GABAergic input on dopamine neurons due to the quantity and distribution of 5-HT3 
receptors in the CNS could account for the indirect effects on dopamine levels.10 
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 MD-354 is a unique 5-HT3 receptor partial agonist, as it can behave as either an 
agonist or an antagonist, that binds at 5-HT3 receptors with relatively high affinity (Ki = 
35 nM).11 When administered alone, MD-354 does not produce a locomotor stimulant 
effect, or might not penetrate the BBB; the latter is a possibility due to its low Log P 
value of -0.64.12,13 
 The effects of psychomotor stimulants can be evaluated through locomotor 
activity assays.  Although locomotor activity assays can analyze various parameters, 
some of the more common parameters involved in locomotor stimulation include 
increases in movement distance and movement time, and decreased movement episodes.    
 Since MD-354 is a 5-HT3 receptor partial agonist, and 5-HT3 receptors have been 
shown to affect dopamine levels, MD-354 may either potentiate or antagonize the effect 
of psychomotor stimulants in locomotor activity assays.  However, it is possible that MD-
354 may have no effect on the psychomotor stimulants because it might not readily 
penetrate the BBB. 
 The purpose of this study is to determine the effect that MD-354 might have on 
the psychomotor stimulants, and to characterize this effect as working through either a 5-
HT3 receptor agonist or 5-HT3 receptor antagonist mode of action.  Also, since MD-354 
may or may not cross the BBB, more lipophilic prodrugs will be synthesized and tested in 
locomotor activity assays to determine the effect.  QSAR studies will be conducted on a 
set of arylguanidine and arylbiguanide 5-HT3 receptor agonists and partial agonists in 
order to improve Dukat’s current working 5-HT3 receptor pharmacophore model.14  
Conformationally-constrained analogs will be incorporated into the model to account for 
4 
rotameric binding and CoMFA studies will be conducted to predict the binding affinities 
of novel arylguanidine derivatives. 
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II. Background 
 
A.  Drug Abuse/Drug Addiction 
 Drug abuse has social, medical, economic, and criminal impacts costing 
Americans millions of dollars per year, making treatment pertinent.  The term “drug 
abuse” is very vague, as its definition is based on social perceptions.  Some of the more 
common definitions for drug abuse entail any use of an illegal substance, use of legal 
substances in excessive amounts, or even use of legal substances regardless of the 
amount.1 A drug’s positive effects such as euphoric feelings, stress relief, and 
improvement of performance, are key factors in why drugs readily become abused.1 
Tolerance occurs when the rewarding effects are no longer achieved by the initial dose; 
therefore a higher dose is necessary to achieve an earlier effect.  Drug abuse and 
tolerance can lead to addiction and psychic dependence (i.e., continuous administration is 
necessary to achieve a euphoric feeling, regardless of the harmful consequences).1 This is 
not to be confused with physical dependence, which involves a physiological reaction, 
such as withdrawal symptoms, to the absence of the drug.1 Withdrawal symptoms are 
negative physical symptoms such as irritability, anxiety, fatigue, and even nausea.1 Drug 
addiction and dependence are not synonymous, because not all addicts are dependent 
upon the drug. 1     
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 The extent to which a drug has pharmacological properties that are able to predict 
a drug’s likelihood of abuse and dependence is termed “abuse liability”.15  If a drug is 
determined to have abuse potential, it can then be regulated under the Controlled 
Substances Act (CSA) as a scheduled drug.  This legislation was created in 1970, as a 
reorganization of government agencies, to regulate these drugs.  Schedule I drugs have a 
high potential for abuse, with no accepted medical use or safety for use.  Substances in 
Schedule II – V have medical use, with differences in abuse potential.16  Schedule II 
drugs have high abuse potential resulting in high psychological and/or physical 
dependence, whereas substances in Schedules III-V have lower abuse potential, as well as 
moderate to low physical or psychological dependence.16 Some countries and agencies 
further divide controlled substances into a sixth schedule that can be broken into three 
parts: Part 1 includes Class A precursors, Part 2 includes Class B precursors, and Part 3 
contains any preparation or mixture set out in Part 1 or Part 2.17  Some examples of 
Schedule VI Part 1 substances include acetic anhydride, lysergic acid, piperonal, and 
potassium permanganate.17 Part 2 substances include acetone, ethyl ether, hydrochloric 
acid, sulfuric acid, and toluene.17 
 In addition to the abuse of legal substances such as alcohol and nicotine, and the 
abuse of prescription drugs, some of the most widely abused substances include opioids, 
stimulants, hallucinogens, and related designer drugs.18 Even though abused drugs are 
easily classified on the basis of abuse potential, they might act by different mechanisms.  
By understanding the mechanisms of action of each drug, it might be easier to find 
effective treatments for drug abuse and addiction and, possibly, drug abuse prevention.   
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B.  Classification 
 1.  Opioids 
 The use and abuse of opium was reported as far back as 200 B.C.; opium is a 
substance occurring naturally from poppy seeds of Papaver somniferum.19  Opioids can 
be defined as opium alkaloids, their synthetic derivatives, and peptides with morphine-
like pharmacological effects that are antagonized by an opioid antagonist.19  These agents 
are thought to work through one or more of three major opioid receptors: mu (μ), kappa 
(κ), and delta (δ), to help with postoperative analgesia, myocardial infarction, trauma, 
burns, and orthopedic pain.20  Most opioids, such as morphine, the principle alkaloid of 
opium, codeine, hydrocodone, and oxycodone, are Schedule II drugs that help with 
moderate to severe pain, and that have abuse and addiction potential.21  Opioids are 
commonly abused due to their euphoric, analgesic, and sedative effects.20  However, an 
opioid overdose can lead to respiratory failure.20  Heroin, an acetylated form of morphine, 
is currently a Schedule I drug that is highly addictive.21  However, once heroin is no 
longer available to a heroin addict, intense withdrawal symptoms occur, such as nausea, 
vomiting, diarrhea, anxiety, and depression.20  Currently there are two drug replacement 
therapies for heroin addicts: methadone and buprenorphine.20,22   
 With most other drugs of abuse, prevention is the only treatment for addiction, as 
no other medications are available.  Because “replacement therapy” is available here, and 
because replacement therapy might be possible for other types of drug abuse, drug 
replacement therapy and drug abuse treatment are a major area of interest to help treat 
drug addiction. 
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2.  Stimulants 
  a)  Analeptics 
 Psychostimulants are drugs that have a direct neurological effect such as 
increased alertness and energy, appetite suppression, and euphoria.23 There are two main 
categories of stimulants: analeptics and behavioral stimulants.  Analeptic stimulants are 
not as readily abused as behavioral stimulants; analeptics work primarily on autonomic 
centers generally affecting respiration and circulation.18  Some examples of analeptics 
include strychnine and caffeine.  Strychnine is considered an analeptic stimulant because 
it increases respiration and blood pressure, but is a convulsant that can be lethal at high 
doses.24  Sometimes, “street drugs” such as cocaine and (+)lysergic acid diethylamide 
(LSD) are “laced” with small amounts of strychnine for respiratory stimulation.24  
Caffeine, a xanthine, is considered the most widely used psychoactive drug in the world 
because it reduces drowsiness and fatigue while increasing heart rate and blood pressure.1 
It is found in tea from Thea sinensis (and other species), and in coffee from Coffea 
Arabica (and other species).25  Interestingly, although craving is observed regardless of 
its lack of euphoric effects upon withdrawal of the caffeinated beverage, caffeine is not 
considered addicting.1 
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  b)  Behavioral Stimulants 
   i. Non-Phenylalkylamines 
 Behavioral stimulants have more of a central stimulatory effect than analeptics, 
resulting in changes in motor activity. The class of behavioral stimulants can further be 
divided into non-phenylalkylamine and phenylalkylamine (PAA) stimulants.  The most 
common non-phenylalkylamine stimulant is cocaine, a psychotropic drug used for the 
past 2000 years with 25.6% of 26-34 year olds using cocaine at least once in their 
lifetime;26 about five million people, just in the United States, use cocaine each year.27 
Cocaine, a naturally occurring drug, is found as a constituent of the Erythoxylon coca 
species of plants in South America.18  In the 1860’s, cocaine was used in several different 
tonics, which gave them “magic properties”.26  It was even found as the main stimulant in 
Coca Cola.18  In the late 1800’s cocaine served medical purposes such as treatment for 
morphine addiction and as a topical anesthetic in ophthalmology.26  Due to its stimulant 
properties, as well as the fact that it alleviated hunger, and allowed people to forget 
reality, it became a highly abused drug, eventually labeled as a Schedule II substance.26  
Cocaine has many different street names, such as “blow”, “crack”, “rock”, and “coke”, 
along with different forms: hydrochloride salt and free base.  Cocaine, a positive 
reinforcer, has a high abuse potential due to its rapid onset of action with “rush” central 
stimulatory effects including intense euphoria, psychic energy, heightened sexual 
excitement, and increased self-confidence.26,28,29  However, cocaine abusers  can also 
experience paranoia, hallucinations, and dysphoria, during their subsequent “crash”, with 
toxic concentrations potentially leading to fatal cardiac arrhythmias.26  
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 Cocaine works through dopamine (DA), norepinephrine (NE), and serotonin (5-
HT) mechanisms, with its stimulant effect mainly a result of the dopaminergic 
mechanism.  Dopamine nerve terminals contain a dopamine transporter (DAT), located 
perisynaptically, which terminates the actions of dopamine by a transport mechanism.2 
Cocaine works by blocking the DAT, preventing reuptake of dopamine into the 
presynaptic nerve terminal.2 This increases extracellular dopamine levels, producing a 
heightened state of euphoria.2  It is important to note that although cocaine blocks the 
dopamine transporter, it itself is not transported into the nerve terminal.2 
 Cocaine’s reinforcing effects are due to its ability to bind to the dopamine 
transporter and block reuptake of dopamine into the presynaptic terminal.6  The better 
able an agent to bind to the dopamine transporter, the greater the blockade, allowing more 
dopamine in the synapse, which accounts for the euphoric effect.  Structure-activity 
studies show that there are some key aspects to the structure of cocaine that can enhance 
or decrease its activity.  By simply switching the configuration of cocaine from R to S, by 
switching the carbomethoxy group from the C-2 position to the C-4 position, the activity 
of cocaine decreases more than 100-fold (1; Figure 1).30  The presence of the 
carbomethoxy group at the 2-position is optimal for cocaine-like activity.30  Removal of 
this group or replacement with most other substituents decreases activity, with one 
exception; different ester groups can replace the carbomethoxy substituent with only 
small alterations in activity.30 Also, at this position stereochemistry is important: 
epimerization from β to α substantially decreases activity.30  Similar decreases in activity 
are observed with the same epimerization at the C-3 position.30  Changes at the nitrogen 
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position can have varying effects.  For example, changing the length of the substituent 
chain has little to no effect on activity, whereas changing the functional group such as 
from an amine to an amide or even conversion from a tertiary amine to a quaternary 
amine significantly reduces activity.30  Interestingly, it was observed that the nitrogen 
atom can be moved from the 8-position to the 6- or 7-position without decreasing binding 
affinity to the dopamine transporter.30  These, as well as other, structural changes allow 
for a better understanding of the binding profile of cocaine.   
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Figure 1.  Structure of cocaine (1) labeled for discussion of structure-activity relationship 
studies. 
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ii.  Phenylalkylamines  
 Several different drugs make up the stimulant class of phenylalkylamines: agents 
that contain a phenyl group, an alkyl chain, and an amine.18  The most widely recognized 
stimulant is amphetamine (2; Figure 2), a central stimulant, anorectic, and 
sympathomimetic agent.18  Sympathomimetic drugs are drugs that mimic the actions of 
endogenous neurotransmitters stimulating the sympathetic nervous system.24  Of the 
stimulant phenylalkylamines, amphetamine is considered the prototypical drug, with 
others referred to as “amphetamine-like” or “amphetaminergic”.18  Unlike many drugs of 
abuse, amphetamine is not naturally occurring.  It was first synthesized in 187724 as an 
optical isomer; (+)amphetamine is the more potent of the two isomers.31  In 1930, 
amphetamine began to be used therapeutically in the treatment of narcolepsy and 
depression.24  However, its positive effects of mood elevation, euphoria, alleviation of 
fatigue, and improving task performance, resulted in abuse.24  Finally, in 1970 the Drug 
Enforcement Administration (DEA) labeled amphetamine as a Schedule II drug.21   
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Figure 2.  Structures of amphetamine and some important derivatives.                       
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Currently, amphetamines, such as Dexedrine®, Ferndex®, and Oxydess II® are 
used to treat narcolepsy, attention deficit hyperactivity disorder (ADHD), and obesity.24  
Both with prescribed and illicit amphetamines, toxic levels can create “amphetamine 
psychosis”, aggression, delusions, arrhythmias, and convulsions.32 “Amphetamine 
psychosis” is a paranoid-hallucinatory psychosis in a setting of clear consciousness in 
which formal aspects of thought are relatively intact, but in which delusions evoke 
intense fear.32 Sometimes, patients with amphetamine psychosis are misdiagnosed as 
having schizophrenia, a disease for which the symptoms are indistinguishable.23 
Amphetamine withdrawal can result in a  dysphoric state resulting in anhedonia, 
depression, anxiety, and social inhibition.33,34  Therefore, some attempts have been made 
to treat amphetamine addicts with antidepressants such as mirtazapine, fluoxetine, and 
imipramine.35,36  Amphetamine abuse poses a severe problem as there currently is no 
effective treatment on the market for addicts, whose withdrawal symptoms could be 
detrimental. 
 Methamphetamine (3; Figure 2), a derivative of amphetamine with a methylated 
amine, is a more popular street drug than amphetamine, as it generally has the same type 
of effects as amphetamine, but with a higher potency.18  Methamphetamine’s popularity 
is due to its ease of synthesis, with over 50% of clandestine labs seized in 1981 being 
“meth” labs.24  Methamphetamine synthesis is so easy it can be made in the trunk of a car 
using the “special ingredients” and two-liter bottles.37 Methamphetamine can be 
synthesized by numerous routes, the most common using (-)-ephedrine or (+)-
pseudoephedrine, ingredients in over-the-counter decongestants and bronchodilators.24  
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For this reason, over-the-counter medications with these ingredients have recently been 
under strict control.  The therapeutic forms of methamphetamine are Desoxyn®, Adipex®, 
and Methedrine® which are used for ADHD and obesity.2,24  However, street versions of 
methamphetamine include “meth”, “speed”, “crank”, “go”, “crystal”, and “ice”, all of 
which are hydrochloride salts for greater bioavailability.24 Methamphetamine is a 
Schedule II drug.21 Like amphetamine, methamphetamine use causes euphoria, increased 
alertness, self-confidence, and suppresses fatigue.38 However, withdrawal from 
methamphetamine use also causes a depressive state, with 49.4% of arrested “meth” 
addicts stating they had thoughts of suicide.39  As with amphetamine, treatment for 
methamphetamine addicts is also elusive. 
 Stimulatory effects of phenylalkylamines mainly result from their effect on 
dopamine levels, primarily D1 receptors.40  Amphetamine, and amphetamine-like 
phenylalkylamines that have a stimulant effect, such as methamphetamine, work by 
increasing the release of dopamine by affecting vesicular monoamine transporter-2 
(VMAT-2), preventing reuptake of dopamine into presynaptic terminals, and affecting 
monoamine oxidase isozymes MAO-A and MAO-B.4,5  This increase of dopamine levels 
causes central stimulant actions.  Also, the activity of dopamine receptors can be 
modulated by NE and 5-HT.40  Some of the non-stimulant phenylalkylamines do not 
readily effect dopamine, but have a greater effect on 5-HT levels.41  The different effects 
of phenylalkylamine stimulants on DA, NE, and 5-HT can be largely attributed to minor 
structural changes. 
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 It is observed that small modifications to the structure of amphetamine, the 
prototypical phenylalkylamine stimulant, can cause vast changes in the activity, potency, 
effects, and even mechanism of action, of the drug.  When analyzing structure-activity 
relationships of phenylalkylamine stimulants, there are five key points to be considered: 
terminal amine, chiral center, α-methyl group, β-position, and aromatic substitution.  
With the amine group, it is observed that primary amines are more potent than secondary 
amines (with the exception of methamphetamine), which are more potent than tertiary 
amines.18  Length of the amine substituent has an effect on secondary amines, with a 
decrease in activity as the length of the substituent is increased.18  There is a limit of bulk 
tolerance as larger substituents usually result in agents having little to no stimulant 
character.18   
 The α–methyl group seems pertinent for effect as demethylation to 
phenylethylamine results in loss of stimulant activity.18  Also, homologation to larger, 
bulkier substituents decreases stimulant effect.18  The presence of an α-methyl group 
creates a chiral center; the S(+) isomer is more potent than the R(-) isomer.18  Changes at 
the β-position have varying effects.  Hydroxylation of the β-carbon to norephedrine and 
norpseudoephedrine decreases stimulant actions.18  Ephedrine and pseudoephedrine (4; 
Figure 2) are β-oxidized analogs of methamphetamine.18  The abuse potential of 
ephedrine and pseudoephedrine is low but dependence can occur.25  Some side effects of 
these drugs include anxiety, headache, tachyarrhythmia, and hypertensive crisis.25 
 However, oxidation of norephedrine to cathinone results in an agent that retains 
equal to or greater potency as compared to amphetamine.18,42   Cathinone (5; Figure 2) is 
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a constituent of Catha edulis, the “Khat” shrub which is predominantly found in East 
Africa.25  Its stimulant effects are similar to that of amphetamine, including euphoria, 
excessive talkativeness, focus, excitement, elimination of hunger, and insomnia, with a 
high chance of tolerance occurring.41,43  The toxic effects of cathinone are limited, but 
include aggressive behavior, hallucinatory psychosis, and fatal hyperthermina.25  The N-
monomethyl analog of cathinone, methcathinone (6; Figure 2), a name originally coined 
in the Glennon laboratories,44 is a designer drug synthesized from ephedrine, linking it to 
its common name ephedrone.25 S(-)Methcathinone, which is found more often in the 
clandestine market than the R(+)-isomer or the racemic mixture is referred to as “CAT”.45  
As cathinone’s effects are similar to those of amphetamine, methcathinone is equally 
similar to methamphetamine.25 
 Lastly is manipulation of the ring by adding substituents.  For the most part, 
adding substituents to the ring decreases and may even abolish amphetamine-like 
stimulant action as seen with p-chloroamphetamine (PCA) and fenfluramine (7 and 8, 
respectively; Figure 2).18  PCA depletes serotonin levels in the brain, and produces a 
neurotoxic effect.46  Instead of the euphoric effect caused by amphetaminergic agents, 
PCA causes aggression, anxiety, and panic disorders.46  (±)Fenfluramine, marketed as 
Pondimin®, and its more potent stereoisomer (+)fenfluramine (Redux®), are non-
amphetaminergic phenylalkylamine derivatives once used clinically for appetite 
suppression.41  However, due to the side effects of cardiovalvulopathy, as well as primary 
pulmonary hypertension, these two drugs were withdrawn from the market in 1997.41  
Like PCA, fenfluramine also depletes serotonin levels in the brain.46  However, this 
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decrease is selective and may account for the development of tolerance to fenfluramine.  
Some, negative effects of fenfluramine include depression and aggravated psychosis.46     
 One of the key designer drugs on the market is N-methyl-1-(3,4-
methylenedioxyphenyl)-2-aminopropane, more commonly referred to as MDMA.18 
MDMA (9; Figure 2) was first synthesized in 1914 as an appetite suppressant and for 
psychotherapy to facilitate communication, but never had legal therapeutic use.24,25  
MDMA is an empathogen, in so much as it increases sociability, empathy, and feelings of 
well being.24 Also, there are readily observed physical reactions, such as trismus (jaw 
clenching) and bruxism (teeth grinding), which account for “ravers” usually chewing 
gum or sucking on a pacifier.47 Overdoses can cause panic, paranoia, psychosis and 
delirium with toxic (fatal) effects including convulsions, hyperthermia, behavioral 
changes, and acute renal failure.24  There are several street names for MDMA, including 
“Ecstasy”, “XTC”, “M&M”, “Zen”, and “Adam”.18,24  Its lack of therapeutic use resulted 
in its placement in Schedule I.21  The demethylated form of MDMA is 1-(3,4-
methylenedioxyphenyl)-2-aminopropane (MDA), which has both hallucinogenic and 
stimulant character based on optical isomers.18  Other structural changes of the 
phenylalkylamines result in hallucinogenic agents. 
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3.  Non-stimulant Phenylalkylamines 
 Hallucinogens, upon administration of a single effective dose, consistently 
produce changes in thought, mood, and perception with little memory impairment, 
produce little stupor, narcosis, or excessive stimulation, produce minimal autonomic side 
effects, and are non-addicting.48  The classical hallucinogens are hallucinogens that bind 
at 5-HT2 serotonin receptors (5-HT2 hypothesis of hallucinogen action)18 and are 
recognized by animals trained to discriminate 1-(2,5-dimethoxy-4-methylphenyl)-2-
aminopropane (DOM) (10; Figure 3) from vehicle.31,49  The family of 5-HT2 receptors 
can be further divided into 5-HT2A, 5-HT2B, and 5-HT2C receptors with evidence that 5-
HT2A receptors play the major role in the hallucinogenic action.50 The classical 
hallucinogens can further be divided into several other classes:  lysergic acid derivatives 
(e.g. LSD), phenylethylamines (e.g. mescaline), indolealkylamines (e.g. DMT), and other 
indolic derivatives (β-carbolines).18   The main focus of the present study is on 
phenylalkylamines, which includes both phenylisopropylamines and 
phenylethylamines.18   
 Mescaline (11; Figure 3), one of the most commonly known phenylethylamines, 
is naturally occurring from cactus, usually peyote (Lophophora williamsii).51  Onset of 
action usually has some negative effects such as nausea, vomiting, and diarrhea, but once 
subsided, visual hallucinations and perceptual distortions occur.51  Some side effects 
include emotional instability and anxiety, with toxic effects of bradycardia, hypotension, 
and respiratory depression: death is a rare result of toxicity.51 There is no therapeutic use 
for mescaline, it is currently classified as a Schedule I drug.18   
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Figure 3. Structures of common phenylalkylamine hallucinogens.  
 
 DOM (10; Figure 3), 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane is a 
phenylisopropylamine used as the prototypical hallucinogen in drug discrimination 
studies.18  The R(-)-isomer of DOM is more potent than the S(+)-isomer or the racemic 
mixture.52 At low doses, DOM increases self-awareness, while producing feelings of 
anxiety, euphoria, and dysphoria, without producing a hallucinogenic effect.3 However, 
at higher doses, DOM produces hallucinogenic effect similar to LSD and mescaline;3 
DOM is >80 times more potent than mescaline.53  One of the original street names for 
DOM was “STP”.3 DOM has proven to be more hazardous than LSD, as it has a longer 
onset of action.  Therefore, impatient people could take multiple doses of DOM causing 
an overdose and even hospitalization.54  DOM is believed to work as an agonist at central 
serotonin (5-HT) sites,55 more specifically through a 5-HT2 mechanism.56,57 
 Structural changes to DOM, the prototypical hallucinogen, cause changes in 
potency and activity.  With respect to the terminal amine of DOM, a primary amine is 
more potent than a secondary amine, and homologation of the α-methyl group decreases 
potency.18  However, opposite effects are observed at the chiral center as well as with 
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aromatic substitution, when compared with amphetamine.18  Effect of substitution at the 
β-position is highly dependent upon configuration.  Addition of a β-hydroxy group in the 
R-configuration has little effect on affinity versus DOB, however the same addition in the 
S-configuration decreases affinity by 50-fold from R(-)DOB.58  Also, addition of a β-
methoxy group has a 100-fold decrease in affinity in the S-configuration but maintains 
affinity in the R-configuration.58 Increasing the length of the 4-methyl group enhances 
potency.18  However, if this lengthening surpasses n-propyl then potency decreases.18  
Activity is maintained with substitution at the 4-position with electron-withdrawing 
groups such as bromine or iodine (i.e., DOB or DOI respectively).18 The R(-)isomer has 
been shown to be more active than the S(+)isomer which in some cases has zero 
activity.18  Also, reduction in activity and potency can be observed through N-
monomethylation.18  This comparison between amphetamine and DOM is summarized in 
Table 1. 
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Table 1.  Comparative structure-activity relationships of amphetamine-like stimulants vs. 
DOM-like hallucinogens.18 
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Position  Amphetamine-like action  DOM-like action 
Terminal Amine N-Methyl > NH2 > NHR > NR2 NH2 > NHR > NR2 
Chiral Center  S(+) >(±) > R(-)   R(-) > (±) > S(+) 
α- Methyl group Homologation decreases     Homologation decreases  
   potency    potency 
   Replacement by H decreases            Replacement by H decreases  
   potency               potency 
β-position  β-OH reduces potency  β-OH reduces potency 
   β=O retains activity and potency β=O not well investigated 
Aromatic  Unsubstituted ring preferred  2,5-Dimethyl-substitution 
substitution       preferred 
        4-Substitution further   
        modulates activity 
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The behavioral actions of arylalkylamines, in this case phenylalkylamines, can 
fall into one of three categories: classical hallucinogen (H), central stimulant (S), and 
PMMA-like (P) (Figure 4).18,59,60 Each category contains a prototypical drug used to 
characterize other drugs in drug discrimination studies: DOM represents the 
hallucinogens, (+)amphetamine represents the stimulants, and PMMA, N-methyl-1-(4-
methoxyphenyl)-2-aminopropane, represents PMMA-like actions.18,59,60  Most 
phenylalkylamine drugs of abuse fall into one of these three categories, or behave similar 
to more than one category.  For example, MDMA would fall under intersect 2 as it 
produces both amphetamine-like and PMMA-like activity.18,59,60  R(-)MDA has both 
hallucinogenic-like activity as well as PMMA-like activity, placing it in intersect 3.  
However the (±)MDA, produces amphetaminergic, hallucinogenic, and PMMA-like 
activity, placing it in the center.18,59,60   It is important to note that through this 
classification, there should be three different mechanisms of action as well as three 
separate structure-activity relationships. 
 
Figure 4.  A modified Venn diagram of behavioral effects of arylalkylamines.59,60 
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C.  Mechanism of Action of Stimulants 
 The behavioral pharmacology and addictive properties of the stimulants cocaine, 
amphetamine, and methamphetamine are related to the monoamines, serotonin, 
norepinephrine, and dopamine.  Serotonin is involved with mood, fear, sleep, appetite, 
anxiety, reward, and aggression.2 Serotonin is produced in the raphe nuclei of the 
brainstem and moves to the cortex, thalamus, basal ganglia, hippocampus, and 
amygdala.2 Norepinephrine is involved with arousal, attention, memory, and mood, and is 
produced in the locus coeruleus.2 It is also found in the hypothalamus, cortex, 
hippocampus, and striatal regions, along with several other parts of the brain.2  Dopamine 
is involved in many processes such as movement, cognition, memory, and reward,61 and 
plays a primary role in the reinforcing effects of cocaine, known as the dopamine 
hypothesis.  Dopamine makes up approximately 80% of the catecholamine content in the 
brain.62  All three of these neurons express transporter proteins that belong to the Na+/Cl- 
superfamily, (norepinephrine transporter, NET; dopamine transporter, DAT; and 5-HT 
transporter, SERT) which function to regulate monoaminergic activity in the brain.63,64  
Interestingly, psychostimulants affect all three transporters; cocaine binds with almost 
equal affinity to all three transporters, whereas (+)amphetamine and 
(+)methamphetamine bind with substantially higher affinity to DAT and NET than SERT 
as seen in Table 2.2  However, addictive properties of psychostimulants are due to their 
effect on dopamine.2  
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Table 2.  Stimulant drug affinities (Ki) at monoamine transporters (cocaine affinities at 
DAT and SERT are expressed as IC50 values).2 
Drug    DAT   NET   SERT 
(-)Cocaine   478 nM65  779 nM7    304 nM65 
(+)Amphetamine    34 nM7    39 nM7  3830 nM7 
(+)Methamphetamine  114 nM66    48 nM66  2137 nM66 
  
 Sometimes synonymous with addiction is withdrawal symptoms when the drug of 
abuse is no longer administered.  Rothman et al. proposed a dual deficit model of 
stimulant addiction, stating withdrawal symptoms are a result of drug-induced dopamine 
and serotonin dysfunction as seen in Figure 5.67  Dysfunction occurs when withdrawal 
from chronic stimulant use leads to a decrease in availability of dopamine and 
serotonin.67  Dopamine deficit consists of decreased synaptic dopamine, altered dopamine 
transporter function, and/or postsynaptic receptor changes resulting in anhedonia and 
psychomotor retardation.67 Serotonin deficit consists of decreased synaptic serotonin, 
decreased serotonin cell activity, and/or decreased synaptic dopamine, which results in 
depressed mood, obsessive compulsive thoughts and behaviors, and lack of impulse 
control.67 Therefore, drugs that release dopamine or serotonin should effectively treat the 
withdrawal symptoms observed with addiction (i.e., such as d-amphetamine, a dopamine 
releasing agent, in the treatment of withdrawal symptoms from cocaine abuse).67  
Rothman et al. also stated that a drug that acts as both a dopamine and serotonin releasing 
agent could treat addiction with limited abuse liablility.67 
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Figure 5. Dual-deficit model of psychostimulant addiction.67 
 
 1.  Dopamine 
 Dopamine (12; Figure 6) is a catecholamine neurotransmitter found both in the 
central and peripheral nervous system, that activates dopamine G-protein coupled 
receptors (GPCR).2 In the peripheral nervous system it modulates cardiovascular and 
renal function, gastrointestinal motility, and the endocrine system.68  In the central 
nervous system, dopamine effects cognition, emotion, locomotor activity, hunger, and 
regulation of the endocrine system.68  Dopamine is produced in the substantia nigra (SN), 
the ventral tegmental area (VTA), and the hypothalamus.2  
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Figure 6. The structures of three important monoamine neurotransmitters. 
 
 The dopamine synapse consists both of presynaptic and postsynaptic nerve 
terminals.  In the presynaptic terminal, dopamine is packaged into vesicles by VMAT-2 
for storage, release, and protection from oxidation and reactive consequences.69 When 
DA is released into the synapse it can bind to postsynaptic dopamine receptors D1, D2, 
D3, D4, and D5.68  Dopamine receptors can be divided into two groups containing the five 
different dopamine receptor subtypes.  The D1-like group consists of D1 and D5 receptors 
and is associated with stimulatory function and located postsynaptically, whereas the D2-
like group is located both pre- and postsynaptically, is associated with inhibitory 
function, and includes D2, D3, and D4 receptor subtypes.68,70,71  Agonists and/or 
antagonists can bind selectively to D1-like receptors over D2-like receptors and with 
selectivity within the D2-like group.68  However, currently no compounds can selectively 
differentiate between D1 and D5 receptors.68   
 The structure of the dopamine receptors varies slightly between each subtype, as 
some contain more amino acids than others.68 However all have a few of the same key 
elements.  For example, there is an NH2-terminal stretch containing various numbers of 
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N-glycosylation sites between subtypes that stretches between seven transmembrane 
domains and ends with the carboxy terminus.68  The carboxy terminus varies in length, 
but all contain serine, threonine, and a cysteine residue.68,71  Two cysteine residues are 
present in the second and third extracellular loop which creates a disulfide bridge, 
providing structure stability.71 As mentioned before, D1-like receptors are involved with 
stimulatory function, due to their short third intracellular loop that interacts with G-
stimulatory (Gs) proteins to stimulate cAMP production.68,71  D2-Like receptors are just 
opposite as their longer third intracellular loop interacts with G-inhibitory (Gi) proteins, 
to inhibit cAMP production.68,71 
 Activation of G-proteins affects adenylyl cyclase (AC) activity, which in turn 
affects cAMP accumulation modulating protein kinase A by phosphorylation or 
dephosphorylation (Figure 7).62  Protein kinase A is responsible for regulating the 
synthesis of cytoplasmic and nuclear proteins, the function of membrane channels, and 
sensitization or desensitization of different G-protein coupled receptors.62  Dopamine 
receptors are also involved with modulating the activity of phospholipase C, the release 
of arachidonic acid, the activity of calcium and potassium channels, the activity of Na/H 
exchangers, and Na-K ATPase.68   
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Figure 7. Activation of G-protein coupled receptors by a drug causes the dissociation of 
the αβγ complex.  The α/GTP complex then activates second messenger systems such as 
cAMP or PLC.72 
 
 The euphoric feeling resulting from stimulant use is due to an increase in 
dopamine levels that can occur through several different routes.73  The DAT and VMAT-
2 regulate dopamine in both the synapse and cytosol; psychostimulants alter the function 
of both of these types of transporters.73 Cocaine works primarily by blocking reuptake of 
dopamine into the presynaptic terminal by blocking the DAT (Figure 8).30  Amphetamine 
and methamphetamine both can block the reuptake of dopamine, like cocaine, but also 
can cross the plasma membrane by lipophilic diffusion and act directly on vesicular 
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monoamine carriers by releasing transmitters from the vesicle.63,74  Also, both 
amphetamine and methamphetamine promote efflux of transmitter (e.g. DA) by a 
transporter-mediated exchange.63   
 
 
 
Figure 8.  Schematic representation of a dopaminergic nerve terminal.  Cocaine prevents 
reuptake (“A”), whereas amphetamine and methamphetamine cause release of dopamine 
from intracellular vesicles.2,18 
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2.  Norepinephrine 
 Since repeated data support that dopamine plays a role in the reward/ 
reinforcement behavior observed in animal models,7 the next question was to determine 
the effect of norepinephrine (13; Figure 6).  Both amphetamine and methamphetamine 
increase NE concentrations by stimulation of release,75 whereas cocaine increases NE by 
blocking reuptake.76  However, blocking reuptake may not increase extracellular 
neurotransmitters as much as substrate-releasing agents, since it is nerve impulse-
dependent.7,77  Evidence shows that the release of NE may contribute to the positive 
subjective effects, such as the “high” produced by stimulants, coined the “noradrenergic 
hypothesis”.7 Since cocaine is unable to increase NE levels as much as substrate releasers 
like amphetamine, the subjective effects cannot be accounted for with this type of 
stimulant.7 
  
3.  Serotonin 
 As already discussed, central stimulants can increase synaptic levels of serotonin 
(e.g. see Table 2).  This increase in serotonin levels can activate various populations of 5-
HT receptors.  The 5-HT receptor family will be described in the next section.  Because 
emphasis of the present work is on 5-HT3 receptors (and their ligands), these receptors 
will be discussed in detail. 
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D.  Serotonin Receptors 
 1.  Classification 
 Serotonin (5-HT) (14; Figure 6), is a neurotransmitter involved in anxiety, 
aggression, depression, schizophrenia, appetite control, drug abuse, and hallucinogenic 
activity.78  Currently, there are seven families of serotonin receptors, 5-HT1-5-HT7, some 
of which are divided into subpopulations.78  These families are characterized based on 
three components: drug binding characteristics, receptor-effector coupling, and structural 
sequences for the nucleotides and amino acids.79  The majority of 5-HT receptors have 
been cloned as either human, mouse, rat, or guinea pig receptors leading to the 
generalization of their amino acid sequence homology.78 
 All of the serotonin receptors are G protein-coupled receptors except for 5-HT3 
receptors which are ligand-gated ion channel (LGIC) receptors.78  G Protein-coupled 
receptors consist of seven transmembrane (TM) spanning helices, with an extracellular 
N-terminus, an intracellular C-terminus, and loops connecting the helices;72 the 
intracellular loop between TM5 and TM6 is rather large and thought to be involved with 
second messenger system coupling.78 Serotonin receptors can be coupled to two types of 
second messenger systems: adenylyl cyclase (AC), where coupling can occur positively 
or negatively, or phospholipase C.78  All of the different subpopulations, with the 
currently accepted nomenclature, and their second messenger systems are summarized in 
Table 3. 
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Table 3.  Classification of current populations of serotonin receptors.78 
Currently Accepted Name    Second Messenger System 
5-HT1 
 5-HT1A      AC(-) 
 5-HT1B      AC(-) 
 h5-HT1D      AC(-) 
 h5-HT1B      AC(-) 
 5-HT1E       AC(-) 
 5-ht1F       AC(-) 
5-HT2 
 5-HT2A      PI 
 5-HT2B      PI 
 5-HT2C      PI 
5-HT3        Ion Channel  
5-HT4        AC(+) 
5-HT5 
 5-ht5A       ? 
 5-ht5A       ? 
5-HT6        AC(+) 
5-HT7        AC(+) 
   
 
2.  5-HT3 Receptors 
  a)  Structure and Distribution 
  5-HT3 receptors, formerly known as “M” receptors, due to inhibition of their 
response to morphine, are in the Cys-loop family of ligand–gated ion channel receptors, 
along with nicotinic acetylcholine (nACh) receptors, γ-aminobutyric acid type A 
(GABAA) receptors, and glycine receptors.8,80 LGIC receptors, of the 5-HT3-type, consist 
of five homopentameric subunits, each made of four transmembrane-spanning amino acid 
chains (M1-M4), which form a pore; the M2 chain faces the pore.78  This pore rapidly 
opens when neurotransmitter binds to the receptor,  and is permeable to sodium, 
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potassium, and calcium cations.81  M1 through M4 are connected by extracellular and 
intracellular loops, with both a carboxy and amino terminus, as seen in Figure 9.78  Ion 
selectivity and gating of the receptor is controlled by residues found between M1 and M3 
(i.e., M2).8  
 Homology-based models of the extracellular domain were previously based on the 
crystal structure of acetylcholine-binding protein (AChBP), however recent discoveries 
have identified the crystal structure of the extracellular domain of the mouse nicotinic 
acetylcholine receptor (nAChR) α1 subunit.8,82-85 These receptors are found both in the 
peripheral and central nervous system.  There currently are five different subtypes of 5-
HT3 receptors; A, B, C, D, and E, but 5-HT3A and 5-HT3B are the only two shown to form 
functional receptors.86  
Figure 9.  (A) Pore formed from five subunits, with M2 (shaded) facing the pore. (B) 
Four transmembrane-spanning amino acid chains.78  
A M1 M2 M3 M4
NH3+
COO- 
B
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5-HT3 receptors are found in both the peripheral nervous system, on the terminals 
of sympathetic, parasympathetic, and sensory neurons, and in the central nervous 
system.9 In the central nervous system serotonin is produced in the raphe nuclei in the 
brainstem and then is able to project into the cortex, thalamus, basal ganglia, 
hippocampus, and amygdala.87  Evidence suggests that 5-HT3 receptors are presynaptic 
excitatory receptors allowing it to regulate the release of acetylcholine, dopamine, 
noradrenaline, cholecystokinin and serotonin.9  Some studies have shown that 5-HT3 
receptor antagonists attenuate cocaine and amphetamine induced locomotor effects, 
suggesting that 5-HT3 receptors modulate mesolimbic dopamine activity.9  This 
modulation however is indirectly related to the increases in mesolimbic dopamine 
induced from psychomotor stimulants alone.9  These effects are only observed with 
locomotor activity, and cannot be replicated with drug discrimination or self-
administration studies, providing little information about abuse liability.88-91  Evidence, 
however, does suggest that deficits in dopamine and serotonin neuronal function are 
observed with stimulant abuse withdrawal.92  Since studies show there’s an indirect 
correlation between 5-HT3 receptor antagonists and mesolimbic dopamine activity, as 
well as evidence supporting that increased serotonin levels decrease withdrawal 
symptoms, stimulants could be working, at least in part, through a 5-HT3  receptor 
mechanism.9    
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  b)  Function 
 5-HT3 receptors themselves, as well as 5-HT3 receptor antagonists, have a wide 
array of functions.  Activation of 5-HT3 receptors increases intracellular Ca2+, modulates 
neurotransmitter release (dopamine and norepinephrine), excites central and peripheral 
neurons, and mediates emetic and inflammatory responses.86,93  More specifically, the 
receptors are involved in dopamine and acetylcholine release, as well as control of the 
GABA-ergic system.80,94 This ability to indirectly regulate dopamine is why 5-HT3 
receptors might be involved with drug dependence.9 Not much is known about the 
function of 5-HT3 receptor agonists, although emesis may be an occurring side effect, or 
partial agonists, which seem to portray an anxiolytic profile.95  However, antagonists 
have been shown to relieve several types of ailments. Some 5-HT3 receptor antagonists 
treat chemotherapy-induced or radiation-induced vomiting, and migraines.96,97 Some are 
used in the treatment of anxiety, depression, pain, and dementia. Some 5-HT3 receptor 
antagonists may suppress withdrawal symptoms in alcoholics, as well as nicotine-, 
cocaine-, and amphetamine-addicts.94,96 Moreover, some are able to block the abuse-
related effects of drugs.9 
 
  c)  Antagonists 
 Hundreds of different 5-HT3 receptor antagonists have been discovered since the 
initial selective 5-HT3 receptor antagonist bemesetron (15; MDL 72222) was reported.78 
Bemesetron was formed by a slight structural modification to cocaine (a 5-HT-M 
receptor antagonist), by the removal of a carbomethoxy group, and addition of two 
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chlorine atoms.78  Current antagonists fall into two groups, keto compounds and 
imidazoles.  Some of the more common keto compounds include granisetron (16), 
tropisetron (17), and zacopride (18), as seen in Figure 10.78  The imidazole-containing 
compounds (Figure 11) include ondansetron (19), alosetron (20), fabesetron (21), and 
ramosetron (22).78  Granisetron (16), ondansetron (19), and tropisetron (17) are of special 
interest as they are highly selective and potent 5-HT3 receptor antagonists used in the 
treatment of emesis associated with anticancer chemotherapy.98  Several pharmacophore 
models have been reported for 5-HT3 receptor antagonists.99-104 
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Figure 10.   Keto-group-containing 5-HT3  receptor antagonists.78 
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Figure 11.  Imidazole-containing 5-HT3 receptor antagonists.78 
  
  d)  Agonists 
 Currently, there are not many known 5-HT3 receptor agonists/partial agonists, 
however the few that exist fall into one of five categories: tryptamines, arylpiperazines, 
arylbiguanides, arylguanidines, and miscellaneous agents.14  There is renewed interest in 
arylpiperazines which generally were initially considered non-selective for 5-HT3 
receptors, or could behave as 5-HT3 receptor agonists, partial agonists, or antagonists.78  
Quipazaine (23; Figure 12) binds both at 5-HT3 and 5-HT2A receptors with a Ki value of 
around 1 nM.105 However, it acts as an agonist in some assays and as an antagonist in 
others.  Structure-activity studies have shown that appropriate structural modifications 
can result in more selective 5-HT3 receptor agonists.  For example, piperazine N4-
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methylation, creating N-methylquipazine (NMQ) (24; Figure 12) enhances the selectivity 
of the compound for 5-HT3 receptors.106  Also, ring-fusion creates the partial agonist MR 
18445 (25; Figure 12).78 
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 Quipazine (23)             NMQ (24)       MR 18445 (25) 
Figure 12.  A few examples of arylpiperazine 5-HT3 receptor agonists and partial 
agonists. 
 
Serotonin itself is a nonselective 5-HT3 receptor agonist that does not bind with 
high affinity (Ki= ca 500-1,000 nM).107  By methylating this structure to obtain 2-methyl-
5-HT (26; Figure 13), a partial agonist, selectivity increases while binding affinity 
remains unchanged.107  However, Glennon et al. showed that 2-methyl 5-HT (26) also 
binds to 5-HT6 receptors with high affinity.108  Structure-affinity studies identified a 
limited region of bulk tolerance at the terminal amine of serotonin for agonism at 5-HT3 
receptors.  Subsequently, studies by our laboratory showed, using brain 5-HT3 receptors, 
that N,N-dimethylated structure bufotenine (Ki= 280 nM) and the N,N,N-trimethylated 
structure 5-HTQ (27; Figure 13)  (Ki= 75 nM), bind with higher affinity and selectivity 
than serotonin.109  However, the quarternary structure of 5-HTQ (27) may prevent it from 
crossing the blood-brain barrier (BBB).109   Previous structure-activity studies had shown 
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that di- and tri-methylation of serotonin resulted in potent serotonin agonists in a superior 
cervical ganglionic cell preparation.110  Another potent and specific 5-HT3 receptor 
agonist, that does not belong to the tryptamine-derived category is 4-amino-(6-chloro-2-
pyridyl)-1piperidine hydrochloride, more commonly known as SR 57227A (28, Figure 
13), which is a potent agonist that crosses the BBB.111 
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Figure 13.  5-HT3 receptor agonists and partial agonists.109,111  
  
 Phenylbiguanide (29; Table 4) is a low affinity 5-HT3 receptor agonist (Ki~1000 
nM) that falls into the arylbiguanide classification.112  Structure-affinity studies have 
shown that introduction of a chloro group at the 2-, 3-, or 4-position results in higher 
binding affinity, with meta-chlorophenylbiguanide (mCPBG) (30) having a Ki value of 
about 17 nM (Table 4).11  Benz-fusion at the 3- and 4- positions of the phenyl ring as 
seen with the 2-naphthyl analog (i.e. 31) mimics the effect of the 3-chloro group.11,113 
Improvements in affinity from the parent phenylbiguanide were observed with di- and tri-
chloro substitution of the phenyl ring.114 By adding an electron-withdrawing nitro group, 
a five-fold increase in affinity was observed versus the phenylbiguanide.11,113  However, 
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the addition of the electron-withdrawing 3-trifluoromethyl group resulted in lower 
affinity, around the 700 nM range; similar results were observed with the addition of a 
methyl substituent to phenylbiguanide.11,113,114  The high affinity of the N-(2-
phenylethyl)guanidine analog 52 supported the idea that the biguanide moiety was not 
essential for binding.11  This led to a new series of structure-activity studies. 
 By shortening the biguanide chain, arylguanidines were created, with m-
chlorophenylguanidine (m-CPG or MD-354) (42; Table 4) as a lead compound with a 
binding affinity at 5-HT3 receptors of Ki = 35 nM.11,113  The same types of structural 
modifications were made to the arylguanidines as in the arylbiguanides, which displayed 
similar results.  For example, higher binding affinities were observed with di- and tri-
chloro substituted phenyl rings (i.e. 48-50; Table 4), and high binding affinity was 
observed upon benz-fusion as seen with the 2-napthyl analog (i.e. 43; Table 4).11,14,113 
This information supports the concept that parallel structural changes result in parallel 
shifts in affinity. Also, affinity decreased with the addition of 3-methyl or 3-
trifluromethyl substituents (i.e. 46, 47; Table 4).11 The 3-trifluromethyl substituent is 
electron-withdrawing, which is seemingly favored, however it is much bulkier than the 
chloro-substituted analogs, which may result in its lack of binding affinity when added to 
phenylguanidine.115 Lipophilic substituents are favored at the 4-position, but only up to a 
certain size, as wider lipophilic substituents decrease affinity.115   
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Table 4. Binding affinities of arylbiguanide and arylguanidine 5-HT3 receptor 
agonist/partial agonist derivatives.11,14,113-115 
HN N
H
NH
NH2
NH
R
          
HN NH2
NH
R
        
N
H
Cl
NH2
HN
       
   29-39        40-50          52 
Aryl-  Approximate         R    Aryl-   Approximate  
biguanides Ki  (nM)      guanidines  Ki  (nM) 
29  ~1,000   H      41   2,340 
30         17   3-Cl      42         35 
31         12   3,4 fused phenyl  43        25 
32         62   2-Cl      44      190 
33       200   4-Cl      45      320 
34       220   3-NO2      -----     ----- 
35       780   3-CH3      46   6,520 
36       700   3-CF3      47   5,700 
37          0.4  2,3,5-Cl     -----     ----- 
38        12   3,4-Cl      48         3.1 
39         1.8  3,5-Cl      49         5 
40         2.7  3,4,5-Cl     50         0.7 
-----  -----   3-CF3, 4-Cl     51       36 
-----  -----   -----      52       40 
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 Few pharmacophore models have been proposed for 5-HT3 receptor 
agonists/partial agonists, and none include all the different types of ligands.  Glennon et 
al. proposed a pharmacophore model for ligands containing an indole moiety, stating that 
the distance from the aromatic centroid to the terminal amine is pertinent for binding.116  
Later, Yamada et al. proposed a 3-point pharmacophore model consisting of an aromatic 
region, an adjacent nitrogen atom, and a terminal amine.117  However, a limitation to this 
model is that it only deals with 5-HT3 receptor agonist binding at gut 5-HT3 receptors.117  
Rault et al. proposed a more complex 5-point pharmacophore model using seven 
different structural classes of ligands.95 This model consisted of two hydrogen bond 
acceptors, an aromatic moiety, a hydrophobic group, and an ionizable site that 
corresponds to the terminal amine.95  However, none of these models accounts for the 
two major classes of 5-HT3 receptor agonist ligands: arylguanidines and arylbiguanides.   
  A current working pharmacophore model (Figure 14) proposed by Dukat 
accounts for binding of arylbiguanides and arylguanidines.  This model consists of N1  
 
 
 
 
 
 
Figure 14. Current working pharmacophore model for 5-HT3 receptor agonists and 
partial agonists.14 
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which is located 2.7Å from an aryl centroid (Du) (i.e. A), and a terminal amine located 
4.5-4.9Å from Du (i.e. B).14  All three guanidine nitrogen atoms are believed to be 
required, with limited substitution; the N1 position contains a steric block.14  Lastly, there 
is a region where affinity can be enhanced with substituents at the meta and para 
positions.14  However, this model might not account for rotameric binding, since meta-
substitution is preferred and two meta positions are present: the 3- and 5- position.115 
Further studies are required to resolve this problem. 
 
E.  Quantitative Structure-Activity Relationships 
 Pharmacophore models are extremely helpful in predicting the behavior of new 
molecules.  Although, they are in fact, “just a model”, information from a pharmacophore 
model can be helpful in the design of new ligands for particular receptors.  The 
correlation between the biological activities of drugs with their physiochemical properties 
is known as quantitative structure-activity relationships (QSAR), which is employed to 
create pharmacophore models.118  Methods used to describe structure-activity 
relationships include comparative molecular field analysis (CoMFA) and comparative 
molecular similarity indices analysis (CoMSIA). 
  In general, development of pharmacophore models usually separates agonists and 
antagonists, as agonists generally stabilize the active conformation of the receptor, 
whereas antagonists stabilize the inactive conformation.118 Therefore, by placing both 
agonists and antagonists into the same receptor model, the predictability of the model 
might be low due to opposing biological factors.   
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 In order to create a pharmacophore model using either CoMFA or CoMSIA, a 
“training set” of ligands with known biological activity is aligned within a fixed lattice.119  
This set should exemplify all types of ligand substituents equally (e.g. electron-
withdrawing groups, electron-donating groups, bulky substituents), in all possible 
substitution locations.  Once aligned, a partial least squares analysis is conducted to 
correlate the field values with biological data, usually binding affinity.118  The “fit” of the 
binding affinity values is expressed by the squared correlation coefficient, r2 which 
usually is high if the ligands  are well aligned.118   The predictability of the model is 
determined through cross-validation, and is expressed as q2.118  Predictability values of 
0.6 and above exemplify a “good model”, which can be used to predict the binding 
affinity of new receptor ligands.119  The higher the q2 value, the better the model should 
be at predicting the binding affinity of new ligands.  The quality of this model can be 
verified using a test set of compounds not included in the training set, but for which 
biological data are known.  If predicted binding affinities are similar to the actual binding 
affinities of test set compounds, then this further validates the predictability of the 
model.118 
 Other than predicting the binding affinity of new receptor ligands, QSAR models 
can assist in the design of new ligands.  This is due to the fact that CoMFA and CoMSIA 
studies provide important information about the location of favorable and unfavorable 
substituents.  For example, CoMFA studies provide information to where electrostatic 
fields are favorable or unfavorable, as well as to favorable and unfavorable steric bulk 
regions.119    Once again, this information is based solely on ligands used in the training 
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set employed to create the model. CoMSIA studies also give information about the 
electrostatic and steric regions as well as hydrophobic, H-bond donor, and H-bond 
acceptor regions that are favorable or unfavorable.120  With this information, the binding 
affinity of new compounds can be predicted, or novel ligands can be designed through 
analysis of favorable regions. 
 
F.  Behavioral Assays 
 There are several different rodent behavioral studies used to characterize 
stimulant drugs including drug discrimination, self-administration, and locomotor activity 
studies.  Stimulants can act as discriminative stimuli in a drug discrimination (DD) 
paradigm from which information can be obtained on a drug’s duration of action, time of 
onset, mechanism of action, potency, and structure-activity relationships.121  Self-
administration studies are used to determine the reinforcing efficacy of the drug.122  Since 
it is already known that behavioral stimulants have a central stimulatory effect which 
results in changes in motor activity, locomotor activity assays are used to evaluate this 
change. 
 Locomotor activity assays are conducted in square transparent chambers 
surrounded by infared photo detectors; one bank of detectors measures activity at the 
plane of the floor, whereas another is positioned centimeters above the floor to measure 
vertical activities.123  These measure the coordinates of an animal’s location, as well as 
the type of motion.123  Stimulants commonly increase motor activity such as the amount 
of movement.  Some commonly analyzed parameters induced by stimulants include 
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movement time, distance, velocity, and episodes.  Movement time is the sum of time of 
all movements in the floor plane as measured in seconds.123  For example, if mouse 
movements were analyzed for 2700s, but the animal only moved a total of 1200s, the 
latter would be considered its movement time.123  Movement distance is the sum of all 
vector coordinate changes in the floor plane, and movement episodes are total 
movements in the floor plane.123  So, if a mouse continues to walk for one minute, then 
stops, this equates to one movement episode, whereas every centimeter the mouse walked 
in that one episode is counted in movement distance.123  An average of the movement 
time and movement distance can be calculated as velocity (cm/min), which is considered 
the average speed of floor-plane coordinate-change defined movements.123  Typical 
results for stimulants include increases in movement distance and movement time, but a 
decrease in movement episodes.  These same parameters (time, distance, and episodes) 
can be applied to vertical entries, more commonly known as “rearing”, which includes 
entries in the vertical plane that activate the upper infared photo-detectors.123  
 Some stimulant parameters that give insight into anxiolytic versus anxiogenic 
activity are margin distance, margin time, center distance, center time, and center entries.  
Margin distance is the same as movement distance, but is only calculated within a 2.5-
beam-margin-of-space toward the interior walls.123  Margin time is the amount of time 
spent within this same margin of space.123  Mice that tend to stay near the margin display 
thigmotaxis, which can be related to either anxiety or agoraphobia.124,125 Center distance 
and center time are the distance, in centimeters, and time, in seconds, spent in the center 
arena.123  Center episodes include the number of times the mouse enters the center arena, 
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characterized by anything outside of the 2.5-beam-margin-of-space.123  The more time 
spent near the margins is characterized as an anxiogenic-like effect as the mouse is 
thought to be more fearful.123  When the opposite occurs, where the mouse spends more 
time in the center of the chamber, the animal is thought to be displaying anxiolytic-like 
character.123  
 As in most behavioral assays, the actions of a test drug (i.e., stimulant) are 
compared to the actions induced by saline.  All drug administration parameters remain 
the same such as duration of test, route of administration, pre-injection time, as well as 
habitat conditions.  When the study is complete, the results are analyzed using a one-way 
analysis of variance (ANOVA) test on the mean response of each parameter, followed by 
a post-hoc test to determine statistical significance.123  Results from many stimulant 
studies result in an inverted U-shaped function, due to the fact that locomotor activity 
increases as stimulant dose increases; however, after a certain dose, the effect either 
remains steady or decreases.126  This type of behavioral assay should provide insight into 
the effects of stimulants as well as other drugs on mouse locomotor activity. 
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III. Specific Aims 
 
 Psychomotor stimulants such as (+)amphetamine (2), (+)methamphetamine (3), 
and cocaine (1) increase dopamine levels which, in turn, can increase locomotor activity 
when administered to rodents.  However, recent studies have shown that activation of 
serotonin systems, more specifically 5-HT3 receptors, may modulate dopamine release.  
5-HT3 receptor agonists have been shown to release dopamine in the striatum and nucleus 
accumbens.127,128  5-HT3 receptor antagonists such as tropisetron (17; previously known 
as ICS 205-930), zacopride (18), and MDL 72222 (15) attenuate stimulant parameters 
when co-administered with acute treatments of cocaine in locomotor activity studies 
using rats.129  The 5-HT3 receptor antagonist ondansetron (19) was able to attenuate the 
effects of chronic treatment of cocaine and acute treatment of amphetamine on 
hyperlocomotion.130,131  Similar results were observed using mice with acute treatments 
of cocaine in combination with tropisetron (17) and zacopride (18).132  These data, as well 
as other studies, suggest that 5-HT3 receptor agonists might indirectly increase dopamine 
levels, whereas 5-HT3 receptor antagonists decrease dopamine levels, in different areas of 
the brain.9 
 MD-354 (42; Figure 15) is a 5-HT3 receptor partial agonist that binds at 5-HT3 
receptors with rather high affinity (Ki = 35 nM).11   MD-354 (42) behaves both as an 
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agonist and antagonist in different assays, with antagonist activity being more commonly 
associated with higher doses, such as in antagonizing cisplatin-induced emesis.133  
 
 
HN NH2
NH
Cl  
MD-354 (42) 
Figure 15.  Structure of the arylguanidine mCPG, more commonly known as MD-354. 
  
 One purpose of the present studies was to determine the effects of MD-354 (42) 
on the locomotor actions of psychomotor stimulants; that is, might MD-354 potentiate (or 
antagonize) the locomotor effects of (+)amphetamine?  Previous data have shown that 
MD-354, at doses of 1.0-10 mg/kg, does not produce a statistically significant difference 
on any locomotor parameter.12 When administered alone, MD-354 behaves like saline. 
But, if in combination with psychomotor stimulants it potentiates the drug’s locomotor 
effects, MD-354 might be used as a form of drug replacement therapy.  Drug replacement 
therapy consists of combination treatment to wean a patient off the abused drug by 
decreasing the dose of the drug of abuse while maintaining its positive effects due to its 
combination with another non-stimulant drug.  
 Behavioral effects of MD-354 (42), as well as of several stimulants, will be 
analyzed using a mouse locomotor activity assay.  (+)Amphetamine (2) and 
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(+)methamphetamine (3) are phenylalkylamine stimulants with similar mechanisms of 
action.  Therefore, results should be similar, except that methamphetamine is a more 
potent stimulant.  These data will be compared to those obtained with cocaine (1), a non-
phenylalkylamine stimulant with a different mechanism of action (reuptake blocker, 
cocaine, versus substrate releaser).  DOM (10) will be used as control, because it is 
structurally similar to amphetamine, but is a non-stimulant phenylalkylamine 
hallucinogen.   
   Dose response curves will be obtained for each drug to determine an effective 
dose, which is a dose that produces a statistically significant effect versus saline.  An 
effective dose will be used in combination studies with varying doses of MD-354 (42).  
The preinjection times, as well as the recording-time of the assays, will be determined 
based on each drugs’ known onset of action and duration of action determined from 
literature data.  Statistical analysis will be performed on commonly used stimulant 
parameters such as movement distance, movement time, and movement episodes, as well 
as other informative parameters (center distance, center time, center entries, margin 
distance, margin time, and vertical entries).   Potentiation of stimulant parameters (i.e., an 
increase in movement distance and movement time or a decrease in movement episodes) 
when MD-354 is administered in combination with an effective stimulant dose, would 
suggest that MD-354 (42) is working through an agonist mechanism.  However, 
attenuation of stimulant parameters would indicate an antagonist mechanism of action.    
 To further support or refute the determined mode of action of MD-354 (42), a 
combination study of (+)amphetamine (2) and the 5-HT3 receptor antagonist ondansetron 
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(19) will be performed.  Since MD-354 is a partial agonist, it may behave as 5-HT3 
receptor agonist, which should increase dopamine levels (increasing locomotor activity), 
or as a 5-HT3 receptor antagonist, which could have the opposite effect.  If the results of a 
combination study of a 5-HT3 receptor antagonist (e.g. ondansetron) with 
(+)amphetamine are similar to those obtained with MD-354 (42) in combination with 
(+)amphetamine (2), then MD-354 could be working through a 5-HT3 receptor antagonist 
mode of action.  However, if results differ from what is shown in the combination of 
MD-354 (42) with the stimulants, then MD-354 may be working through a 5-HT3 
receptor agonist mechanism.   
 This idea will further be evaluated by conducting a similar study using a 5-HT3 
receptor agonist, SR 57227A (28); a combination study of (+)amphetamine (2) and SR 
57227A will be performed.  If the results of the combination study are similar to those 
observed using (+)amphetamine in combination with MD-354 (42), then MD-354 may be 
working through a 5-HT3 receptor agonist mechanism, which should further support or 
refute the data found in the combination study of ondansetron with (+)amphetamine.   
 Since the phenylalkylamine stimulants (+)amphetamine (2) and 
methamphetamine (3) work through a different mechanism of action than the non-
phenylalkylamine stimulant cocaine (1), similar results from combination studies with 
MD-354 (42) may or may not be observed.  This could be due to differences in 
mechanism of action, instead of the overall effect of increased synaptic dopamine levels.  
The data from these studies will be compared to the combination studies of cocaine with 
MD-354 to determine if MD-354 is working through a 5-HT3 receptor agonist or 5-HT3 
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receptor antagonist mechanism of action.  This will be compared to the effects obtained 
in combination studies with amphetamine to determine if MD-354 behaves similarly with 
phenylalkylamine stimulants as with non-phenylalkylamine stimulants (which work 
through different mechanisms of action). 
 Combination studies will also be conducted using the 5-HT3 receptor agonist SR 
57227A (28) in combination with cocaine as well as the 5-HT3 receptor antagonist 
ondansetron (19) in combination with cocaine to determine if MD-354 (42) is working 
through a 5-HT3 receptor agonist or antagonist mechanism. This study will help 
determine whether MD-354 is behaving similarly in combination with cocaine as with 
(+)amphetamine.  Differences in the two studies once again could be associated with the 
different mechanisms of action of the two psychomotor stimulants. 
 Since DOM (10) is a hallucinogen instead of a stimulant, locomotor activity 
parameters such as movement distance or movement time might not increase following 
DOM administration.  However, consistent with what is known about hallucinogens,3 
DOM might increase vertical entries (“rearing”). 
 MD-354 does not produce a locomotor stimulant effect by itself.12  Either it is 
devoid of such action or MD-354 may not penetrate the BBB (i.e., it is assumed that a 
central action is responsible for locomotor stimulation).  MD-354 has a Log P value of       
-0.64 which may prevent it from crossing the blood-brain barrier.13  Compounds with low 
Log P values such as MD-354 may cross the BBB, however BBB penetration is more 
commonly observed with compounds having a Log P value between 1.5-2.5.134  
Therefore, a more lipophilic compound, the methyl carbamate analog of MD-354 (42), 
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will be synthesized and tested as a prodrug.135  Data from pharmacological assays 
suggested that the methyl carbamate analog of MD-354 acted similarly to MD-354.12  
This could be a result of insufficient lipophilicity, causing difficulty in crossing the BBB, 
or that hydrolysis to MD-354 (42) occurred before it was able to cross the BBB.135  
Therefore, another purpose of the present study is to synthesize more lipophilic 
carbamate analogs of MD-354 that might act as prodrugs of MD-354 (Figure 16).  These 
carbamate analogs include the phenyl carbamate 53, the phenyl carbamate with an 
electron-withdrawing group, 4-chlorophenyl carbamate 54, and the phenyl carbamate 
with an electron-donating group, 4-methoxyphenyl carbamate 55.  Although the Log P 
values of these three carbamates are currently unknown, because they have yet to be 
prepared, they can be predicted; using conversion ratios with the predicted Log P value of 
MD-354 versus its known Log P value (octanol/water), the predicted Log P values of the 
phenyl carbamates can be compared to MD-354.  The phenyl carbamate was predicted to 
have a Log P value of 1.62 which is greater than that of MD-354 (42) and falls within the 
range of values which usually allows an agent to cross the BBB.  Addition of the 
electron-withdrawing chloro-group to the phenyl carbamate 54 increases lipophilicity, 
with a predicted Log P value of 1.83.  The addition of the electron-donating methoxy-
group to the phenyl carbamate (i.e., 55) decreases lipophilicity slightly (Log P = 1.56) 
from the phenyl carbamate 53.  Since all three of the carbamates had predicted Log P 
values in the range of 1.5-2.5, they should all cross the BBB, as they are predicted to be 
more lipophilic than MD-354. These three carbamates should also display differences in 
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rates of hydrolysis based on differences in hydrolytic stability due to the addition of 
electron-donating and electron-withdrawing groups to the phenyl carbamate 53. 
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Figure 16.  Three proposed carbamate analogs of MD-354. 
 
 Once synthesized, the carbamates will be tested in rodent locomotor activity 
assays.  These carbamates should be more lipophilic than MD-354 (vide supra), should 
more readily penetrate the BBB than MD-354 because of their increased lipophilicity, 
and should be hydrolyzed to MD-354 in vivo by brain tissue esterases. Thus, if MD-354 
possesses latent stimulant properties but simply does not penetrate the BBB, then more 
lipophilic carbamates might produce locomotor stimulation. 
 In addition to the synthesis of the carbamate analogs, a conformationally 
constrained analog of MD-354 (42) will be synthesized.  Previous literature reported the 
synthesis of 2-amino-7-chloro-3,4-dihydroquinazoline (56);13 however, a review of 
available data suggested that the structure may have been misassigned and was actually 
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the 6-chloro analog (i.e., 57).  Therefore, 2-amino-6-chloro-3,4-dihydroquinazoline (57) 
will be synthesized and compared to the earlier sample for clarification of structure. 
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Figure 17. Conformationally constrained analogs of MD-354. 
 
 Once the correct structure (i.e., 56 or 57) is identified, this constrained analog as 
well as 2-amino-5-chloro-3,4-dihydroquinazoline (58)135 will be used to further develop 
and test our current working pharmacophore model for 5-HT3 receptor agonists and 
partial agonists (as shown in Figure 14).  The use of conformationally-constrained 
analogs in the working pharmacophore model is necessary to account for rotameric 
binding.  Some arylguanidine and arylbiguanide analogs contain substituents at the meta-
position.  However, it is not known at which meta position the substituents are located: 
the 3-position or the 5-position.  This is due to the fact that rotameric binding might occur 
between the N1-position of the guanidine moiety and the phenyl ring (Figure 14).  By 
examining conformationally-constrained analogs, rotameric binding can be accounted 
for, indicating at which meta-position a chloro group is more favorable for binding.     
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 A final goal of this work is to examine the quantitative structure-activity 
relationships (QSAR) for the binding of arylguanidines and arylbiguanides at 5-HT3 
receptors. As well as the conformationally-constrained analogs, about 40 other 
arylguanidine and arylbiguanide analogs will be employed as the training set.  This 
training set will be aligned and analyzed using Comparative Molecular Field Analysis 
(CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA).  Results 
will be validated using a test set of five compounds not included in the training set, but 
for which binding data are available.  These studies will attempt to identify regions 
favorable for steric, electrostatic, and hydrophobic interactions.  This information will be 
used to predict the binding affinity of five new analogs that have been synthesized in our 
laboratories, binding data for which are not yet available. 
 The overall focus of these studies is to determine the effect of MD-354 (42) on 
psychomotor stimulants, to synthesize phenyl carbamate analogs of MD-354, and 
evaluate them in the mouse locomotor activity assay in order to determine whether or not 
MD-354 penetrates the BBB and lacks stimulant effect or possesses stimulant-like 
activity but does not cross the BBB.  Another goal is to prepare a conformationally-
constrained arylguanidine and conduct QSAR studies to further develop our current 
working pharmacophore model for 5-HT3 receptor ligands.  
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IV. Results and Discussion 
A.  Behavioral Studies 
 1.  Results 
  a)  MD-354 (42)  
 Our laboratory has previously shown that, when administered alone, MD-354 (42) 
produces saline-like effects in the mouse locomotor activity assay.12  In the present 
investigation, to more thoroughly document this effect,  locomotor activity assays were 
conducted using i.p. injection doses of 1.0, 3.0, 6.0, and 10 mg/kg of MD-354 (42) with a 
30-min pre-injection time, and a 45-min recording-time, as well as a 0-min pre-injection 
time and a 1-h recording-time.  Current data are in agreement with, and extend, that in the 
literature; MD-354 (42) did not show a statistically significant difference versus saline in 
the measured stimulant parameters [e.g. movement episodes, movement time (Figure 18), 
movement distance, or vertical entries (data not shown)].   
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Figure 18.   Effect (± S.E.M.) of MD-354 (42) (30-min pre-injection time) on total 
movement episodes and total movement time with a 45-min recording-time (n = 6 
mice/treatment). 
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 Other parameters analyzed, such as margin time (Figure 19) and center time 
(Figure 19), as well as, margin distance, center distance, or center entries (data not 
shown) also lacked a statistically significant difference versus saline.  It is important to 
note that mice injected with MD-354 (42) or saline typically spent more time around the 
margin of the chamber than in the center as shown in Figure 19.  These data support the 
notion that mice normally display as much anxiogenic-like activity in the presence of 
MD-354 as they do following administration of saline alone. 
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Figure 19.  Effect (± S.E.M.) of MD-354 (42) (30-min pre-injection time) on total 
margin time and total center time with a 45-min recording-time (n = 6 mice/treatment).  
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  b)  Ondansetron (19) 
 MD-354 is a 5-HT3 receptor partial agonist that can display both agonist and 
antagonist character (vide supra).  The purpose of the current study was to determine the 
effect of MD-354 (42) on the locomotor effects of psychomotor stimulants.  To further 
characterize the function of MD-354 (42), a 5-HT3 receptor agonist and a 5-HT3 receptor 
antagonist were used in combination with psychomotor stimulants.  Comparison of the 
results from a combination of MD-354 with stimulants, to that of SR 57227A (28), a 5-
HT3 receptor agonist, and ondansetron (19), a 5-HT3 receptor antagonist, with stimulants, 
should provide insight about the function of MD-354 (42). Therefore, dose-response 
studies were conducted with ondansetron (19) and SR 57227A (28), alone, and in 
combination with the stimulants amphetamine (2) and cocaine (1).   
 The present study analyzed the locomotor activity of the 5-HT3 receptor 
antagonist ondansetron (19) at doses 0.1, 0.5, and 1.0 mg/kg.  The protocol remained the 
same, with a 30-min pre-injection time followed by a 45-min recording-time.  When 
administered alone, ondansetron (19) produced saline-like effects on stimulant 
parameters (movement episodes, movement time, movement distance, and vertical entries 
as shown in Figure 20) as well as on non-stimulant parameters (margin distance, margin 
time, center distance, center time, and center entries, as shown in Figure 21), which was 
consistent with literature data indicating that ondansetron lacks central stimulant action 
when administered via the i.p. route.136 
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Figure 20.  Effect (± S.E.M.) of varying doses of ondansetron (19) (30-min pre-injection 
time) on total movement episodes, total movement time, total movement distance, and 
vertical entries versus saline with a 45-min recording-time (n = 6 mice/treatment). 
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Figure 21.  Effect (± S.E.M.) of varying doses of ondansetron (19) (30-min pre-injection 
time) on total margin distance, total margin time, total center distance, total center time, 
and total center entries versus saline with a 45-min recording-time (n = 6 mice/treatment). 
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 c) SR 57227A (28) 
 Locomotor activity assays were conducted with various doses of the agonist SR 
57227A (28) (1.0, 3.0, and 10 mg/kg) which were injected i.p. 30 min prior to the test 
with a recording-time of 45 min.  The same parameters were analyzed as with MD-354 
(42) with similar results; SR 57227A (28) produced saline-like effects as shown in Figure 
22.  Analysis of center entries using a t-test instead of one-way ANOVA showed that SR 
57227A (28) had a statistically significant effect versus saline at a 1.0 mg/kg dose, as SR 
57227A suppressed center entries, suggesting that SR 57227A displayed anxiogenic-like 
behavior in mice (Figure 23).  Even though SR 57227A doses were not statistically 
significant versus saline for either center distance or center time, the observed effect 
occurred in a dose-responsive manner, as a 1.0 mg/kg dose of SR 57227A was indicative 
of the upward slope of a dose-response curve. 
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Figure 22. Effect (± S.E.M.) of varying doses of SR 57227A (28) (30-min pre-injection 
time) on total movement episodes, total movement time, total movement distance, and 
total vertical entries versus saline with a 45-min recording-time (n = 7 mice/treatment). 
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Figure 23. Effect (± S.E.M.) of varying doses of SR 57227A (28) (30-min pre-injection 
time) on total margin distance, total margin time, total center distance, total center time, 
and total center entries versus saline with a 45-min recording-time (n = 7 mice/treatment).   
Asterisk denotes statistical significance compared to the saline control group; *P<0.05; t-
test.    
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  d) (+)Amphetamine (2) 
   i. Dose Response 
 A locomotor activity assay was performed with varying doses of (+)amphetamine 
(2) to determine an effective dose (i.e., a dose that produces a statistically significant 
effect versus saline).  In the present investigation, (+)amphetamine doses of 0.3, 1.0, 2.0, 
3.0, and 6.0 mg/kg were injected to the mice, which were immediately placed into the 
chamber (0-min pre-injection time) with a recording-time of 45 min.  After 15 min, 
(+)amphetamine (2) doses of 3.0 and 6.0 mg/kg produced a statistically significant 
stimulant effect on movement episodes, movement time, and movement distance (Figure 
24).  Similar effects were observed for the entire duration of the experiment.   
 Upon analyzing other parameters, it was observed that (+)amphetamine (2) 
produced no statistically significant difference versus saline on vertical entries, margin 
time, center distance, center time, and center episodes (Figure 25).  However, doses of 
3.0 and 6.0 mg/kg of (+)amphetamine statistically significantly increased margin distance 
during the entire recording-time as shown in Figure 24. 
 In order to visualize the stimulant effect of an effective dose of (+)amphetamine 
(2), a picture of the actual movements made by the animals following a 3.0 mg/kg dose of 
(+)amphetamine versus saline is shown in Figure 26.  
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Figure 24. Effect (± S.E.M.) of (+)amphetamine (2) injected 0 min prior to examination 
on total movement episodes, total movement time, total movement distance, and total 
margin distance with a 45-min recording-time (n = 6-8 mice/treatment).  Asterisk denotes 
a significant difference compared to the saline control group; **P<0.01, ***P<0.001; 
one-way ANOVA (F5,43 = 15.46 (movement episodes), F5,43 = 7.44 (movement time), 
F5,43 = 7.44 (movement distance), F5,43 = 8.05 (margin distance)) followed by a Newman-
Keuls post-hoc test. 
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Figure 25.  Effect (± S.E.M.) of (+)amphetamine (2) injected 0 min prior to examination 
on total vertical entries, total margin time, total center distance, total center time, and 
total center entries with a 45-min recording-time (n = 6-8 mice/treatment).  
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Figure 26.  Graphical representation of the movement distance for the entire duration (45 
min) of the experiment.  A) The actual locomotion of a mouse when injected with saline.  
B) Stimulation by injection of an effective dose of (+)amphetamine (3.0 mg/kg). 
 
   ii. Combination of (+)Amphetamine (2) and MD-354 (42) 
 An effective dose of (+)amphetamine (3.0 mg/kg) was examined in combination 
with varying doses of MD-354 (42).  The protocol entailed injecting varying doses of 
MD-354 (1.0, 3.0, and 10 mg/kg) i.p. 30 min prior to the test.  (+)Amphetamine (2) was 
injected 0 min prior to the experiment and the mice were placed in the chamber with a 
45-min recording-time.  Combination of MD-354 with an effective dose of 
(+)amphetamine neither potentiated or modulated the stimulant effect of 
(+)amphetamine. For both stimulant and non-stimulant parameters (movement episodes, 
movement time, movement distance, vertical entries, margin distance, margin time, 
center distance, center time, and center entries), which were separated for convenience, 
results were essentially the same following administration of (+)amphetamine (2) alone, 
and following administration of (+)amphetamine in combination with doses of MD-354 
(42) (Figure 27 and Figure 28).  Although combinations of MD-354 with 
A B
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(+)amphetamine were not statistically significant, the effects of MD-354 on 
(+)amphetamine were dose dependent for the parameters center distance and center 
entries. 
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Figure 27. Effect (± S.E.M.) of combination of (+)amphetamine (2) (3.0 mg/kg) with 
varying doses of MD-354 (42) on total movement episodes, total movement time, total 
movement distance, and vertical entries following a 30-min pre-injection time of MD-354 
and a 45-min recording-time (n = 7-8 mice/treatment).  
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Figure 28. Effect (± S.E.M.) of combination of (+)amphetamine (2) (3.0 mg/kg; 0-min 
pre-injection time) with varying doses of MD-354 (42) (30-min pre-injection time) on 
total margin distance, total margin time, total center distance, total center time, and total 
center entries with a 45-min recording-time (n = 7-8 mice/treatment).  
 
 72
 A similar study was conducted using doses of 1.0, 3.0, and 10 mg/kg of MD-354 
(42) (30-min pre-injection time) in combination with a moderate dose of (+)amphetamine 
(2) (2.0 mg/kg; 0-min pre-injection time).  The obtained results were similar to those 
observed with an effective dose of (+)amphetamine (3.0 mg/kg) alone, on all parameters 
observed (data not shown). 
 
   iii. Combination of (+)Amphetamine (2) and Ondansetron (19) 
 The effect of the 5-HT3 receptor antagonist ondansetron (19) on the actions of an 
effective dose of (+)amphetamine (2) was examined.  Doses of 0.1, 0.5, and 1.0 mg/kg of 
ondansetron were injected i.p., 30 min prior to the test.  (+)Amphetamine (2; 3.0 mg/kg) 
was injected 0 min before the test and a 45-min recording-time was employed.  In 
combination, ondansetron (19) neither potentiated nor modulated the action of an 
effective dose of (+)amphetamine.  For parameters analyzed (movement episodes, 
movement distance, movement time, vertical entries, margin distance, margin time, 
center time, and center entries), the effect of ondansetron pre-treatment on the actions of 
(+)amphetamine were not different than that following administration of (+)amphetamine 
alone (Figure 29 and Figure 30), except at a 1.0 mg/kg dose of ondansetron, which 
potentiated the effect of (+)amphetamine on the parameter center distance (Figure 30).  
Since doses of ondansetron in combination with (+)amphetamine decreased margin 
distance and margin time, while increasing center measures, ondansetron in combination 
with (+)amphetamine was producing an anxiolytic-like effect.  Even though this effect 
was not statistically significant in most cases, it was dose dependent. 
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Figure 29.  Effect (± S.E.M.) of varying doses of ondansetron (19) (30-min pre-injection 
time) in combination with 3.0 mg/kg of (+)amphetamine (2) (0-min pre-injection time) 
on the stimulant parameters of total movement episodes, total movement time, total 
movement distance, and total vertical entries with a 45-min recording-time (n = 6-8 
mice/treatment). 
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Figure 30.  Effect (± S.E.M.) of varying doses of ondansetron (19) (30-min pre-injection 
time) in combination with 3.0 mg/kg of (+)amphetamine (2) (0-min pre-injection time) 
on total margin distance, total margin time, total center distance, total center time, and 
total center entries with a 45-min recording-time (n = 6-8 mice/treatment). 
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   iv. Combination of (+)Amphetamine (2) and SR 57227A (28) 
 To determine the effects of the 5-HT3 receptor agonist SR 57227A (28) on the 
effects produced by a moderate dose of (+)amphetamine (2) (2.0 mg/kg), studies with 
combinations of both drugs were conducted.  In the present investigation, SR 57227A 
(28) was administered 30 min prior to testing at i.p. doses of 1.0, 3.0, and 10 mg/kg.  
(+)Amphetamine (2) was administered 0 min prior to test.  Within 15 min of the initiation 
of the experiment, potentiation of stimulant effects was observed; the effects lasted 30 
min.  The parameters affected by this combination included movement episodes, 
movement time, movement distance and margin distance for the first 15-min interval, and 
only movement episodes and movement distance for the second 15-min interval.  For the 
parameters mentioned above, potentiation occurred at a 3.0 mg/kg dose of SR 57227A 
(28) with 2.0 mg/kg of (+)amphetamine (2), except movement episodes, where 
potentiation was observed with both 3.0 mg/kg and 10 mg/kg doses of SR 57227A 
(Figure 31).  The other parameters (vertical entries, margin time, center distance, center 
time, and center entries) revealed amphetamine-like effects throughout the entire 
experiment (Figure 32).  Comparison of the data indicated that SR 57227A (28) 
potentiated the stimulant effect of a moderate dose of (+)amphetamine (2) and that this 
potentiation occurred in a dose-dependent manner.   
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Figure 31.  Effect (± S.E.M.) of varying doses of SR 57227A (28) (injected 30 min prior 
to examination) on a moderate dose of (+)amphetamine (2) (injected 0 min prior to 
examination) after the first 15-min interval of a 45-min protocol (n = 8 mice/treatment).  
Asterisk denotes a significant difference compared to a 2.0 mg/kg dose of 
(+)amphetamine; *P<0.05, **P<0.01, and ***P<0.001; one-way ANOVA (F4,41 = 19.52 
(movement episodes), F4,41 = 16.15 (movement time), F4,41 = 13.68 (movement distance), 
and F4,41 =  10.36 (margin distance)) followed by a Newman-Keuls post-hoc test. 
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Figure 32.  Effect (± S.E.M.) of varying doses of SR 57227A (28) (30-min pre-injection 
time) on a moderate dose of (+)amphetamine (2) (2.0 mg/kg, 0-min pre-injection time) on 
total vertical entries, total margin time, total center distance, total center time, and total 
center entries with a 45-min recording-time (n = 6-8 mice/treatment).     
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  e)  (+)Methamphetamine (3) 
   i. Dose Response 
 A mouse locomotor activity assay was conducted to determine an effective dose 
of (+)methamphetamine (3).  Varying doses of (+)methamphetamine (0.3, 1.0, 1.5, 3.0 
and 10 mg/kg) were injected i.p. 0 min before the mice were placed in the chamber with a 
recording-time of 60 min.  Within the first 15-min interval, doses of 
(+)methamphetamine (3) displayed statistically significant stimulant effects versus saline.  
These effects varied between different doses and different parameters for the entire 60-
min trial.  Upon analysis of stimulant parameters, (+)methamphetamine (3) produced a 
statistically significant stimulant effect versus saline at doses of 1.5, 3.0 and 10 mg/kg on 
movement episodes, movement time, and movement distance within the first 15 min 
(Figure 33) and on various doses for the same three parameters for the entire duration of 
the experiment (Figure 34). These stimulant effects were observed at lower doses, than 
with those of (+)amphetamine, supporting the idea the (+)methamphetamine is the more 
potent stimulant. (+)Methamphetamine (3) also produced a statistically significant effect 
on vertical entries and margin distance from the first 15-min interval throughout the 
experiment (Figure 34).  Center entries were statistically significantly increased within 30 
min (data not shown) and continued so for the duration of the 60-min experiment (Figure 
34).  Parameters not affected by varying doses of (+)methamphetamine (3) include 
margin time, center distance, and center time (Figure 35).   
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Figure 33.  Effect (± S.E.M.) of varying doses of (+)methamphetamine (3) (0.3, 1.0, 1.5, 
3.0, and 10 mg/kg; 0-min pre-injection) on the stimulant parameters of movement 
episodes, movement time, and movement distance within 15 min of a 60-min protocol (n 
= 6-8 mice/treatment).  Asterisk denotes a significant difference compared to the saline 
control group; **P<0.05, **P<0.01, ***P<0.001; one-way ANOVA (F5,39 = 14.83 
(movement episodes), F5,39 = 15.49 (movement time), F5,39 = 10.08 (movement distance)) 
followed by a Newman-Keuls post-hoc test. 
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Figure 34.  Effect (± S.E.M.) of varying doses of (+)methamphetamine (3) (0-min pre-
injection) on total movement episodes, total movement time, total movement distance, 
total vertical entries, total margin distance, and total center entries with a 60-min protocol 
(n = 6-8 mice/treatment).  Asterisk denotes a significant difference compared to the saline 
control group; **P<0.05, **P<0.01, ***P<0.001; one-way ANOVA (F5,39 = 13.58 
(movement episodes), F5,39 = 14.63 (movement time), F5,39 = 25.01(movement distance), 
F5,39 = 13.89 (vertical entries), F5,39 = 7.89 (margin distance), F5,39 = 5.16 (center entries)) 
followed by a Newman-Keuls post-hoc test. 
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Figure 35.  Effect (± S.E.M.) of varying doses of (+)methamphetamine (3) (0-min pre-
injection time) on total margin time, total center distance, and total center time with a 60-
min recording-time (n = 6-8 mice/treatment).   
 
   ii.  Combination (+)Methamphetamine (3) and MD-354 (42) 
 The effect of varying doses of MD-354 (42) on an effective dose of 
(+)methamphetamine (3) was examined.  MD-354 (42) doses of 0.3, 1.0, 3.0, and 6.0 
mg/kg were administered i.p. 0 min prior to the experiment.  (+)Methamphetamine (1.5 
mg/kg) was administered 0 min prior to the experiment and the recording-time was 1 h.  
For all parameters analyzed, administration of MD-354 in combination with 
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(+)methamphetamine neither potentiated nor modulated the stimulant effect of 
(+)methamphetamine.  A combination of MD-354 (42) and (+)methamphetamine (3) 
produced similar effects as (+)methamphetamine administered alone.  The parameters 
analyzed included movement episodes, movement time, movement distance, vertical 
entries, margin distance, margin time, center distance, center time, and center entries as 
shown in Figure 36 and Figure 37. 
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Figure 36. Effect (± S.E.M.) of varying doses of MD-354 (42) (0.3, 1.0, 3.0, and 6.0 
mg/kg; 0-min pre-injection time) on an effective dose of (+)methamphetamine (3) (1.5 
mg/kg; 0-min preinjection time) on total movement episodes, total movement time, total 
movement distance, and total vertical entries with a 60-min recording-time (n = 6-8  
mice/treatment). 
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Figure 37.  Effect (± S.E.M.) of varying doses of MD-354 (42) (0.3, 1.0, 3.0, and 6.0 
mg/kg; 0-min pre-injection time) on an effective dose of (+)methamphetamine (3) (1.5 
mg/kg; 0-min preinjection time) on total margin distance, total margin time, total center 
distance, total center time and total center entries with a 60-min recording-time (n = 6-8 
mice/treatment). 
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 A similar protocol was employed using a 3.0 mg/kg dose of (+)methamphetamine 
(3) in combination with 1.0, 3.0, and 6.0 mg/kg doses of MD-354.  The pre-injection and 
recording-times remained the same, resulting in similar effects as observed with a 
combination of 1.5 mg/kg (+)methamphetamine (3) and varying doses of MD-354 (42): 
combination of MD-354 with (+)methamphetamine neither potentiated nor modulated the 
stimulant effects of (+)methamphetamine (data not shown).   
 
  f)  DOM (10) 
   i. Dose Response 
 A locomotor activity assay was conducted to determine an effective dose of DOM 
(10) and to determine its effects on mouse locomotor actions.  Varying doses of DOM 
(0.3, 1.0, and 3.0 mg/kg) were injected i.p. 0 min before the mice were placed in the 
chamber, with a recording-time of 60 min.  After 15 min, DOM (10) behaved similarly to 
saline at all administered doses.  However, within 30 min of the experiment, movement 
distance and margin distance were statistically significantly increased following all doses.  
Within 45 min, doses of 0.3 and 1.0 mg/kg of DOM (10) statistically significantly 
increased movement distance and margin distance.  However, only a 0.3 mg/kg dose of 
DOM (10) increased vertical entries.  Following 60 min post administration, DOM 
increased locomotor activity on the parameters of movement time, movement distance, 
vertical entries, and margin distance versus saline as shown in Figure 38.  Throughout the 
entire study, DOM produced a saline-like effect on the parameters of movement episodes, 
margin time, center distance, center time, and center entries (Figure 39).   
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Figure 38.  Effect (± S.E.M.) of varying doses of DOM (10) (0-min pre-injection time) 
on total movement time, total movement distance, vertical entries, and margin distance 
with a 60-min recording-time (n = 6-8 mice/treatment).  Asterisk denotes statistical 
significance compared to the saline control group; *P<0.05, **P<0.01, ***P<0.001; one-
way ANOVA (F3,28 = 3.5 (movement time), F3,28 = 5.03 (movement distance), F3,28 = 
4.15 (vertical entries), F3,28 = 6.54 (margin distance)) followed by a Newman-Keuls post-
hoc test. 
 
 
 
 86
 
Saline 0.3 1.0 3.0
0
150
300
450
600
                           DOM Dose (mg/kg)
M
ov
em
en
t E
pi
so
de
s
Saline 0.3 1.0 3.0
0
900
1800
2700
3600
                         DOM Dose (mg/kg)
M
ar
gi
n 
Ti
m
e 
(s
)
Saline 0.3 1.0 3.0
0
300
600
900
1200
                         DOM Dose (mg/kg)
C
en
te
r 
D
is
ta
nc
e 
(c
m
)
Saline 0.3 1.0 3.0
0
300
600
900
                       DOM Dose (mg/kg)
C
en
te
r 
Ti
m
e 
(s
)
 
Saline 0.3 1.0 3.0
0
100
200
300
                      DOM Dose (mg/kg)
C
en
te
r 
En
tr
ie
s
 
Figure 39.  Effect (± S.E.M.) of varying doses of DOM (10) (0-min pre-injection time) 
on total movement episodes, total margin time, total center distance, total center time, 
and total center entries with a 60-min recording-time (n = 6-8 mice/treatment).  
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   ii.  Combination of DOM (10) and MD-354 (42) 
 The next step was to determine the effect of MD-354 (42) on an effective 
behavioral dose of DOM (10).  A study was conducted using 0.1, 1.0, 3.0, and 6.0 mg/kg 
doses of MD-354 (42) (30-min pre-injection time) in combination with a 0.3 mg/kg dose 
of DOM (10) (0-min pre-injection time).  The recording-time of the experiment was 60 
min.   Within 15 min of the initiation of the experiment, a low dose of MD-354 (0.1 
mg/kg) antagonized the effect of DOM on movement distance, vertical entries, and center 
entries (a 1.0 mg/kg dose of MD-354 also antagonized the effect DOM displayed on 
vertical entries).  As the experiment continued, MD-354 (42) antagonized various other 
parameters at various doses.  Some parameters effected include movement time, 
movement distance, vertical entries, margin distance, center distance, and center entries 
as shown in Figure 40.  The effect DOM (10) had on vertical entries alone and in 
combination with MD-354 (42) is shown in Figure 41.  Combination of MD-354 with 
DOM produced similar results as DOM administered alone on movement episodes, 
margin time, and center time throughout the duration of the experiment (as shown in 
Figure 42). 
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Figure 40.  Effect (± S.E.M.) of varying doses of MD-354 (42) (30-min pre-injection 
time) on an effective dose of DOM (10) (0.3 mg/kg; 0-min pre-injection time) on total 
movement time, total movement distance, total vertical entries, total margin distance, 
total center distance, and total center entries with a 60-min recording-time (n = 6-8 
mice/treatment).  Asterisk denotes statistical significance compared to a 0.3 mg/kg dose 
of DOM; *P<0.05, **P<0.01, ***P<0.001; one-way ANOVA (F5,41 = 2.74 (movement 
time), F5,41 = 4.43 (movement distance), F5,41 = 5.31 (vertical entries), F5,41 = 4.49 
(margin distance), F5,41 = 1.30 (center distance) F5,41 = 2.48 (center entries)) followed by 
a Newman-Keuls post-hoc test. 
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Figure 41.  Graphical representation of vertical entries for the entire duration (60 min) of 
the experiment. A) Vertical entries of mice when administered saline. B) Vertical entries 
of mice when administered 0.3 mg/kg dose of DOM.  C) Vertical entries of combination 
of 1.0 mg/kg dose of MD-354 and 0.3 mg/kg dose of DOM. 
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Figure 42.  Effect (± S.E.M.) of varying doses of MD-354 (42) (30-min pre-injection 
time) on an effective dose of DOM (10) (0.3 mg/kg; 0-min pre-injection time) on total 
movement episodes, total margin time, and total center time with a 60-min recording-
time (n = 6-8 mice/treatment). 
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  g) Cocaine (1) 
   i. Dose Response 
 The present study was conducted to determine an effective dose of cocaine (1).  
Varying doses of cocaine (1) (1.0, 3.0, 10, and 30 mg/kg) were administered i.p. 0 min 
prior to the experiment.  The mice were placed in the chamber and tested for 45 min.  
Within the first 15 min, locomotor activity was statistically significantly decreased versus 
saline on the stimulant parameter of movement episodes (30 mg/kg), whereas activity 
was significantly increased for movement time (30 mg/kg) and movement distance (10 
and 30 mg/kg) as shown in Figure 43, as well as following 10 and 30 mg/kg doses of 
cocaine (1) on the non-stimulant parameters of margin distance and margin time (Figure 
43).  Statistically significant decreases in center distance and center time were observed 
versus saline at doses of 10 and 30 mg/kg of cocaine (Figure 44).  Within 30 min, the 
only effects observed were statistically significant increases on the stimulant parameters 
of movement episodes, movement time, movement distance, and margin distance. By 45 
min, movement time, movement distance, and margin distance were still increased 
following 10 and 30 mg/kg doses of cocaine, as well as statistically significantly increase 
in vertical entries versus saline (Figure 45).   Overall, cocaine produced a saline-like 
effect at all doses administered on total vertical entries, total margin time, total center 
distance, total center time, and total center entries (Figure 46), however the effects on 
vertical entries, center distance and center time were dose-dependent. 
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Figure 43. Effect (± S.E.M.) of varying doses of cocaine (1) (0-min pre-injection time;  
45-min recording-time) on movement episodes, movement time, movement distance and 
margin distance within the first 15-min (n = 6-8 mice/treatment). Asterisk denotes 
statistical significance compared to the saline control group; *P<0.05, **P<0.01, 
***P<0.001; one-way ANOVA (F4,43 = 6.78 (movement episodes), F4,43 = 5.37 
(movement time), F4,43 = 6.32 (movement distance), F4,43 = 6.45 (margin 
distance))followed by a Newman-Keuls post-hoc test. 
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Figure 44. Effect (± S.E.M.) of varying doses of cocaine (1) (0-min pre-injection time; 
45-min recording-time) on margin time, center distance and center time within the first 
15-min (n = 6-8 mice/treatment). Asterisk denotes statistical significance compared to the 
saline control group; *P<0.05, **P<0.01, ***P<0.001; one-way ANOVA (F4,43 = 4.91 
(margin time) F4,43 = 4.36 (center distance), F4,43 = 4.91 (center time)) followed by a 
Newman-Keuls post-hoc test. 
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Figure 45.  Effect (± S.E.M.) of varying doses of cocaine (1) (0-min pre-injection time; 
45-min recording-time) on total movement episodes, total movement time, total 
movement distance, total margin distance (n = 6-8 mice/treatment). Asterisk denotes 
statistical significance compared to the saline control group; **P<0.01 and ***P<0.001; 
one-way ANOVA (F4,43 = 5.09 (movement episodes), F4,43 = 7.67 (movement time), F4,43 
= 9.02 (movement distance), F4,43 = 8.31 (margin distance)) followed by a Newman-
Keuls post-hoc test. 
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Figure 46.  Effect (± S.E.M.)  of varying doses of cocaine (1) (0-min pre-injection time; 
45-min recording-time) on total vertical entries, total margin time, total center distance, 
total center time, and total center entries (n = 6-8 mice/treatment). 
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ii. Combination of Cocaine (1) and MD-354 (42) 
 The effect of varying doses of the 5-HT3 receptor partial agonist, MD-354 (42) 
(1.0, 3.0, and 10 mg/kg) on an effective dose of cocaine (1) (10 mg/kg) was examined.  
MD-354 (42) was administered 30 min prior to examination, followed by cocaine (1) 
administered 0 min prior to examination.  The recording-time for the present 
investigation was 45 min.  Within the first 15 min, in combination with cocaine (1), MD-
354 (42) potentiated the stimulant effect that cocaine displayed when administered alone.  
This potentiation was observed with a decrease in movement episodes and an increase in 
movement time as shown in Figure 47.  Within this first 15 min all other parameters 
behaved similarly to cocaine when administered alone (data not shown).   
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Figure 47.  Effect (± S.E.M.) of varying doses of MD-354 (42) (30-min pre-injection 
time) on a effective dose of cocaine (1) (10 mg/kg; 0-min pre-injection time) within the 
first 15-min of the 45-min protocol (n = 6-8 mice/treatment). Asterisk denotes statistical 
significance compared to a 10 mg/kg dose of cocaine; *P<0.05 and **P<0.01; one-way 
ANOVA (F4,43 = 16.90 (movement episodes) and F4,43 = 23.73 (movement time)) 
followed by a Newman-Keuls post-hoc test. 
  
 
 97
 Within 30 min of the experiment, a separate set of parameters were affected.  
Instead of stimulant parameters being potentiated as within the first 15 min, vertical 
entries, center distance, and center entries were potentiated as shown in Figure 48.  
Vertical entries were potentiated at all doses of MD-354 (42) versus cocaine (1), whereas 
6.0 mg/kg dose of MD-354 in combination with cocaine potentiated the effect on the 
parameters center distance and center entries versus cocaine alone (Figure 48).   
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Figure 48.  Effect (± S.E.M.) of varying doses of MD-354 (42) (30-min pre-injection 
time) on an effective dose of cocaine (1) (0-min pre-injection) within 30 min of the 45-
min protocol (n = 6-8 mice/treatment).  Asterisk denotes statistical significance compared 
to a 10 mg/kg dose of cocaine; *P<0.05 and **P<0.01; one-way ANOVA (F4,43 = 17.92 
(vertical entries), F4,43 = 2.37 (center distance), F4,43 = 5.88 (center entries)) followed by a 
Newman-Keuls post-hoc test. 
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 Movement distance, margin distance, margin time, and center time were not 
affected by the combination of MD-354 (42) with cocaine (1) at any dose combinations 
administered. For these parameters, combination of MD-354 with an effective dose of 
cocaine (10 mg/kg) produced a cocaine-like effect (Figure 49).  
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Figure 49.  Effect (± S.E.M.) of varying doses of MD-354 (42) (30-min pre-injection 
time) on an effective dose of cocaine (1) (0-min pre-injection time) for total movement 
distance, total margin distance, total margin time, and total center time with a 45-min 
recording-time (n = 6-8 mice/treatment). 
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   iii. Combination of Cocaine (1) and Ondansetron (19) 
 The effect of varying doses of the 5-HT3 receptor antagonist ondansetron (19) was 
examined in combination with an effective dose of cocaine (1).  Varying doses of 
ondansetron (0.1, 0.5, and 1.0 mg/kg) were injected i.p. 30 min prior to the experiment.  
A 10 mg/kg dose of cocaine was injected 0 min prior to the experiment; the recording-
time of the experiment was 45 min.  Within the first 15 min only one parameter was 
affected; movement episodes were suppressed by a 0.5 mg/kg dose of ondansetron (19) 
as shown in Figure 50.  The stimulant effect of cocaine was potentiated by addition of the 
5-HT3 receptor antagonist ondansetron (19).   
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Figure 50.  Effect (± S.E.M.) of varying doses of ondansetron (19) (30-min pre-injection 
time) on an effective dose of cocaine (1) (10 mg/kg; 0-min pre-injection time) observed 
within the first 15-min of the 45-min protocol (n = 6-8 mice/treatment).  Asterisk denotes 
statistical significance compared to a 10 mg/kg dose of cocaine; *P<0.05; one-way 
ANOVA (F4,40 = 8.11 (movement episodes)) followed by  a Newman-Keuls post-hoc 
test. 
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Within 30 min, only one parameter was affected by the combination of 
ondansetron (19) with cocaine (1); when administered together, ondansetron (0.5 and 1.0 
mg/kg doses) potentiated the effect of cocaine on center entries as shown in Figure 51. 
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Figure 51.  Effect (± S.E.M.) of varying doses of ondansetron (19) (30-min pre-injection 
time) on a 10 mg/kg dose of cocaine (1) (0-min pre-injection time) observed within 30-
min of the 45-min protocol (n = 6-8 mice/treatment).  Asterisk denotes statistical 
significance compared to a 10 mg/kg dose of cocaine; *P<0.05 and **P<0.01; one-way 
ANOVA (F4,40 = 5.81 (center entries)) followed by Newman-Keuls post-hoc test. 
  
Within 45 min of initiation of the experiment, the effect of ondansetron (29) on 
cocaine (1) shifted to margin distance. The effect of cocaine was suppressed by 0.1 and 
1.0 mg/kg of ondansetron in an inverted U-shape dose response manner as shown in 
Figure 52. 
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Figure 52.  Effect (± S.E.M.) of varying doses of ondansetron (19) (30-min pre-injection 
time) on a 10 mg/kg dose of cocaine (1) (0-min pre-injection time) observed within 45-
min (n = 6-8 mice/treatment).  Asterisk denotes statistical significance compared to a 10 
mg/kg dose of cocaine; *P<0.05; one-way ANOVA (F4,40 = 4.59 (margin distance)) 
followed by a Newman-Keuls post-hoc test. 
 
 Only one parameter was affected by the combination of ondansetron with cocaine 
in each 15-min interval.  However, upon analysis of the entire study, combination of 
varying doses of ondansetron (19) with an effective dose of cocaine (1) neither 
potentiated nor antagonized the effect of cocaine when administered alone.  This was 
observed for all parameters analyzed for total time of the experiment (movement 
episodes, movement time, movement distance, margin distance, margin time, center 
distance, and center time as shown in Figure 53 and Figure 54) except center entries 
which were potentiated at 0.5 and 1.0 mg/kg doses of ondansetron.  Although statistically 
significant changes were not observed, the effects of ondansetron on cocaine were dose 
dependent. 
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Figure 53.  Effect (± S.E.M.) of varying doses of ondansetron (19) (30-min pre-injection 
time) in combination with an effective dose of cocaine (1) (0-min pre-injection time) on 
total movement episodes, total movement distance, total movement time, total vertical 
entries with a 45-min recording-time (n = 6-8 mice/treatment). 
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Figure 54.  Effect (± S.E.M.) of varying doses of ondansetron (19) (30-min pre-injection 
time) in combination with an effective dose of cocaine (1) (0-min pre-injection time) on 
total margin distance, total margin time, total center distance, total center time, and total 
center entries with a 45-min recording-time (n = 6-8 mice/treatment). 
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iv. Combination of Cocaine (1) and SR 57227A (28) 
 Combination studies of the 5-HT3 receptor agonist SR 57227A (28) with an 
effective dose of cocaine on locomotor activity were conducted.  The present 
investigation employed 1.0, 3.0, and 10 mg/kg doses of SR 57227A (28) (30-min pre-
injection time) in combination with a 10 mg/kg dose of cocaine (1) (0-min pre-injection 
time) administered i.p.  The recording-time of the experiment was 45 min.  Within the 
first 15 min, the stimulant effect of cocaine was potentiated as evidenced by increasing 
the parameters of movement episodes and movement time.  This effect was observed 
following all three administered doses of SR 57227A (28) in combination with cocaine as 
opposed to the effect observed with cocaine (1) administered alone (Figure 55).  Also, 
within the first 15-min interval, the effect of cocaine was antagonized by a 1.0 mg/kg 
dose of SR 57227A.  When administered alone, cocaine (1) suppressed center entries, 
however in combination with SR 57227A (28), the number of center entries was 
increased (Figure 55). 
 These were the only parameters influenced by the combination of varying doses 
of SR 57227A with an effective dose of cocaine.  For the duration of the experiment, the 
combination of SR 57227A (28) and cocaine (1) behaved similarly to cocaine 
administered alone for all parameters analyzed (movement episodes, movement time, 
movement distance, vertical entries, margin distance, margin time, center distance, center 
time and center entries as shown in Figure 56 and Figure 57). 
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Figure 55.  Effect (± S.E.M.) of SR 57227A (28) (30-min pre-injection time) on an 
effective dose of cocaine (1) (0-min pre-injection time) within the first 15-min of the 
experiment of a 45-min protocol (n = 6-8 mice/treatment).  Asterisk denotes statistical 
significance compared to a 10 mg/kg dose of cocaine; *P<0.05, **P<0.01, ***P<0.001; 
one-way ANOVA (F4,40 = 20.38 (movement episodes), F4,40 = 25.01 (movement time), 
F4,40 = 2.55 (center entries)) followed by Newman-Keuls post-hoc test. 
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Figure 56.  Effect (± S.E.M.) of SR 57227A (28) (30-min pre-injection time) in 
combination with cocaine (1) (0-min pre-injection time) on total movement episodes, 
total movement distance, total movement time, and vertical entries with a 45-min 
recording-time (n = 6-8 mice/treatment). 
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Figure 57.  Effect (± S.E.M.) of SR 57227A (28) (30-min pre-injection time ) in 
combination with cocaine (1) (0-min pre-injection time) on total margin distance, total 
margin time, total center distance, total center time, and total center entries with a 45-min 
recording-time (n = 6-8 mice/treatment). 
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 2. Discussion 
 The purpose of the present study was to determine the influence of the 5-HT3 
receptor partial agonist MD-354 on the locomotor actions of psychomotor stimulants (as 
5-HT3 receptor ligands have been shown to indirectly affect dopamine levels) and if this 
effect could be characterized as acting through a 5-HT3 receptor agonist or 5-HT3 
receptor antagonist mode of action.  The present investigation was conducted in order to 
determine the locomotor effects of the phenylalkylamine stimulant (+)amphetamine (2) in 
combination with MD-354 (42), ondansetron (19), and SR 57227A (28) as compared to 
similar tests using cocaine (1) (a non-phenylalkylamine stimulant) with the same 5-HT3 
receptor ligands.  (+)Methamphetamine (3) (a structurally similar amphetamine 
phenylalkylamine stimulant) and DOM (10) (a phenylalkylamine non-stimulant used as a 
control) were also administered in combination with MD-354 to determine the effects of 
MD-354 in combination with these drugs of abuse, on locomotor activity.  The overall 
effects of these agents and drug combinations are shown in Table 5. 
 Varying doses of the 5-HT3 receptor ligands were administered alone to determine 
whether or not they bestowed an effect versus saline.  When administered alone, MD-354 
had no effect on mouse locomotor activity (Table 5).  These data are consistent with and 
further extend earlier findings.  Dukat et al. investigated the effect of MD-354 (42) on 
mouse locomotor activity at doses ranging from 1.0 to 10 mg/kg; results suggested that 
MD-354 produces saline-like effects on locomotor activity.12   Ondansetron was found to 
behave similarly to MD-354; the saline-like effect of ondansetron was consistent with  
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Table 5.  Summary of the effects of all drugs tested in the mouse locomotor activity assay.a 
Measure:     Movement   Movement Movement Vertical Margin      Margin Center        Center  Center 
         Episodes        Time    Distance  Entries Distance    Time Distance      Time Entries 
MD-354                -     -        -      -        -            -                  -  -       - 
Ondansetron         -     -        -      -        -            -                  -  -       - 
SR 57227A         -     -        -      -        -            -                  -  -      ↑ 
(+)Amph         ↓    ↑       ↑      -        ↑               -       -                 -                - 
 + MD-354             -     -        -                 -                         -               -                  -                -                 - 
 + Ondan                -     -        -      -        ↓            ↓                  ↑  -       - 
 + SR 57227A         ↓     ↑                         ↑      -                   ↑            -                  -                -                 -  
(+)Meth        ↓    ↑       ↑      ↑        ↑            -                  -                -                ↑ 
  + MD-354            -                  -                         -                      -                        -               -                   -               -                 - 
DOM          -    ↑                        ↑                     ↑                        ↑              -                   ↓               -                 -       
  + MD-354            -                 ↓                        ↓                     ↓                        ↓              -                   ↓               -                ↓ 
Cocaine                  ↓                ↑                        ↑                     ↑                        ↑              ↑                  ↓               ↓                 - 
  + MD-354            ↓                ↑                         -                      ↑                        -              -                  ↑                -                ↑  
  + Ondan               ↓                 -                         -                     -                        ↓               -                   -                -               ↑ 
  + SR 57227A        ↓                ↑                         -                     -                          -              -                   -                -               ↑ 
a. The “-” symbol indicates no change in effect compared to control, the “↑” symbol indicates an increase in effect versus 
control, and the “↓” indicates a decrease in effect versus control.  See text for a more detailed description and discussion of the 
effects.
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that which was found in the literature.  Ramamoorthy et al. published a paper discussing 
the antidepressant potential of the 5-HT3 receptor antagonist ondansetron (19).137  In this 
study, locomotor activity was characterized as “locomotor scores”, analyzing various 
doses of ondansetron (0.005-1000 μg/kg).137  For the entire dose range, ondansetron 
produced saline-like effects in mice.137  Analysis of SR 57227A, when administered 
alone, also resulted in saline-like effects, with the exception of center entries (Table 5); 
this effect was only statistically significant when analyzed using the t-test instead of a 
one-way ANOVA which was employed for testing the significance of other parameters.  
The saline-like effect of SR 57227A is consistent with literature findings. Yoo et al. 
analyzed the effect of SR 57227A (28) on locomotor activity and showed that SR 
57227A did not produce locomotor stimulation when administered alone on the stimulant 
parameter of distance traveled (movement distance).138 For all three 5-HT3 receptor 
ligands, the results observed in the present investigation are consistent with literature 
findings, even though not exactly the same types of parameters were measured. The 5-
HT3 receptor ligands are considered to not display any effect on mouse locomotor 
activity when administered alone. 
 For each drug of abuse, varying doses were administered in order to determine an 
effective dose of each drug.  An effective dose of (+)amphetamine (2) was determined to 
be 3.0 mg/kg as this dose (as well as a 6.0 mg/kg dose) increased the effect on the 
common stimulant parameters of movement time and movement distance, while 
decreasing movement episodes. Movement episodes are counted as one movement 
episode being equivalent to the entirety of the movement between the initial start until the 
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rodent stops.  Therefore, if the mouse is continuously walking, movement time and 
distance would increase, whereas movement episodes would decrease. The effect on 
margin distance was also potentiated by 3.0 and 6.0 mg/kg doses of (+)amphetamine (2), 
suggesting that the activity of the rodent was not only stimulated by (+)amphetamine, but 
the rodent also began to display anxiogenic-like behavior.   Mcgeehan et al. showed that 
the locomotor activity parameter average distance traveled was significantly increased 
following administration of 3.0 and 5.0 mg/kg doses of (+)amphetamine versus saline.139  
Data from Glennon et al.  further support this idea as locomotor activity (measured as 
interruptions of photocell beam breaks) at even lower doses (1.0 mg/kg doses) of racemic 
amphetamine injected i.p. increased locomotion in mice.140  However, doses of 0.3 mg/kg 
produced saline-like effects.140  It is important to note, although Glennon’s study was 
conducted using racemic amphetamine instead of one isomer, such as (+)amphetamine 
(2) used in the current study, the use of a different type of locomotor activity apparatus 
might account for the lower effective dose observed in the Glennon studies.140  Bushnell 
also reported on the dose-dependent stimulant response of (+)amphetamine (0.3 to 10 
mg/kg i.p.) on locomotor activity in mice;141 the findings of the present investigation 
were consistent with the literature findings.  It is important to note that an immense 
amount of research has been published (thousands of papers) on dose response curves of 
all four drugs ((+)amphetamine, (+)methamphetamine, DOM, and cocaine) in locomotor 
activity assays using both mice and rats. Since this literature is so exhaustive, only a few 
references have been cited.  But, in general where literature data are available, they are 
not inconsistent with the present findings. 
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 With many drugs of abuse, dose-response studies can be conducted to 
demonstrate how increasing doses have an effect on particular parameters, such as 
increasing movement distance with increasing doses of (+)amphetamine (2).  Eventually, 
however, a threshold is reached, where the dose of administered drug results in 
stereotypy.  In dose response curves this is often observed as either a plateau or even a 
decrease in effect, creating an inverted U-shaped curve.126 
 Since MD-354 (42) is a 5-HT3 receptor partial agonist, it has the potential to 
behave as either an agonist or an antagonist, and could possibly potentiate or antagonize 
the effect of (+)amphetamine (2) when administered in combination by indirectly 
influencing dopamine levels.   Therefore, both an effective dose (3.0 mg/kg) and 
moderate dose (2.0 mg/kg) of (+)amphetamine (2) were used in combination with MD-
354 (42), in case MD-354 was to potentiate the effect of (+)amphetamine to the point of 
stereotypy.  Drug discrimination studies in rats have been conducted using similar dose 
combinations of (+)amphetamine and MD-354; data showed MD-354 enhances the 
stimulus effects of moderate doses of (+)ampethamine.142  Although there is a difference 
in species and type of study conducted, the results support the notion that MD-354 can 
potentiate a behavioral action of (+)amphetamine.  However, in the present investigation, 
neither dose combination resulted in potentiation or antagonism of the (+)amphetamine 
(2) effect when compared to the effect of the stimulant administered alone.  These results 
were observed both with stimulant and non-stimulant parameters throughout the entirety 
of the experiment. 
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 For comparison, an effective dose of (+)amphetamine (2) (3.0 mg/kg) was 
administered in combination with the 5-HT3 receptor antagonist ondansetron (19).    
Costall et al. indicated that the 5-HT3 receptor antagonist GR38032F (known as 
ondansetron) inhibited hyperlocomotion (measured as counts) induced by intra-
accumbens injections in rats.131     However in the present investigation, the 5-HT3 
receptor antagonist ondansetron did not behave in a similar manner when administered in 
combination with (+)amphetamine.   Similar to the results observed with a combination 
of MD-354 (42) and (+)amphetamine, ondansetron (19) neither potentiated nor 
antagonized the stimulant effect of (+)amphetamine (2) compared to (+)amphetamine 
administered alone.  This effect was observed throughout the entirety of the experiment 
for all stimulant parameters. However, a 1.0 mg/kg dose of ondansetron was able to 
potentiate the effect of (+)amphetamine on the parameter center distance; that is, 
ondansetron in combination with (+)amphetamine displayed an anxiolytic-like effect. The 
difference in effect between the present investigation and that observed by Costall et 
al.131 could be due to the difference in species, route of administration, and method of 
determining locomotor activity. With the exception of this non-stimulant parameter 
(center distance), it was concluded that in combination with (+)amphetamine (2), MD-
354 (42) is either behaving similar to a 5-HT3 receptor antagonist, or MD-354 is devoid 
of action.  Since the effects of the combination of MD-354 and (+)amphetamine on 
locomotor activity parameters were similar to those observed with the combination of 
ondansetron and (+)amphetamine, the conclusion that MD-354 is behaving  in a similar 
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manner to a 5-HT3 receptor antagonist is supported.  However, the lack of potentiation or 
antagonism of effect could also suggest MD-354 is devoid of action. 
 Combination of an effective dose of (+)amphetamine (2) with the 5-HT3 receptor 
agonist SR 57227A (28) was examined.  Whereas neither MD-354 (42) nor ondansetron 
(19) altered the effect of (+)amphetamine (2) when administered in combination, SR 
57227A (28) influenced the effect of a moderate dose of (+)amphetamine (2.0 mg/kg).  A 
moderate dose of (+)amphetamine was used instead of the effective dose in case the 5-
HT3 receptor agonist potentiated the stimulant effect of (+)amphetamine (2) to the point 
of stereotypy.  The four parameters that were affected by administration of 
(+)amphetamine (2) alone at a 3.0 mg/kg dose were also affected when (+)amphetamine 
was administered in combination with SR 57227A (28).  The combination of SR 57227A 
(3.0 and 10 mg/kg doses) with (+)amphetamine potentiated the effect (+)amphetamine on 
movement episodes (i.e., the number of movement episodes was decreased).  This 
potentiation was more significant at the 3.0 mg/kg SR 57227A dose than the 10 mg/kg 
dose.  The combination of SR 57227A (28) with (+)amphetamine (2) also potentiated the 
effect of (+)amphetamine on the stimulant parameters of movement time and movement 
distance, as well as the non-stimulant parameter margin distance.  This potentiation was 
observed as an inverted U-shaped curve as the 3.0 mg/kg SR 57227A dose was the only 
one that potentiated (+)amphetamine’s actions on all three parameters.  For the other 
parameters, vertical entries, margin time, center distance, center time, and center entries, 
the combination of (+)amphetamine (2) with SR 57227A (28) behaved similarly to 
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(+)amphetamine when administered alone.  Analysis of these results showed that 
(+)amphetamine when administered alone produced a saline-like effect.   
 Results from combinations of (+)amphetamine (2) (3.0 mg/kg) with varying doses 
of the 5-HT3 receptor antagonist ondansetron (19) indicated that the combination behaved 
similarly to the results observed with (+)amphetamine and MD-354. The 5-HT3 receptor 
agonist SR 57227A (28) behaved differently than either MD-354 (42) or ondansetron 
(19) when administered in combination with (+)amphetamine (2).  That is, SR 57227A 
potentiated certain aspects of (+)amphetamine-induced locomotor stimulation, whereas 
both MD-354 and ondansetron in combination with (+)amphetamine produced 
(+)amphetamine-like effects.  Hence, two conclusions are possible.  Either MD-354 lacks 
sufficient agonist potential to mimic the actions of SR-57227A, or too little MD-354 is 
penetrating the BBB to reach its central sites of action, as drug discrimination studies 
suggest that MD-354 is centrally acting;142 however, peripheral effects cannot be 
excluded. 
  (+)Methamphetamine (3), a psychomotor stimulant structurally similar to 
(+)amphetamine, was also tested in locomotor activity assays.  Literature states that 
(+)methamphetamine is a more potent central stimulant than (+)amphetamine (2);16 
similar central stimulant effects should be evident at lower doses.  This idea was 
supported as stimulant measures were increased at a 1.5 mg/kg dose of 
(+)methamphetamine as compared to 3.0 mg/kg dose of (+)amphetamine.  Doses of 
(+)methamphetamine (3) increased movement time and movement distance while 
suppressing movement episodes; this was similar to the results observed following 
 116
administration of an effective dose of (+)amphetamine (2) alone.  These effects also 
created an inverted U-shaped curve as doses of 1.5 mg/kg increased stimulant parameters, 
where a dose of 10 mg/kg had less of an effect; in some cases, no effect was observed.  
Not only did (+)methamphetamine (3) potentiate the effect on stimulant parameters, but 
lower doses (as low as 0.3 mg/kg) somewhat potentiated the three key stimulant 
parameters (movement episodes, movement distance, and movement time) as well as 
vertical entries, margin distance, and center entries after the first 15 min of the 
experiment.  Glennon et al. analyzed racemic methamphetamine in similar male ICR 
mice and also observed an increase in locomotion (measured as interruptions of photocell 
beams) at 1.0 mg/kg and above, whereas a 0.3 mg/kg dose of racemic methamphetamine 
produced a saline-like effect.140  Once again, variances in effective dosage amounts could 
be due to the use of racemic methamphetamine (3) as compared to its more potent 
isomer.   
 In the present investigation, center entries was the only parameter increased by 
(+)methamphetamine (3) that was not affected by (+)amphetamine (2), suggesting that 
(+)methamphetamine is behaving more in an anxiolytic nature than (+)amphetamine.   
However, both (+)methamphetamine and (+)amphetamine, at all doses administered, 
produced saline-like effects on margin time, center distance, and center time. 
 Studies with 1.5 and 3.0 mg/kg doses of (+)methamphetamine (3) in combination 
with varying doses of MD-354 (42) were conducted to determine if MD-354 was 
behaving similarly to (+)amphetamine in combination with a structurally similar 
psychomotor stimulant.  For all combinations, MD-354 (42) plus (+)methamphetamine 
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(3) produced results similar to those observed following administration of 
(+)methamphetamine alone; this was observed for all nine parameters analyzed for the 
entire duration of the experiment.  Data from the combination of MD-354 (42) and 
(+)methamphetamine (3) paralleled the results observed with combinations of MD-354 
and (+)amphetamine (2).  Apparently, the effect of MD-354 on the motor actions of 
(+)methamphetamine and (+)amphetamine are similar. 
 DOM (10), a non-stimulant phenylalkylamine structurally similar to amphetamine 
was used as a control.  Supposedly lacking significant central stimulant properties, DOM 
was not expected to influence “stimulant” measures of activity.  However, it has been 
previously shown that hallucinogens can produce both a stimulant effect in locomotor 
activity assays as well as stimulus generalization; stimulus effects can be block by 
serotonin antagonists.54 
 Results of the present investigation showed that DOM (10) at a low dose (0.3 
mg/kg) significantly increased vertical entries.  This is an activity measure that was not 
affected by administration of either the psychomotor stimulant (+)amphetamine (2) or 
(+)methamphetamine (3).  Also, DOM doses did not have an effect on movement 
episodes, which was decreased by varying doses of psychomotor stimulants. This 
increase in vertical entries, as well as no effect on movement episodes differentiates 
DOM from the psychomotor stimulants.   Other parameters affected by the administration 
of DOM (10) included movement time, movement distance, and margin distance 
suggesting the drug displayed some stimulant activity, which is consistent with literature 
that states that low doses of DOM may produce stimulant effects.3 Yamamoto and Ueki 
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analyzed the effect of DOM on locomotor activity in mice, and observed increases in 
locomotor activity at 0.5 -1.0 mg/kg doses injected i.p.3  However, at 0.1 mg/kg, head 
twitches, a hallucinogenic parameter was increased.3 Data observed in the present 
investigation is consistent with Yamamoto and Ueki’s3 results, although the present study 
did not analyze head twitches, but rearing as a hallucinogenic parameter.   
 By increasing vertical entries, the animal is in motion more, which in turn will 
increase the amount of time the animal is in motion (i.e., movement time).  Also, when 
animals display rearing behavior, it is usually around the margins of the chamber, as the 
mice look as if they are trying to climb out of the chamber; this can increase both margin 
distance, margin time, and movement distance. Therefore, as vertical entries increase, it 
is not uncommon for movement time, movement distance, margin distance, or margin 
time to also increase.  Further analysis of the effects of varying doses of the hallucinogen 
DOM (10) showed results similar to those observed following administration of 
(+)amphetamine (2) and (+)methamphetamine (3) (i.e., no effect), as DOM produced 
saline-like effects for margin time, center distance, center time, and center entries.   
 Results of combination studies of an effective dose of DOM (10) (0.3 mg/kg) with 
MD-354 (42) differed from those observed from combination of MD-354 with 
(+)amphetamine (2) and (+)methamphetamine (3).   With both phenylalkylamine 
stimulants, combination of MD-354 with (+)amphetamine or (+)methamphetamine 
produced effects similar to the stimulant when administered alone.  However, in 
combination with DOM (10), MD-354 (42) antagonized stimulant parameters as well as 
other parameters analyzed.  In particular, DOM (10) is a hallucinogen; vertical entries 
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should be increased,123 which was observed with DOM administered alone as well as in 
combination with MD-354.  However, in combination with MD-354 (42), the effect of 
DOM (10) on vertical entries, as well as movement time, movement distance, margin 
distance, center distance and center entries were all completely blocked, resulting in a 
saline-like effect.  The only parameters not affected by this combination were movement 
episodes, margin time, and center time, which were saline-like when DOM was 
administered alone.  Literature has shown that 5-HT2 antagonists block the stimulus 
effect of DOM,54 therefore, similar results could be observed with a 5-HT3 partial agonist.   
 Cocaine (1) was evaluated as a non-phenylalkylamine stimulant that has a 
different mechanism of action than (+)amphetamine or (+)methamphetamine, to 
determine if MD-354 (42) behaves similarly or differently in combination than with 
phenylalkylamine stimulants.  Administration of varying doses of cocaine (1) indicated 
that the stimulant significantly increased the effect on the same four parameters increased 
by (+)amphetamine (2) and (+)methamphetamine (3).  These four parameters, movement 
episodes, movement time, movement distance, and margin distance, were significantly 
increased at doses 10 mg/kg and 30 mg/kg; stereotypy was not observed at the high (30 
mg/kg) dose.  The present results are consistent with literature data as Mcgeehan et al. 
showed that the average distance traveled was significantly increased following doses of 
15 and 30 mg/kg of cocaine (1).139 Cocaine produced a saline-like effect on total vertical 
entries, total margin time, total center distance, total center time, and total center entries 
which coincides with the data found in both the (+)amphetamine (2) and 
(+)methamphetamine (3) studies.  This indicates that all three psychomotor stimulants are 
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producing similar locomotor effects, regardless of their differences in mechanism of 
action, since the overall effect is an increase in synaptic dopamine levels. 
 Studies were conducted to determine if MD-354 (42) behaved similar in 
combination with cocaine (1) to combination with (+)amphetamine (2).  An effective 
dose of cocaine (10 mg/kg) was used in combination with the 5-HT3 receptor partial 
agonist MD-354 (42).  Potentiation of the effect of cocaine administered alone was 
observed when in combination with MD-354 for several parameters: movement episodes, 
movement time, vertical entries, center distance, and center entries (at various time 
intervals).  A decrease in movement episodes and an increase in movement time and 
vertical entries was observed at all doses of MD-354 (42) in combination with cocaine 
(1).  Center distance and center entries were only affected at a higher dose of MD-354.  
These results were observed at different time intervals.  Analysis of the overall effect of 
the combination indicated that MD-354 potentiated the effect of cocaine on center entries 
at a 6.0 mg/kg dose.  These results differed from those observed with a combination of 
MD-354 (42) and (+)amphetamine (2), as the combination with MD-354 produced effects 
similar to those observed with (+)amphetamine alone. 
 Combination of the same dose of cocaine (1) (10 mg/kg) with the 5-HT3 receptor 
antagonist ondansetron (19) displayed results similar to the combination of MD-354 (42) 
and cocaine.  The effect of cocaine was potentiated in combination with ondansetron (19) 
for movement episodes (i.e., movement episodes decreased).  The effect of cocaine was 
also potentiated in combination with ondansetron for center entries, whereas ondansetron 
decreased the effect of cocaine on margin distance.  The effect of cocaine (1) 
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administered alone increases margin distance; however in combination with ondansetron, 
the effect was blocked, resulting in a saline-like effect.  The effect of ondansetron on 
cocaine varied between different time intervals.  However, analysis of the total effect of 
the combination of drugs on the nine parameters showed that only center entries were 
affected at 0.5 and 1.0 mg/kg doses of ondansetron (potentiated the effect of cocaine).  
 Several different 5-HT3 receptor antagonists (i.e., zacopride, tropisetron, 
bemesetron, and ondansetron) have been studied in combination with cocaine, usually 
resulting in attenuation of the effect of cocaine. Le et al. analyzed locomotor activity 
counts in male DBA/2N mice,143   which differed from the ICR strain of mice used in the 
present studies. Low doses of ondansetron (19), 0.001, 0.01, and 0.1 mg/kg were 
administered s.c. in combination with cocaine (1) to yield slightly different results from 
those observed in the present investigation, as the combination of ondansetron did not 
potentiate or antagonize the stimulant effects of cocaine.143  The differences in the results 
could be due to the type of rodent used as well as the route of administration.  King et al. 
indicated that varying doses of ondansetron (1.0 -16 mg/kg i.p.) attenuated the effect of 
cocaine (15 mg/kg i.p.) in male Sprague Dawley rats.130 Locomotion was measured using 
the Ellinwood and Balster rating scale.130   Svingos and Hitzemann conducted a study 
analyzing the effect of zacopride, tropisetron, and bemesetron on an effective (10 mg/kg) 
dose of cocaine.129  All three 5-HT3 receptor antagonists (injected i.p.) attenuated the 
effect of cocaine in rats when analyzing locomotion (measured as the number of quadrant 
crossovers).129  Further support for attenuation of the effect of cocaine by 5-HT3 receptor 
antagonists was determined by Reith.132  The effect of tropisetron (injected s.c), as well 
 122
as zacopride (injected i.p.), in combination with a 25 mg/kg dose of cocaine were 
determined; combination resulted in attenuation of locomotor counts in male 
C57BL/6ByJ mice.132  In the present study, ondansetron behaved similarly to the 
different 5-HT3 receptor antagonists discussed by attenuating the effect of cocaine on 
margin distance.  However, other parameters were potentiated by the combination of 
ondansetron with cocaine. The differences in attenuation of effect observed with several 
5-HT3 receptor antagonists and the present study could be due to route of administration, 
doses, difference in species, as well as the method used for determining locomotor 
activity.   
 For the present study, a combination of cocaine (1) with ondansetron (19) 
produced effects similar to those observed with combinations of cocaine and MD-354 
(42).  Analysis of data suggests that MD-354 is behaving similar to the 5-HT3 receptor 
antagonist ondansetron when administered in combination with an effective dose of 
cocaine (1).  This is because combination studies of MD-354 and cocaine, as well as 
ondansetron and cocaine, produced similar effects on cocaine. This is similar to the 
results observed with MD-354 (42) in combination with (+)amphetamine (2), suggesting 
that in combination with psychomotor stimulants, regardless of mechanism of action, 
MD-354 either behaves similar to a 5-HT3 receptor antagonist or is devoid of action. 
 A combination study was conducted using the 5-HT3 receptor agonist SR 57227A 
(28) with a 10 mg/kg dose of cocaine (1).  The dosage was not altered for cocaine as in 
the (+)amphetamine (2) study, as the cocaine dose-response curve suggested that there 
was a large range of effective doses of cocaine before the threshold of stereotypy was 
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reached.  The results of the combination study showed that SR 57227A (28) potentiated 
the stimulant effect of cocaine by decreasing movement episodes, and increasing 
movement time and center entries at various time intervals; these same three parameters 
were affected in a similar manner by the addition of MD-354 (42) to cocaine (1), 
suggesting MD-354 is behaving like a 5-HT3 receptor agonist.  However, analysis of the 
results of the total effect showed that the only parameter affected by the combination was 
center entries; SR 57227A potentiated the effect of cocaine on center entries when 
analyzed using an un-paired t-test.   
 The results of the present study were further investigated as MD-354 (42) was 
seemingly behaving as both a 5-HT3 receptor agonist and 5-HT3 receptor antagonist when 
analyzing the total effect of each 5-HT3 receptor ligand in combination with cocaine: 
analysis of all nine parameters showed that the 5-HT3 receptor ligands displayed no effect 
on cocaine except with the parameter center entries.   Since similar effects were observed 
when analyzing total parameters, the effect of the combination of 5-HT3 receptor ligands 
on cocaine were analyzed at different time intervals.  Combination studies of MD-354 
and cocaine, ondansetron and cocaine, and SR 57227A and cocaine all potentiated the 
effect of cocaine on movement episodes and center entries.  Since MD-354 is a 5-HT3 
receptor partial agonist, it has the potential to behave as either/both an agonist and 
antagonist.   It was concluded that in combination with cocaine (1), MD-354 (42) 
behaved similarly to a 5-HT3 receptor agonist, based on the evidence provided by other 
locomotor activity parameters analyzed.  Three parameters, movement episodes, 
movement time, and center entries were potentiated by both ondansetron (19) and 
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SR57227A (28), suggesting MD-354 (42) worked as both a 5-HT3 receptor agonist and a 
5-HT3 receptor antagonist.  Ondansetron (19) also antagonized the effect of cocaine (1) 
on margin distance. This antagonism was distinct, and not observed in combination 
studies of cocaine with MD-354 (42) or SR 57227A (28).  By actually antagonizing the 
effect instead of modulating the effect on margin distance, as compared to MD-354 and 
SR 57227A studies, the antagonist is blocking effect of the drug.  Since neither the 5-HT3 
receptor partial agonist or 5-HT3  receptor full agonist display this or similar effects (i.e., 
attenuation of effect of cocaine on margin distance), it is supported that MD-354 (42) is 
working through a 5-HT3 receptor agonist mechanism in combination with cocaine (1).  
Table 5 summarizes the results of the locomotor activity studies conducted in the present 
investigation. 
 For the three psychomotor stimulants ((+)amphetamine (2), (+)methamphetamine 
(3), and cocaine (1)) margin distance was increased when the drug of abuse was 
administered alone.  This could be a result of the drugs inducing anxiogenic-like 
behavior.  However, this could just be a result of stimulation.  It is normal for rodents to 
display anxiogenic-like activity, which is supported by the high values obtained for 
margin distance and margin time as opposed to center distance and center time.  When a 
psychomotor stimulant was administered, the mice displayed increased locomotion.  If 
the mice are walking more following the administration of a stimulant, and generally tend 
to walk around the margins, then it is likely the mice will walk more around the margins 
when administered a stimulant.  The stimulants may be producing anxiogenic-like 
behavior, but also could be displaying thigmotaxis in a stimulated manner. 
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 In conclusion MD-354 (42) may either behave as a 5-HT3 receptor antagonist in 
combination with phenylalkylamine stimulants, or be devoid of action as it neither 
potentiates nor antagonizes effective doses of (+)amphetamine (2) nor 
(+)methamphetamine (3).  However, in combination with a non-phenylalkylamine 
stimulant, that releases dopamine through a different mechanism of action, MD-354 (42) 
might behave as a 5-HT3 receptor agonist, by potentiating several stimulant and non-
stimulant parameters as seen with the 5-HT3 agonist SR 57227A.  The differences in 
mode of action of MD-354 may be a result of the mechanism of action of each stimulant 
to release dopamine. 
MD-354 is a 5-HT3 partial agonist with a low Log P value suggesting it does not 
cross the BBB.  However, drug discrimination studies, which can indicate whether or not 
a drug acts centrally (i.e., crosses the BBB), have shown that MD-354 serves as a 
discriminative stimulus11 and that MD-354 enhances the discriminative stimulus action of 
(+)amphetamine in rats.143  Currently it is unknown whether MD-354 works peripherally.  
Analysis of ex vivo studies indicated that the 5-HT3 receptor agonist, SR 57227A, crosses 
the BBB and acts both centrally and peripherally.111 Since MD-354 neither potentiated 
nor antagonized the stimulant effect of (+)amphetamine in the locomotor activity assay it 
is not displaying a central effect, compared to the central acting 5-HT3 agonist which 
potentiated the stimulant effect of (+)amphetamine.  Although locomotor activity assays 
are in vivo studies that analyze central effects, the possibility of a peripheral effect of 
MD-354 can not be excluded.   
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 Comparison of MD-354 and (+)amphetamine with MD-354 and cocaine suggests 
differences in mode of action, as MD-354 potentiated the effect of cocaine on various 
parameters, at various time intervals.  Similar effects were observed with SR 57227A 
suggesting that in combination with a stimulant that has a different mechanism of action, 
MD-354 may behave both centrally and peripherally. 
 In conclusion, in combination with phenylalkylamine stimulants, the 5-HT3 
receptor partial agonist MD-354 may be devoid of action because it is not lipophilic 
enough to cross the BBB, crosses the BBB, but at a dose too low to cause an effect if 
MD-354 is a centrally acting agent, or is behaving similar to a 5-HT3 receptor antagonist.  
However, in combination with a non-phenylalkylamine stimulant, MD-354 behaves 
similar to SR 57227A which acts both centrally and peripherally. 
 
B.  Synthesis 
 1.  Preparation of phenyl carbamate analogs of MD-354. 
 MD-354 (42) was prepared as previously described (Scheme 1).144 
NH2
Cl
a
NH2
Cl
x HCl
b,c
HN NH2
NH
Cl
x HNO3
 
        59                                60                                  42 
Scheme 1.  a. HCl/Et2O; b. NH2CN, EtOH, reflux; c. NH4NO3, H2O. 
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 Several different methods were used to synthesize carbamate analogs of MD-354.  
For the methyl carbamate analog 62, a one-pot synthesis by Khasanov145 was employed 
(Scheme 2).  
NH2
Cl
Cl O
O
CH3
CaCN2 O
O
CH3
N
H
NC
b+ a +
HN
Cl
N
H
NH
O
O
CH3
x HCl61 62
60  
Scheme 2.  a. H2O, 45 °C; b. 40% NaOH, reflux, 4.5 h. 
  
The first attempt to prepare the phenyl carbamate 53 was to follow the same 
method used in the synthesis of the methyl carbamate 62 (Scheme 3).145 Calcium 
cyanamide was allowed to react with phenyl chloroformate (63).  3-Chloroaniline 
hydrochloride (60) was added to the filtrate and the pH was adjusted to 4.  The precipitate 
was collected by suction filtration and recrystallized from anhydrous MeOH.  1H NMR 
spectral analysis indicated that the product was not the desired carbamate 53, but a dimer 
of 3-chloroaniline, N,N’-bis(3-chlorophenyl)urea (64).  Urea 64 is a known146 compound.  
Comparison of the melting point of 64 with literature data supported this 
characterization.146  The structure of 64 was also supported by microanalysis for C, H, 
and N. 
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Scheme 3.  a. H2O, 45 °C, 30 min; b. 40% NaOH, reflux overnight. 
 
 This same procedure was followed using 4-chlorophenyl chloroformate (65) and 
4-methoxyphenyl chloroformate (66) (Scheme 4).  In both instances, the resultant white 
precipitate was also identified as the 3-chloroaniline dimer 64.   
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Scheme 4.  a.  H2O, 45 °C, 30 min; b. 40% NaOH, reflux overnight. 
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 In general, there are numerous methods available to synthesize ureas.  For the 
most part, ureas are extremely stable, and most of the routes of synthesis are very clean 
and easy to perform.147  Interestingly, one of the common methods to synthesize ureas 
includes carbamates as starting material.  Liu et al.  reported a two-step synthesis which 
used a chloroformate and an amine to obtain a carbamate, followed by the addition of  an 
amine to form a urea.147 This reaction could be conducted both in organic and aqueous 
solvents.  Liu et al.  also stated that the reaction of isocyanates with amines can also 
produce ureas under mild conditions.147 
 Therefore, with the reaction conditions used in Scheme 3 and Scheme 4, the 
desired carbamate may have been synthesized, but was quickly converted to the urea, as 
urea may be a more stable compound than the phenyl carbamate 53.  Further analysis of 
the reaction mechanism showed that several side products other than the desired phenyl 
carbamate can be obtained (i.e., isocyanate derivative).   If an isocyanate had been 
formed, it too could have been converted into the urea in the presence of excess amine.  
Since the reaction yielded several products (tlc), which could include both the isocyanate 
(and infrared analysis of the crude reaction mixture showed the possible formation of an 
isocyanate intermediate as evidenced by a band at 2359 cm-1), the desired carbamate, and 
unreacted amine, conditions employed during purification might have resulted simply in 
the isolation of one of these products, the urea 64. 
 Another attempt was made to synthesize the phenyl carbamate analog of MD-354 
using a procedure by Naiman (Scheme 5).148   In this procedure, MD-354 (free base; 42) 
was added to a solution of  triethylamine and dry THF.  A THF solution of phenyl 
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chloroformate (63) was added to the reaction mixture and the reaction was monitored by 
tlc.  The triethylamine hydrochloride precipitate (mp = 261 °C)149 was removed by 
filtration and the solvent was evaporated to obtain an oil which was subjected to flash 
chromatography.  Three products were obtained: two were unstable and decomposed 
rapidly upon standing as evidenced by tlc.  A third product was recrystallized from 
anhydrous MeOH.  1H NMR spectral analysis of the latter product indicated the presence 
of three aliphatic protons (signal at δ = 3.60 ppm) that corresponded to the methyl group 
of methyl carbamate 62.  Melting point and tlc analysis further supported this conclusion: 
Rf = 0.35 (3:2 hexane:EtOAc). 
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Scheme 5. a. Et3N, THF; crystallized from MeOH. 
  
 Looking back at the previous reaction, tlc analysis indicated that a significant 
amount of starting material was still present after the 15-min reaction time.  Therefore, 
the reaction was repeated (Scheme 5), but allowed to continue until all the starting 
material was consumed (17 h).  Several additional products were formed (tlc).  The 
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resultant oil was crystallized from anhydrous MeOH several times to yield a white solid.  
1H NMR spectral analysis and melting point indicated that the methyl carbamate 62 was 
obtained, again with three aliphatic proton signals present in the 1H NMR spectrum.  
Based on this information, it was thought that the desired product could more easily be 
isolated using a shorter reaction time; this was employed in future trials.  However, 
higher yield of the methyl carbamate 62 was obtained during purification using 
recrystallization methods (17%) as opposed to flash chromatography (3%). 
 Synthesis of the methyl carbamate 62 from phenyl chloroformate 63 indicated 
that methanolysis might be occurring.  Two separate purification techniques were 
employed to determine if heat was necessary for this to occur.  The reaction was repeated 
and the resultant oil was divided into two batches.  One batch crystallized upon addition 
of hot MeOH, which yielded the methyl carbamate.  The other batch was subjected to 
MeOH at room temperature.  A solid material precipitated from the addition of MeOH, 
but could not be purified.  This supported the conclusion that heat is necessary for 
methanolysis to occur because methyl carbamate 62 was not isolated from the latter 
reaction.  
 The next attempt to synthesize the phenyl carbamate analog of MD-354 used the 
procedure of Gotz and Zeeh150 (Scheme 6). This method consisted of adding cyanamide 
to water while maintaining a pH of 7-8.  Phenyl chloroformate (63) was added to the 
reaction mixture, and was allowed to stir, followed by the addition of 3-chloroaniline 
(59); pH was adjusted to 3.  Basification of the filtrate resulted in immediate precipitation 
of a white solid (NaCl; mp > 300 ˚C).  A second product was present on tlc which was 
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determined to be phenol (67); Rf  = 0.83 (3:2 hexane:EtOAc).  Synthesis of phenol and 
NaCl prevented the reaction from proceeding to completion. 
NH2
Cl
Cl O
O
NH2CN
O
O
N
H
NC
+
a + b
O
O
N
H
HN
NH
Cl
59
53
63
OH
67  
Scheme 6.  a.  H2O, 50% NaOH, conc. HCl (pH 7-8), 45 °C, 1 h; b. conc. HCl (pH 3), 
reflux, 45 min. 
  
 Further analysis of the literature suggested that commercially available phenyl 
chloroformate is not very stable, and could be hydrolyzed to phenol or decompose in the 
presence of water, heat, or air, all three of which were present in the previous attempts.151  
Therefore, the reaction conditions for the previous reactions were modified.  Using the 
method of Khasanov145 (Scheme 7), acetone rather than water was used as solvent in the 
first step of the reaction, and the reaction was conducted at room temperature instead of 
at 45 °C.  A calcium cyanamide/acetone mixture was added to phenyl chloroformate (63) 
and the reaction mixture was allowed to stir.  3-Chloroaniline hydrochloride (60) was 
added to the filtrate and stirring was continued; the pH was not changed.  The solution 
was evaporated under reduced pressure to yield a white solid.  Recrystallization attempts 
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were made with several solvents (i.e., ethyl acetate, acetonitrile, and acetone) with 
acetone as the only solvent able to dissolve the product without heat.  Once again, 1H 
NMR spectral analysis suggested the product was not the desired phenyl carbamate 53.  
Instead, 1H NMR and elemental microanalysis supported the conclusion that the product 
obtained was the tetra-carbamate analog of MD-354 as its hydrochloride salt (i.e., 68). 
This conclusion was further supported by the IR spectrum that showed a carbamate 
peak(s) at 1586 cm-1. 
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Scheme 7. a. acetone, rt, N2, 45 min; b. rt, N2, 4 h. 
  
 The formation of tetra-carbamate 68 could be due to the fact that the reaction was 
not run in a 1:1 ratio of starting materials.  Instead, a 2:1 carbamate:amine ratio was used, 
which could result in a dicarbamate product.  When running the reaction, it was 
extremely difficult to add the CaCN2/acetone mixture to phenyl chloroformate (63) 
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because calcium cyanamide was not soluble in the solvent.  Therefore, it is likely that not 
all of the calcium cyanamide was added, causing even more of an excess of phenyl 
chloroformate. The basicity of the amines in the presence of excess acid chloride could 
result in multiple couplings, creating tetra-carbamate 68.      
 Another attempt to synthesize the phenyl carbamate analog of MD-354 was made 
using protecting groups (Scheme 8).152,153  In this method, 1H-pyrazole-1-carboxamide 
hydrochloride (69) was allowed to stir with diisopropylethylamine and CH2Cl2.  A 
solution of phenyl chloroformate (63) and CH2Cl2 was added to the mixture.  Once the 
reaction was complete (tlc), the product was extracted using aqueous sodium bicarbonate 
and brine.  The extract was dried (sodium sulfate), filtered, and solvent was evaporated 
under reduced pressure to yield a white, fluffy solid, the phenyl ester 70 of the pyrazole.  
The product was characterized by 1H NMR spectral analysis and elemental analysis. 
 The ester 70 and 3-chloroaniline hydrochloride (60) were allowed to stir in 
refluxing diisopropylethylamine (DIEA).  Once all starting materials were consumed 
(tlc), the solvent was evaporated under reduced pressure and the resultant crude product 
was isolated using column chromatography: 3:2 hexane:EtOAc.  The crude product was 
recrystallized from acetone to yield the urea 64. 
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Scheme 8.  a. DIEA, DCM, rt, 2 h; b.  DIEA, reflux overnight. 
  
 Once again, ureas are easily synthesized by the addition of amine to carbamates.  
Since characterization of intermediate 70 indicated that the desired carbamate had been 
formed, then the phenyl carbamate 53 should be synthesized.  However, the more stable 
urea was isolated.  The literature states that the reaction of protected pyrazole with simple 
primary amines is rapid and needs to be monitored closely.153  However, reduction in 
nucleophilicity drastically increased reaction time sometimes preventing the reaction 
from proceeding (e.g. the amine p-nitroaniline suppressed reaction time completely).153  
Even though m-chloroaniline is more nucleophilic than p-nitroaniline,154 the electron-
withdrawing group may be strong enough to suppress the reaction, resulting in the urea 
64 instead of the desired phenyl carbamate 53.  
 Based on previous synthetic attempts to prepare phenyl carbamate 53 that 
indicated the occurrence of methanolysis, the concept of alcoholysis was analyzed.  The 
theory was put to use with the simple reaction of acid chloride and amine in dry THF to 
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synthesize a carbamate.  Different bulky alcohols (i.e, isoporopanol and n-butanol) would 
then be used to isolate bulky carbamates, such as the isopropyl carbamate or n-butyl 
carbamate.  A THF solution of phenyl chloroformate (63) was added to a solution of MD-
354 (free base; 42), triethylamine, and dry THF (Scheme 9).  The triethylamine 
hydrochloride was removed by filtration and the filtrate was evaporated under reduced 
pressure to yield a yellow oil.  The oil was divided into two separate batches; isopropanol 
was added to one and n-butanol was added to the other at room temperature.  The 
precipitates from each batch were collected and washed with Et2O.  It was expected that 
one reaction would yield the isopropyl carbamate whereas the other would provide the 
butyl counterpart.  Comparison of the two products indicated the same material was 
formed in both cases (melting point, tlc, and 1H NMR spectral analysis).  1H NMR 
spectral analysis and elemental analysis supported the conclusion that the structure was 
that of the desired phenyl carbamate 53.   
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Scheme 9 . a.  ET3N, THF, N2, 15 min; b. isopropanol; c. n-butanol 
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 The purpose of using the bulky alcohols in this reaction was to support the idea 
that alcoholysis was occurring.  However, synthesis of the phenyl carbamate 53 instead 
of either the isopropyl carbamate or the butyl carbamate indicated that this was not the 
case.  Several factors may contribute to this.  It was shown that for methanolysis to occur, 
heat was necessary.  However, at no point was heat used in the purification of the phenyl 
carbamate 53 (Scheme 9).  Therefore, alcoholysis may not have been able to occur since 
heat was not present to hydrolyze the phenyl carbamate 53.  Also, alcoholysis may have 
been prevented due to the actual bulkiness of isopropanol and n-butanol.  Since MeOH is 
a much sterically smaller (less bulky, and/or more acidic) compound, it could attack the 
phenyl carbamate 53 and convert it to the methyl carbamate 62.  However, since the other 
alcohols employed were bulkier, steric interactions due to the structure of the phenyl 
carbamate 53, may have prevented the alcohols from attacking the compound, which in 
turn prevented alcoholysis.  Therefore, the phenyl carbamate 53 was isolated instead of 
the isopropyl or butyl carbamates.  Also, alcoholysis may not have occurred due to the 
polarity of the bulky alcohols; the bulky alcohols are less polar and less acidic than 
MeOH, therefore they are less reactive.  The less polar nature of isopropanol and n-
butanol as opposed to MeOH, may require more extreme conditions, such as the use of 
heat, to allow alcoholysis to occur.      
 The stability of the final product was of concern since so many attempts showed it 
to be unstable.  Therefore, the final product was heated with H2O.  Within 15 min, the 
phenyl carbamate 53 began to hydrolyze and by 30 min there was no phenyl carbamate 
present as evidenced by tlc.  Analysis by tlc indicated that the phenyl carbamate 53 may 
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have been hydrolyzed to its carbamic acid 71 which decarboxylated to form starting 
material, m-chlorophenylguanidine (42, free base), Rf = 0.77 (MeOH) (Scheme 10).  The 
phenyl carbamate also hydrolyzed to MD-354 in room temperature H2O; hydrolysis 
occurred at a slower rate than in refluxing H2O.  It is important to note that heat and 
water were not necessary to decompose the phenyl carbamate; in a separate reaction, the 
product decomposed while in EtOAc in a sealed vial at room temperature.  These data 
support the idea that carbamate 53 is relatively unstable.  Therefore, the carbamate was 
not evaluated in animal studies, as it may hydrolyze or decompose too quickly to attain 
any reliable results.   
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Scheme 10. a. H2O, reflux 
  
 The same procedure was applied to the synthesis of both the 4-chlorophenyl 
carbamate 54 and the 4-methoxyphenyl carbamate 55.  However, attempts at purification 
were unsuccessful.  Also, it was noted that the crude products were extremely unstable, 
and decomposed in sealed vials (tlc).  This lack of apparent product stability was the 
basis for not continuing with the pharmacological aspects of this study. 
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 2. Preparation of a conformationally-constrained analog of MD-354. 
 2-Amino-6-chloroquinazoline hydrochloride (57) was synthesized using a general 
method described by Grosso and Nichols (Scheme 11).155  Commercially available 5-
chloroisatoic anhydride (73) and S-methylisothiourea (72) were heated at reflux in 1,4-
dioxane.  The resulting quinazolinone 74 was reduced with diborane in refluxing THF to 
obtain the free base 57, which was converted to its hydrochloride salt using an HCl/ether 
solution. 
 The progress and purity of each step of the reaction was monitored by tlc using 
3:2 hexane:EtOAc as  eluent.  1H NMR spectroscopy of the final target indicated the 
presence of two aliphatic proton signals at δ = 4.49 ppm that correspond to the methylene 
group of 57 after the reduction of lactam 74.  Similarly, the IR spectrum showed absence 
of the lactam group at 1679 cm-1 seen in 74.  The physicochemical properties of 57 were 
compared with those of a sample previously synthesized in our laboratory but incorrectly 
assigned structure 56.   Both compounds possessed identical melting points, Rf = 0.26 
(H2O), IR, 1H NMR, and microanalytical properties. 
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Scheme 11. a. 1,4-Dioxane, Na2CO3, reflux, overnight; b. BH3-THF, reflux, N2, 2.5 h; c. 
HCl/Et2O, recrystallized from EtOH. 
 
 The conformationally-constrained analog of MD-354 (i.e., 57) was synthesized to 
confirm the structure of a compound previously synthesized in our laboratories, and 
whose structure may have been misassigned.  Previously, it was believed that 2-amino-7-
chloroquinazoline hydrochloride (56) had been obtained; however, analysis of the 
synthesis indicated that the position of the chloro group was in question.  Therefore, two 
reactions were performed using different starting materials, 5-chloroisatoic anhydride and 
4-chloroisatoic anhydride, to yield the respective 6- and 7-chloroquinazolines.  The 7-
chloro analog, 56, has been independently synthesized in our laboratory by an 
unequivocal route and has been shown to be different in structure from that of 57 (Ownby 
and Dukat, unpublished data as shown in Scheme 11). 
 1H NMR spectral analysis indicated that the difference between the 6-chloro 
quinazoline and the 7-chloroquinazoline was a shift of two aromatic hydrogen signals 
upfield.  These data were compared to the 1H NMR data of the previously reported 
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compound, which supported the conclusion that the structure had been misassigned and 
that the 2-amino-6-chloroquinazoline hydrochloride (57) had originally been synthesized.   
 
C.  Molecular Modeling 
 QSAR studies were conducted on 5-HT3 receptor agonists and partial agonists to 
evaluate Dukat’s current working pharmacophore accounting for the binding of 
arylguanidines and arylbiguanides at 5-HT3 receptors.14  Since many of the arylguanidine 
and arylbiguanide ligands are meta-substituted, and because there are two meta-positions 
(3 and 5), rotameric binding can occur.  Therefore, constrained analogs were included to 
better account for the possibility of rotameric binding. 
 An arginine fragment obtained from SYBYL was used to construct a model of 
MD-354 (42), which served as the template for all of the arylguanidine analogs shown in 
Table 6.  The crystal structure of m-chlorophenylbiguanide was obtained from the 
Cambridge Database (Identification name FERDOW), and was used as a template to 
construct the arylbiguanide analogs shown in Table 7.   Since there are two meta-
positions, selection of substitution was based on Ki values; meta-substituted analogs with 
Ki values ≥700 nM were labeled as 5-substituted analogs, whereas those with Ki values 
<700 nM were labeled as 3-substituted analogs.  This classification was based on the 
constrained analogs used in the model; the 5-chloroquinazoline bound with an affinity 
>700 nM, therefore meta-substituents with higher affinity were placed in the 3-position. 
Also, for analogs that were di- and tri-substituted, substitution positions were determined 
based on binding affinity.  For example the 3,6-dichloro arylbiguanide analog was 
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labeled as such, instead of 2,5-dichloro arylbiguanide, because the binding affinity was 
less than 700 nM, which was consistent with monosubstituted 3-chloro analogs.  
 
Table 6.  Arylguanidine 5-HT3 receptor agonists/partial agonists and their respective 
binding affinities used in the present QSAR studies.113,115 
             
HN NH2
NH
R
1
2
3
4
5
6
          
#   R=  pKi  #  R=      pKi   
41  H  5.63  83  4-C2H5      6.11   
42  3-Cl  7.49  43  3,4-fused phenyl  7.74  
47  5-CF3  5.61  84  4-C6H5       8.15   
75  5-OH  5.69  48  3,4-Cl       8.51  
76  3-CN  6.91  51  3-CF3, 4-Cl      7.44  
77  5-OCH3 5.80  85  4,5-OCH3      5.57  
78  4-CH3  6.3  46  5-CH3       5.19  
45  4-Cl  6.49  86  4-C(CH3)3      5.68  
79  4-CF3  6.64  87  4-C6H5       5.60  
80  4-OCH3 6.00  49  3,5-Cl       8.30  
81  3-Cl, 5-OCH3 7.74  50  3,4,5-Cl      9.15  
82  4-CH2C6H5 6.60   
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Table 7.  Arylbiguanide 5-HT3 receptor agonists/partial agonists and their respective 
binding affinities used in the present QSAR studies.115 
HN N
H
NH
R
1
2
3
4
5
6
NH2
NH
 
#  R=  pKi  # R=   pKi   
29  H  5.92  89 3-Cl, 4-CH3  6.65   
30  3-Cl  7.75  39 3,5-Cl   8.74   
37  3,5,6-Cl 9.40  90 3,5-CF3  5.92   
38  3,4-Cl  7.92  91 3,6-Cl   8.54   
40  3,4,5-Cl 8.57  92 2,3-Cl   8.33    
32  6-Cl  7.21  93 4,6-F   6.59   
33  4-Cl  6.68  94 4-F   6.21   
88  4-CH3  6.05  95 4-CF3   6.16   
31 3,4-fused phenyl 7.85   
 
 The structures of 43 arylguanidines and arylbiguanides (with Ki values spanning a 
10,000-fold range), including three constrained analogs (57, 58, and 96; Figure 58) were 
constructed and minimized using Gasteiger Hückel algorithms.  These 43 analogs were 
used as a training set and aligned using a Least Squares Method: the Fit Atom function.  
Alignment was based on three common points of the structure of MD-354 (42): the aryl 
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3-position, the aryl 5-position, and the carbon atom of the guanidine moiety (as shown in 
Figure 59).  
 
N NH
NH2
Cl    
N NH
NH2
Cl    Cl
NH
N
NH2
 
       57           58           96 
 pKi = 7.10   pKi = 6.13   pKi = 6.14 
Figure 58. Constrained analogs and their respective binding affinities used in further 
evaluation of the 5-HT3 receptor working pharmacophore model.13,135 
 
 CoMFA studies were conducted on the training set of 43 arylguanidine and 
arylbiguanide derivatives.  Analysis indicated there was a 63% steric contribution and a 
37% electrostatic contribution (r2 = 0.681, q2 = 0.693) with 5 as the optimal number of 
components.  Since the predictability factor (q2) was above 0.60, the model was 
considered to be acceptable and could be used to predict binding affinities of 
arylguanidine or arylbiguanide analogs.  In general, models with r2 values above 0.60 
have good predictability, however, the closer to 1 the r2 value, the better the 
predictability. 
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HN NH2
NH
R
       
Figure 59.  A)  Three points used for alignment of all 43 training-set compounds.  B)  All 
43 compounds aligned in CoMFA. 
 
 These results differ from those observed in the previous pharmacophore model as 
the previous model only used a total of 33 compounds instead of 43 as employed in the 
current investigation.113  In the previous model, similar compounds were used for both 
arylguanidines and arylbiguanides; mono-, di-, and tri-substituted compounds, as well as 
the 2-napthyl analogs.  However, the previous model did not include bulky substituents at 
the 4-position or any of the constrained analogs.113  It did, however, include substitution 
within the guanidine moiety, which is not included in the current investigation.113  The 
same three points, aryl 3-position, aryl 5-position, and the cationic carbon attached in the 
guanidine moiety were used for alignment.113  However, with the previous model, 
CoMFA studies resulted in r2 = 0.851 and q2 = 0.584.113 
A
B
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 The difference in predictability of the model generated in the present studies 
versus that of the previous model not only could be due to the addition of constrained 
analogs to the training set, but also the function of these constrained analogs.  Currently, 
is not known whether these constrained analogs behave in an agonist or antagonist 
manner. 5-HT3 receptor agonists and antagonists may bind to the receptor in a different 
manner.  If this is the case, and both models are supposed to be representative of 
arylguanidine and arylbiguanide 5-HT3 receptor agonists and partial agonists, the addition 
of ligands with unknown functionality may decrease the predictability of the model. 
 Validation of the model was completed using a test set of five (arbitrarily 
selected) compounds, whose known pKi values were compared to the pharmacophore 
model’s predicted values (Figure 60).  The predictability of the validation set was high as 
some affinities were predicted within 2- to 3-fold.  
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HN NH2
NH
Cl
  
HN NH2
NH
Cl
H3CO
  
HN N
H
NH
Cl
NH2
NH
F3C  
  44    97    98 
Actual pKi:    6.72  (Ki = 190 nM)          6.10  (Ki = 794 nM)     6.52  (Ki = 302 nM) 
Predicted pKi:6.23  (Ki = 588 nM)          6.13  (Ki = 741 nM)    6.00 (Ki = 1000 nM) 
 
 
HN N
H
NH
NH2
NH
CH3   
HN N
N
NH2
Cl  
       99                   100 
Actual pKi:  6.11  (Ki = 776 nM)          5.84  (Ki = 1445 nM)  
Predicted pKi:  5.95  (Ki = 1122 nM)               5.10  (Ki = 7943 nM)  
Figure 60.  Predicted pKi and Ki values of five arbitrarily selected test-set compounds 
from the CoMFA model compared to their known113,115 pKi and Ki values. 
 
 Figure 61 displays the region in the pharmacophore model where electrostatic 
interactions are favorable versus unfavorable.  There was only a small area near the aryl 
5- and aryl 6-positions where negatively charged substituents were favored.  The aryl 3- 
and aryl 4-positions possessed a large region favoring positively charged substituents.  
These interactions were also favored around the guanidine moiety.   
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Figure 61.  CoMFA results analyzing only electrostatic interactions (n = 43).  Blue is a 
region were positively charged substituents are favored, whereas red represents regions 
where negatively charged substituents are favored. MD-354 (42) is displayed in the 
model. 
  
 CoMFA results also displayed regions where steric interactions are favorable 
versus unfavorable (Figure 62).  A small area of bulk tolerance was observed near the 
aryl 3-position.  However, this area did not extend too far away from the aromatic region.  
It was observed that steric interactions were unfavorable to a large extent at the aryl 4-
position.  Therefore, bulky substituents are not favored and, in fact, compounds display 
lower binding affinities when they bear such substituents near this region.  
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Figure 62. CoMFA results analyzing regions of steric tolerance (n = 43).  Green areas are 
regions where bulky groups are favored and yellow represents areas where bulky 
substituents are unfavored.  MD-354 (42) is the compound represented in the model. 
 
 Based on the CoMFA studies, there are more regions of favorable electrostatic 
interactions than favored steric interaction.  This could be due to the number of 
arylguanidines and arylbiguanides that had variable electrostatic substituents versus the 
amount of sterically hindered 5-HT3 receptor agonists/partial agonists employed in the 
training set.  Figure 63 displays the full results of the CoMFA study, which differ from 
Dukat’s pharmacophore model as the previous model provided more information about 
substitution within and around the guanidine moiety.  However, that model included 
analogs with substitution within the guanidine moiety as opposed to the present model 
that did not include these types of analogs. 
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Figure 63.  CoMFA results including favorable and unfavorable regions of steric and 
electrostatic interactions (n = 43). Blue areas are regions where positively charged 
substituents are favored, whereas red areas are regions where negatively charged 
substituents are favored.  Green areas are regions where bulky groups are favored and 
yellow areas are regions where bulky substituents are unfavored. MD-354 (42) is 
compound displayed in the model. 
 This model differs from results of the previous CoMFA model as bulky 
substitutents are favored close  to the aryl 3- and aryl 5-positions, whereas bulky 
substituents are unfavored around the majority of the aryl-positions (further out from the 
aryl 3- and aryl 5-positions) and around the guanidine moiety.113  The present model 
suggests that bulky substituents are favored near the aryl 3-position, and disfavored 
around the aryl 4-position, however, this is the only information the present investigation 
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provides relating favorable and unfavorable regions or steric bulk.   Therefore, the 
present investigation is not as informative as the previous model on the location of where 
regions of bulk are preferred versus unfavorable regions. 
 Also, the present investigation displays large regions where electrostatic 
interactions are favored (i.e., positively charged substituents improve affinity).  This is 
observed near the aryl 3-, aryl 4-, and aryl 5-positions, as well as within the guanidine 
moiety.  The previous model also displays favorable electrostatic interactions within the 
guanidine moiety, as well as near the aryl 5-position, however these interactions are 
unfavored near the aryl 3-position.113  This could be due to assignment of meta-
substituents to the 3- versus 5-position based on binding affinity relative to the 
constrained analogs.  Once again, constrained analogs were not present in the previous 
study.    
 CoMSIA studies can provide information on steric, electrostatic, hydrophobic, H-
bond donor, and H-bond acceptor regions.  All five aspects were analyzed in the present 
study (n = 43), however the r2 values were low (r2 < 0.50) on all parameters analyzed 
except hydrophobic interactions.  With this parameter, slightly better predictability was 
observed (r2 = 0.51, q2 = 0.50), as opposed to H-bond donor/acceptor, electrostatic, and 
steric parameters.  Although this predictability is not too reliable, as r2 is not greater than 
0.60, it still can be used to give some insight into regions where hydrophobic interactions 
are favorable versus unfavorable (Figure 64). 
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Figure 64. CoMSIA results showing regions of hydrophobic interaction (n = 43).  Cyan 
areas are regions were hydrophobic interactions are favored whereas those areas shown in 
purple are regions where hydrophobic interactions are unfavorable. MD-354 (42) is the 
compound displayed in the model. 
  
 Results from CoMSIA studies indicated that hydrophobic interactions are favored 
near the aryl 3-position, the aryl 5-position, and near the terminal amine in the guanidine 
moiety.  There was a much larger area of unfavorable hydrophobic interactions, which 
was observed near the aryl 4-position as well as in the center of the aromatic ring; 
typically, compounds with nonpolar substituents at these positions would be predicted not 
to bind well.   
 From these findings, the binding affinities of five new compounds recently 
synthesized in our laboratories, whose binding affinities have not yet been determined, 
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were predicted as shown in Figure 65.  The binding affinities were predicted using 
CoMFA as this model displayed higher predictability than the CoMSIA model. 
 
HN NH2
NH
I      
HN NH2
NH
F      
HN NH2
NH
Br      
N NH
NH2
Cl      
N NH
NH2
ClCl  
        101             102                 103             56  104 
      7.43           6.68      7.51           7.53  7.76 
Figure 65. Predicted pKi values of five new arylguanidine analogs using CoMFA 
analysis. 
  
 These predictions will be compared to the actual binding affinities of these 
compounds once radioligand binding data become available.   
 This information further extends the current working pharmacophore model for 5-
HT3 arylguanidine and arylbiguanide agonists and partial agonists. Evidence from the 
current investigation supports the idea that binding is sensitive to electronic and lipophilic 
substituents at the aryl 3- and aryl 5-positions as well as lipophilic substituents at the aryl 
4-position.  Information provided from this model gives insight into what features are 
necessary to bind with high affinity to the 5-HT3 receptor.  Based on this, design of novel 
compounds can be facilitated. 
 QSAR studies are extremely helpful in designing novel ligands that could bind 
with high affinity, by understanding which regions of the receptor prefer which type of 
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substituents (i.e., electron-withdrawing versus electron-donating groups).  The present 
investigation shows that electrostatic factors are preferred in the majority of the model 
except at aryl 5- and aryl 6- positions.  However, di-substituted ligands, preferably 
electron-withdrawing groups at the 3- and 5- positions bind with higher affinity than 
mono-substituted ligands.  Therefore, design of novel di-substituted ligands should be 
considered.   
 Not only are QSAR studies useful in design of ligands, but very helpful in 
predicting the binding affinities of ligands.  Even though some of the compounds in 
Figure 65 have already been synthesized (i.e., all but 104), binding data have not yet been 
obtained.  Nevertheless, binding affinities have been predicted and compared to each 
other.  This information can also help in the design of new ligands, as analysis of what 
may increase or decrease binding affinity, such as more electronegative substituents, can 
help to determine new analogs to be synthesized without having to wait for binding 
studies to be conducted.  
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V. Conclusions 
 
 In locomotor activity assays, the goal was to determine the effect, if any, MD-354 
might have on the locomotor effects of different psychomotor stimulants.  This could 
provide information on whether MD-354 is acting through a 5-HT3 receptor agonist or 
antagonist mechanism.  Since MD-354 is a 5-HT3 partial agonist, it has the potential to 
behave as either an agonist or antagonist.  The three 5-HT3 receptor ligands MD-354 
(42), the 5-HT3 receptor antagonist ondansetron (19), and the 5-HT3 receptor agonist SR 
57227A (28) all produced saline-like effects in locomotor activity assays when 
administered alone.  Effective doses of the four drugs of abuse tested ((+)amphetamine 
(2), (+)methamphetamine (3), DOM (10), and cocaine (1)) were determined and used in 
combination with the 5-HT3 receptor ligands.  MD-354 (42) neither potentiated nor 
antagonized the stimulant effect of either (+)amphetamine (2) or (+)methamphetamine 
(3).  These results were similar to those observed with (+)amphetamine in combination 
with ondansetron (19).  They suggest that MD-354 might be acting as an antagonist, or is 
devoid of action. These results differed from the combination of (+)amphetamine with 
SR 57227A, as the 5-HT3 agonist potentiated the stimulant effect of (+)amphetamine on 
the parameters of movement episodes, movement time, movement distance, and margin 
distance. Combination of MD-354 (42) with cocaine (1) resulted in the potentiation of 
stimulant parameters consistent with results observed with a combination of SR 57227A 
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(28) and cocaine. This suggests that MD-354 (42) is working through a 5-HT3 receptor 
agonist mechanism.  These results could be due to the fact that psychomotor stimulants 
display increased locomotion due to increased synaptic dopamine levels, and 5-HT3 
receptor agonists can indirectly cause release of dopamine.  However (+)amphetamine (2) 
and (+)methamphetamine (3) increase dopamine levels through a different mechanism of 
action than cocaine (1).  This could be the reason MD-354 has different effects between 
the phenylalkylamine stimulants versus the non-phenylalkylamine stimulant.  
Combination of MD-354 (42) with the phenylalkylamine control non-stimulant DOM 
(10) resulted in antagonism of the effect that hallucinogens commonly have on various 
parameters.  This antagonism versus potentiation, or no effect at all, could be due to the 
fact that DOM is not a stimulant and does not work through releasing dopamine.  
 Various trials were employed to synthesize the more lipophilic phenyl carbamate 
analogs of MD-354, which were to be used in animal studies as prodrugs of MD-354.  
Lack of stability of the carbamates made isolation of the phenyl carbamate analog of 
MD-354, 53, extremely complex.  However, by avoiding heat, air, and water the phenyl 
carbamate analog of MD-354, 53, could be isolated using bulky alcohols to precipitate 
the product.  However, upon exposure to heat and water, the phenyl carbamate analog 53 
was rapidly hydrolyzed to starting material MD-354 (42).  This lack of stability precluded 
animal studies from being conducted.  Other phenyl carbamate analogs were even more 
unstable, and could not be isolated as they decomposed upon standing. 
 The current working pharmacophore model for arylguanidine and arylbiguanide 
5-HT3 receptor agonists and partial agonists was further developed by the addition of 
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constrained analogs to the model to help account for rotameric binding that can occur 
based on the presence of two meta-substitution positions.  This model indicated that the 
3- and 5-positions are sensitive to lipophilic and bulky substituents.  Information from the 
model can be used to design high affinity 5-HT3 receptor ligands.  CoMFA studies were 
used to predict the binding affinity of several analogs that have been or are being 
synthesized in our laboratory, but for which binding data are not yet available.  Once 
binding data are available, their binding affinities might further validate this model. 
 In conclusion, the 5-HT3 receptor partial agonist MD-354 may behave as either an 
agonist or is devoid of action when administered with psychomotor stimulants that have 
different mechanisms of action.  It is indicated that this is a central action, although 
peripheral action can not be excluded.  The effect of MD-354 on DOM locomotor effects 
is intriguing and requires further investigation.  These effects are very interesting, but 
cannot be explained at this time.  In regards to synthesis, the more lipophilic carbamate 
analogs of MD-354 were unstable preventing use in animal studies as prodrugs of MD-
354 that could possibly cross the BBB. As such, this is the first study to demonstrate that 
phenyl carbamates of guanidines are not stable compounds. QSAR studies were 
conducted including conformationally-constrained analogs to help improve the current 
working 5-HT3 receptor agonist/partial agonist pharmacophore model for arylguanidines 
and arylbiguanides.   
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VI. Experimental 
A. Synthesis 
  Melting points were taken on a Thomas-Hoover melting point apparatus in glass 
capillary tubes and are uncorrected.  1H NMR spectra were recorded with a Varian EM-
390 spectrometer with tetramethylsilane (TMS) as an internal standard.  Peak positions 
are given in parts per million (δ).  Infared spectra were obtained on a Nicolet Avatar 360 
FT-IR spectrophotometer. Microanalyses were performed by Atlantic Microlab Inc. 
(Norcross, GA) for the indicated elements and results are within 0.4% of calculated 
values.  Chromatographic separations were performed on silica gel columns (Silica Gel 
62, 60-200 mesh, Sigma-Aldrich). Flash chromatography was performed on a 
CombiFlash Companion/TS (Teledyne Isco Inc., Lincoln, NE).  Reactions were 
monitored by thin-layer chromatography (tlc) on silica gel GHLF plates (250 μ, 2.5 x 10 
cm; Analtech Inc., Newark, DE).  
 
m-Chlorophenylguanidine nitrate (42). m-Chloroaniline HCl (60) (2.36 g, 14.4 mmol), 
cyanamide (1.21 g, 28.8 mmol), and absolute EtOH (12 mL) were combined and heated 
at reflux overnight.  The solvent was removed under reduced pressure and the crude 
product was dissolved in H2O (6 mL).  Excess NH4NO3 (2.66 g, 33.2 mmol) was added 
to form a precipitate that was collected and recrystallized from H2O.  The resulting HNO3 
salt was collected by filtration, rinsed with anhydrous Et2O (3 x 10 mL), and 
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recrystallized a second time from H2O to yield 1.57 g (31%) of product as white crystals 
42:  mp 170-171 οC (lit.144 mp 171-172 οC). IR (KBr, cm-1) 3420, 3333, 3195, 1659, 1217 
cm-1; 1H NMR (DMSO-d6) δ: 7.22 (m, 1H, ArH), 7.33-7.39 (m, 3H, ArH, NH), 7.47 (t, 
J=7.8 Hz, 1H, ArH), 7.52 (br.s, 3H, NH), 9.72 (br.s, 1H, HNO3). 
 
Phenyl [[(3-chlorophenyl)amino](imino)methyl]carbamate (53).  Method A.  A 
solution of phenyl chloroformate (63) (0.08 mL, 0.63 mmol ) in dry THF (3 mL) was 
added in a dropwise manner to a mixture of m-chlorophenylguanidine (42, free base) 
(0.11 g, 0.63 mmol) and Et3N (0.18 mL, 1.26 mmol) in dry THF (3.5 mL) on ice under a 
N2 atmosphere.  The reaction mixture was allowed to stir for 25 min at room temperature, 
then filtered twice to ensure all Et3N·HCl was collected. The solvent was evaporated 
under reduced pressure.  A few drops of isopropanol were added to the resultant crude 
product and the solution was placed in the refrigerator for 1 h.  The precipitate was 
collected by filtration and washed with anhydrous Et2O.  The solid was dried under 
vacuum for 48 h to yield 0.04 g (19%) of a white crystalline product, 53:  mp 159-161 ºC; 
IR (KBr, cm-1) 3463, 3288, 3051, 1668;  1H NMR (DMSO-d6) δ: 7.09-7.27 (m, 6H, 
ArH), 7.37-7.42 (t, 2H, ArH), 7.61 (s, 1H, ArH), 9.28 (3H, NH, D2O exchangeable).  
Anal. calcd. for  C14H12N3O2Cl•0.25Et2O: C, 58.45; H, 4.74; N, 13.63 Found: C, 58.38; 
H, 4.42; N, 13.77. 
 
Method B. A solution of phenyl chloroformate (63) (0.38 mL, 3.05 mmol ) in dry THF 
(11 mL) was added in a dropwise manner to a mixture of m-chlorophenylguanidine (42, 
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free base) (0.52 g, 3.05 mmol) and Et3N (0.85 mL, 6.10 mmol) in dry THF (16 mL) in an 
ice bath under a N2 atmosphere.  The reaction mixture was allowed to stir for 25 min at 
room temperature, then filtered twice to ensure all Et3N·HCl was collected. The solvent 
was evaporated under reduced pressure.  A few drops of n-butanol were added to the 
resultant crude product and the solution was placed in the refrigerator for 1 h.  The 
precipitate was collected by filtration and rinsed with anhydrous Et2O.  The solid was 
dried under vacuum for 48 h to yield 0.03 g (3%) of a white crystalline product, 53:  mp 
159-160 ºC; 1H NMR (DMSO-d6) δ: 7.07-7.29 (m, 6H, ArH), 7.38-7.42 (t, 2H, ArH), 
7.62 (s, 1H, ArH), 9.28 (3H, NH, D2O exchangeable).   
 
Method C.  A solution of cyanamide (2.5 g, 60 mmol) in H2O (25 mL) was basified with 
50% NaOH (pH 7-8).  Phenyl chloroformate (63) (9.4 g, 60 mmol) was added in a 
dropwise manner and the reaction mixture was allowed to stir at 43 ºC for 1 h. An 
unidentified precipitate was collected by filtration; mp >300 ºC.  A second product was 
determined to be phenol (67) by tlc analysis compared to commercially available phenol; 
Rf = 0.83 (3:2 hexane:EtOAc). 
 
2-Amino-7-chloro-3,4-dihyroquinazoline hydrochloride (56).156  BH3-THF complex 
(12.2 mL, 1 M, 6.1 mmol) was added in a dropwise manner to 105 (0.6 g, 3.07 mmol) 
under a N2 atmosphere. The reaction mixture was heated at reflux for 2.5 h. After cooling 
the reaction mixture to room temperature, a 6 N solution of HCl (2.1 mL) was added in a 
dropwise manner releasing a gas. Then, a 6 N solution of NaOH (8.4 mL) was added to 
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basify the mixture. Upon standing, a white precipitate formed and was removed by 
filtration. The solvent was removed under reduced pressure and the residue was dissolved 
in hot H2O (20 mL), and extracted with hot CHCl3 (20 mL x 3). The solid at the interface 
was collected and dried under reduced pressure for 4 h to give 0.15 g (28%) of a white 
solid (56, free base): mp 178-180 °C, 1H NMR (DMSO-d6) δ: 3.45 (br.s., 1H, NH, D2O 
exchangeable), 4.30 (s, 2H, CH2), 6.11 (br.s., 1H, NH, D2O exchangeable), 6.60 (s, 1H, 
ArH), 6.73 (d, 1H, ArH), 6.89 (d, 1H, ArH). 
 A solution of 56 (free base) (0.13 g, 0.72 mmol) in EtOH was cooled in an 
ice/water bath. Gaseous N2 was bubbled through the solution for 5 min to remove any 
moisture followed by bubbling of gaseous HCl for 15 min. The solvent was removed 
under reduced pressure to give a white solid. The solid was recrystallized from absolute 
EtOH to afford 0.08 g (53%) of a white crystalline solid 56: mp 249-251 °C; IR (KBr, 
cm-1): 3300, 3190, 2979, 2927, 2855, 1700, 1618, 1493, 1091; 1H NMR (DMSO-d6) δ: 
4.45 (s, 2H, CH2), 7.07 (d, 1H, ArH), 7.17 (dd, 1H, ArH), 7.25 (d, 1H, ArH), 7.77 (s, 2H, 
NH2, D2O exchangeable), 8.63 (s, 1H, NH, D2O exchangeable), 11.02 (s, 1H, NH+, D2O 
exchangeable). Anal. Calcd. for C8H8N3Cl · HCl · 0.25 H2O: C, 43.17; H, 4.30; N, 18.89 
Found: C, 43.41; H, 4.05; N, 18.50. 
 
 2-Amino-6-chloro-3,4-dihydroquinazoline hydrochloride (57). The 
quinazolinone 74 (0.52 g, 2.65 mmol) was added to 1M BH3-THF (11 mL) and heated at 
reflux under N2 gas for 2.5 h.  The borate complex was then hydrolyzed by the dropwise 
addition of 6 N HCl (2 mL), then basified with 6 N NaOH (8 mL).  The mixture was 
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concentrated, dissolved in boiling H2O, and extracted with hot CHCl3 (3 x 10 mL).  
Solvent was removed under reduced pressure and the resultant solid was rinsed with Et2O 
to yield 0.26 g (54%) of white solid 57 (free base): mp 225-230 ºC; IR (KBr, cm-1) 3422, 
3102; (DMSO-d6) δ: 4.28 (s, 2H, CH2Ar), 5.63 (br.s, 2H, NH, D2O exchangeable), 6.23 
(br.s, 1H, NH, D2O exchangeable), 6.55-6.58 (d, 1H, ArH), 6.91 (s, 1H, ArH), 6.96-6.99 
(d, 1H, ArH).   
 A solution of HCl/Et2O (20 mL) was added in a dropwise manner to a stirred 
solution of 57 (free base) in hot EtOH (~10 mL).  The reaction mixture was allowed to 
stir at room temperature for 10 min.  The solvent was evaporated under reduced pressure.  
The resultant crude product was recrystallized from hot absolute EtOH to yield 0.06 g 
(19%) of off-white crystals 57: mp 237-238 ºC; 1HNMR (DMSO-d6) δ: 4.49 (s, 2H, 
CH2Ar), 6.99-7.02 (d, 1H, ArH), 7.30-7.38 (d, 2H, ArH), 7.80 (br.s, 2H, NH, D2O 
exchangeable), 8.69 (s, 1H, NH, D2O exchangeable), 11.16 (s, 1H, NH+, D2O 
exchangeable). Anal. Calcd. for C8H8N3Cl·1.25HCl·0.25H2O: C, 41.47; H, 4.24; N, 18.13 
Found: C, 41.89; H, 3.96; N, 18.05. 
 
Methyl [[(3-chlorophenyl)amino](imino)methyl]carbamate (62). Method A.  A 
solution of calcium cyanamide (0.64 g, 8.04 mmol) and H2O (4 mL) was added in a 
dropwise manner to methyl chloroformate (61) (0.56 mL, 7.32 mmol) and the reaction 
mixture was allowed to stir at 45 ºC for 20 min.  The solid was removed by filtration and 
then 3-chloroaniline hydrochloride (60) (0.60 g, 3.66 mmol) was added. The reaction 
mixture was made slightly more basic (pH 4) by the addition of 40% NaOH and heated at 
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reflux for 4.5 h.  The solution was filtered and solvent evaporated under reduced 
pressure.  The crude product was recrystallized from MeOH to yield 0.07 g (9%) of a 
white crystalline solid 62: mp 132-134 ºC (lit.145 138-140 ºC); tlc similar to that of 
previously synthesized sample12 Rf = 0.83 (9:1 CH2Cl2:MeOH); IR (KBr, cm-1) 3443, 
3350, 1741, 1669; 1H NMR (DMSO-d6) δ: 3.6 (s, 3H, OCH3), 7.11-7.15 (d, 1H, ArH), 
7.24-7.36 (m, 2H, ArH),7.48 (3H, NH, D2O exchangeable) 7.69 (s, 1H, ArH).    
 
Method B.  A solution of phenyl chloroformate (63) (0.34 mL, 2.70 mmol) in dry THF 
(10 mL) was added in a dropwise manner to a mixture of m-chlorophenylguanidine (42, 
free base) (0.46 g, 2.70 mmol) and Et3N (0.75 mL, 5.41 mmol) in dry THF (15 mL) in an 
ice bath under a N2 atmosphere.  The reaction mixture was allowed to stir for 15 min at 
room temperature, then filtered.  The solvent was evaporated under reduced pressure to 
yield a yellow oil.  Flash chromatography (3:2 hexane:EtOAc) was conducted to separate 
the products.  The isolated crude product was recrystallized from acetone to yield 0.02 g 
(3%) of a white solid: mp 129-132 ºC  (lit.135 128-129 ºC); 1H NMR (DMSO-d6) δ: 3.55 
(s, 3H, OCH3), 7.05-7.09 (d, 1H, ArH), 7.26-7.31 (m, 2H, ArH), 7.59 (s, 2H, NH, D2O 
exchangeable) 7.78 (s, 1H, ArH), 9.19 (s, 1H, NH, D2O exchangeable).  Anal. Calcd. for 
C9H10N3O2Cl · 0.25 acetone: C, 48.35;  H, 4.79; N, 17.35 Found: C, 48.63; H, 4.61; N, 
17.94.    
 
Method C.  A solution of phenyl chloroformate (63) (0.45 mL, 3.55 mmol) in dry THF 
(13 mL) was added in a dropwise manner to a mixture of m-chlorophenylguanidine (42, 
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free base) (0.60 g, 3.55 mmol) and Et3N (9.90 mL, 7.10 mmol) in dry THF (20 mL) in an 
ice bath under a N2 atmosphere.  The reaction mixture was allowed to stir overnight (17 
h) at room temperature then filtered.  The solvent was evaporated under reduced pressure 
to give a yellow oil.  A solid precipitated upon the addition of hot MeOH and was 
recrystallized from MeOH to yield 0.13 g (17%) of a white crystalline solid 62: mp 136-
138 ºC (lit.145 138-140 ºC); 1H NMR (DMSO-d6) δ: 3.48 (s, 3H, OCH3), 7.02-7.13 (d, 1H, 
ArH), 7.25-7.36 (m, 2H, ArH), 7.53 (s, 2H, NH, D2O exchangeable), 7.78 (s, 1H, ArH), 
9.15 (s, 1H, NH, D2O exchangeable). 
 
N,N’-bis(3-chlorophenyl)urea (64). Method A.  A solution of calcium cyanamide (0.54 
g, 7.74 mmol) and H2O (2 mL) was added in a dropwise manner to phenyl chloroformate 
(63) (0.77 mL, 6.02 mmol).  The reaction mixture was allowed to stir at 45 ºC for 20 min.  
The solid was removed by filtration and 3-chloroaniline hydrochloride (60) (0.50 g, 3.05 
mmol) was added to the solution.  The mixture was made slightly more basic (pH 4) by 
the addition of 40% NaOH and heated at reflux overnight.  The solution was filtered and 
solvent evaporated under reduced pressure.  The crude product was recrystallized from 
MeOH to yield 0.07 g (8%) of white crystalline solid 64:  mp 246-248 ºC (lit.146 245 ºC); 
1H NMR (DMSO-d6) δ: 7.04-7.07 (dd, 2H, ArH), 7.30-7.33 (m, 4H, ArH), 7.73 (s, 2H, 
ArH), 8.99 (s, 2H, NH, D2O exchangeable). 
 
Method B.  A solution of calcium cyanamide (0.64 g, 8.04 mmol) and H2O (2 mL) was 
added in a dropwise manner to 4-chlorophenyl chloroformate (65) (1.02 mL, 7.32 mmol).  
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The reaction mixture was allowed to stir at 45 ºC for 30 min.  The solid was removed by 
filtration and 3-chloroaniline hydrochloride (60) (0.60 g, 3.66 mmol) was added to the 
solution.  The mixture was made slightly more basic (pH 4) by the addition of 40% 
NaOH and was heated at reflux overnight.  The solution was filtered and solvent 
evaporated under reduced pressure.  The crude product was recrystallized from MeOH to 
yield 0.03 g (3%) of white crystalline solid 64:  mp 241-243 ºC (lit.146 245 ºC); 1H NMR 
(DMSO-d6) δ: 7.04-7.07 (dd, 2H, ArH), 7.30-7.33 (m, 4H, ArH), 7.73 (s, 2H, ArH), 8.99 
(s, 2H, NH, D2O exchangeable). 
 
Method C.  A solution of calcium cyanamide (0.54 g, 6.70 mmol) and H2O (2 mL) was 
added in a dropwise manner to 4-methoxyphenyl chloroforomate (66) (0.91 mL, 6.10 
mmol).  The reaction mixture was allowed to stir at 45 ºC for 30 min.  The solid was 
removed by filtration and 3-chloroaniline hydrochloride (60) (0.50 g, 3.05 mmol) was 
added to the solution.  The mixture was made slightly more basic (pH 4) by the addition 
of 40% NaOH and heated at reflux overnight.  The solution was filtered and solvent 
evaporated under reduced pressure.  The crude product was recrystallized from MeOH to 
yield 0.05 g (6%) of a white crystalline solid 64:  mp 239-240 ºC (lit.146 245 ºC); 1H NMR 
(DMSO-d6) δ: 7.04-7.07 (dd, 2H, ArH), 7.30-7.33 (m, 4H, ArH), 7.72 (s, 2H, ArH), 8.98 
(s, 2H, NH, D2O exchangeable). 
 
Method D.  A solution of phenyl chloroformate (63) (0.43 mL, 3.41 mmol) and CH2Cl2 
(1 mL) was added in a dropwise manner to a solution of 1H-pyrazole-1-carboxamide 
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hydrochloride (69) (0.50 g, 3.41 mmol), DIEA (1 mL), and CH2Cl2 (3 mL).  The reaction 
mixture was allowed to stir at room temperature for 2 h, then extracted using NaHCO3 
and brine; the extract was dried for 1 h with Na2SO4.  The solvent was evaporated under 
reduced pressure to yield 0.53 g (68%) of a white solid, 70: mp 101-105 ºC.  1H NMR 
(DMSO-d6) δ: 6.63 (s, 1H, ArH), 7.19-7.28 (m, 4H, ArH), 7.41-7.46 (t, 1H, ArH), 7.97 
(s, 1H, ArH), 8.46-8.47 (d, 1H, ArH), 8.90 (s, 1H, NH, D2O exchangeable), 9.25 (s, 1H, 
NH, D2O exchangeable).  Anal. Calcd for C11H10N4O2: C, 57.39; H, 4.38; N, 24.34 
Found: C, 55.56; H, 4.22; N, 23.46.  
 The pyrazole ester (70) (0.35 g, 1.52 mmol) was added to a mixture of m-
chloroaniline hydrochloride (60) (0.75 g, 4.56 mmol) and DIEA (0.9 mL).  The reaction 
mixture was heated at reflux overnight.  The solvent was evaporated under reduced 
pressure to yield a brown oil.  The product was isolated using column chromatography 
(3:2 hexane:EtOAc) and recrystallized from acetone to yield 0.10 g (23 %) of a white 
solid, 64: mp 244-246 ºC (lit.146 245 ºC); 1H NMR (DMSO-d6) δ: 7.04-7.06 (d, 2H, ArH), 
7.27-7.35 (t, 4H, ArH), 7.71 (s, 2H, ArH), 9.01 (s, 2H, NH, D2O exchangeable).  Anal. 
Calcd for C13H10N2OCl2:  C, 55.54; H, 3.59; N, 9.96 Found: C, 55.51; H, 3.47; N, 9.82. 
 
N,N,N’,N’-Tetrakis(phenylcarbamate)-3-chlorphenylguanidine hydrochloride (68).  
A solution of calcium cyanamide (1.07 g, 13.4 mmol) and acetone (15 mL) was added in 
a dropwise manner to phenyl chloroformate (63) (1.53 mL, 12.2 mmol) and allowed to 
stir at room temperature under an N2 atmosphere for 20 min.  The solid was removed by 
filtration and 3-chloroaniline hydrochloride (60) (1.00 g, 6.10 mmol) was added to the 
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solution; stirring was allowed to continue for another 5 h. The solution was filtered and 
solvent evaporated under reduced pressure.  The crude product was recrystallized from 
acetone to yield 0.19 g (5%) of a white solid 68: mp 84-87 ºC; IR (KBr, cm-1) 3257, 
1710, 1586; 1H NMR (DMSO-d6) δ: 7.11-7.14 (d, 2H, ArH), 7.24-7.48 (m, 20H, ArH), 
7.64 (s, 2H, ArH), 10.50 (s, 1H, NH+). Anal. Cald. For C35H24N3O8Cl · HCl: C, 59.83; H, 
3.80; N, 6.34 Found: C, 61.25; H, 4.02; N, 6.0. 
 
2-Amino-6-chloro-4-dihydroquinazolinone (74).  S-Methylisothiouronium sulfate (72) 
(2.04 g, 7.31 mmol) and Na2CO3 (1.19 g, 11.24 mmol) were added to dry 1,4-dioxane (34 
mL). The suspension was heated until all of the isothiourea was dissolved. 5-
Chloroisatoic anhydride (73) (2.00 g, 10.12 mmol) was added, and the reaction mixture 
was heated at reflux for 21.5 h. The reaction mixture was allowed to cool to room 
temperature and poured into 15 mL of H2O.  The mixture was allowed to stir for 20 min 
at room temperature.  The solid paste 74 was collected by suction filtration and dried 
under vacuum at 60 ºC for 24 h to yield 1.02 g (71%) of yellow solid 74: mp>300 ºC; tlc 
similar to that of previously synthesized product13 Rf = 0.26 (H2O); IR (KBr, cm-1) 3412, 
3174, 3081, 1679; 1H NMR (DMSO-d6) δ: 6.56 (br.s, 2H, NH, D2O exchangeable), 7.20-
7.23 (d, 1H, ArH), 7.56-7.60 (d, 1H, ArH), 7.80 (s, 1H, ArH), 11.22 (br.s, 1H, NH, D2O 
exchangeable). The product was used in the synthesis of 57. 
 
m-Fluorophenylguanidine nitrate (101).156  A mixture of m-fluoroaniline hydrochloride 
(1.00 g, 6.78 mmol) and cyanamide (0.38 g, 9.04 mmol) was heated at reflux in absolute 
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EtOH (5 mL) for 6 h. The solvent was removed under reduced pressure to give a pale 
yellow oil which was dissolved in H2O (2 mL), and NH4NO3 (1.00 g, 12.5 mmol) was 
added in excess. The solvent was removed under reduced pressure and the residue was 
recrystallized (H2O x 4). The light brown crystals were collected by filtration and washed 
with cold Et2O (3 x 5mL) to give 0.81 g (55 %) of a solid product, 101: mp 145-146 °C 
(H2O), 146-147 °C (EtOH) (lit.157 165 °C EtOH); IR (KBr, cm-1): 3342, 3330, 3195, 
1669, 1597, 1493, 1369, 1143; 1H NMR (DMSO-d6) δ: 7.21-7.04 (m, 3H, ArH), 7.53-
7.45 (m, 5H, ArH, NH2, ex with D2O), 9.72 (s, 1H, NH, D2O exchangeable). Anal. calcd 
for C7H8FN3 · HNO3: C, 38.89; H, 4.20; N, 25.92 Found: C, 39.08; H, 4.15; N, 25.89. 
 
m-Iodophenylguanidine nitrate (102).158  m-Iodoaniline hydrochloride (4.4 g, 17.22 
mmol) and cyanamide (2.1g, 50.0 mmol) were added to absolute EtOH (20 mL). The 
reaction mixture was heated at reflux for 24 h and cooled to room temperature. Distilled 
water (5.0 mL) was added to the solution followed by addition of NH4NO3 (10.0 mL). A 
white precipitate was promptly formed and recrystallized from distilled H2O. The product 
was further purified by flash chromatography (9:1 CH2Cl2:MeOH) to afford white 
crystals 0.40 g (7%) 102: mp 166–168 ºC; ¹H NMR (DMSO-d6) δ: 7.25 (t, J = 8.40 Hz, 
1H, ArH), 7.27-7.30 (m, 1H, ArH), 7.49 (br s, 5H, NH2, D2O exchangeable), 7.62-7.63 
(m, 1H, ArH), 7.65-7.69 (m, 1H, ArH). Anal. Calcd for C7H8N3I · HNO3: C, 25.94; H, 
2.80; N, 17.29 Found: C, 25.73; H, 2.72; N, 16.98. 
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m-Bromophenylguanidine nitrate (103).158  3-Bromoaniline hydrochloride (4.0 g, 19.2 
mmol) and cyanamide (2.1g, 50.0 mmol) were added to absolute EtOH (20 mL). The 
reaction mixture was heated at reflux for 24 h and cooled to room temperature. Distilled 
water (5.0 mL) was added to the solution followed by addition of NH4NO3 (10.0 mL). A 
white precipitate was promptly formed and recrystallized from distilled H2O. The product 
was further purified by flash chromatography (9:1 CH2Cl2:MeOH ) to afford white 
crystals 0.72 g (14%) 103: mp 160–162 ºC; ¹H NMR (DMSO-d6) δ: 7.26 (ddd, J = 7.80 
Hz, 1H, ArH), 7.41 (t, J = 7.80 Hz, 1H, ArH), 7.47-7.52 (m, 7H, ArH and NH2, D2O 
exchangeable). Anal. Calcd for C7H8N3Br · HNO3: C, 30.34; H, 3.27; N, 20.22 Found: C, 
30.14; H, 3.16; N, 19.95. 
 
2-Amino-7-chloro-4-dihydroquinazolinone (105).156  4-Chloroisatoic anhydride (1.00 
g, 5.06 mmol) was dissolved in acetonitrile (24 mL, 80%), then S-methylthioisourea 
sulfate (72) (1.4 g, 5.06 mmol) and Na2CO3 (0.58 g, 5.47 mmol) were added to the 
solution. The resulting solution was heated at reflux for 5 h. The reaction mixture was 
allowed to cool to room temperature over 0.5 h. The suspension was filtered and washed 
with acetonitrile (80%, 25 mL x 3). The solvent was evaporated under reduced pressure 
then dissolved in CH2Cl2 (10 mL) and extracted with H2O (10 mL x 3).  The layers were 
separated and the organic layer was dried over MgSO4, filtered, and the solvent removed 
under reduced pressure. The residue was purified by column chromatography (9:1:0.1, 
CH2Cl2:MeOH:NH4OH). The reaction gave 0.64 g (65%) of a pale pink solid 105: mp 
>300 °C (lit.159 >300 °C); IR (KBr, cm-1): 3401, 3133, 1597, 1442, 1101; 1H NMR 
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(DMSO-d6) δ: 6.58 (br.s., 2H, NH2, D2O exchangeable), 7.11 (dd, 1H, ArH), 7.21 (d, 1H, 
ArH), 7.87 (d, 1H, ArH), 11.10 (br.s., 1H, NH, D2O exchangeable).  The product was 
used in the synthesis of 56. 
 
B.  Behavioral Studies 
 1.  Animals 
 Male ICR mice (19-29 g) were used throughout the study (Harlan Laboratories; 
Indianapolis, IN).  Mice were housed in groups of 5-6, with free access to food and water 
in a temperature-controlled environment under a standard 12:12 h dark/light cycle in an 
Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-
approved facility.  The experiments were conducted in accordance to standards set by the 
Institutional Animal Care and Use Committee (IACUC) of Virginia Commonwealth 
University. Mice were allowed to adapt to the testing environment at least 1 h prior to 
any treatment, and weighed the same day as the experiments. 
 
 2. Drugs 
 (+)Amphetamine sulfate and cocaine hydrochloride (Lot 11K1085J) were 
purchased from Sigma-Aldrich Chemical Company (Milwaukee, WI).  (±)1-(2,5-
Dimethoxy-4-methylphenyl)-2-aminopropane (DOM) hydrochloride was obtained from 
the National Institute on Drug Abuse (NIDA; Rockville, MD).  (+)Methamphetamine 
hydrochloride was a gift from Dr. R. A. Glennon (Virginia Commonwealth University).  
SR 57227A (4-amino-(6-chloro-2-pyridyl)-1piperidine) hydrochloride was purchased 
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from Tocris (Batch 1A/45893; Ballwin, MO).  Ondansetron hydrochloride (Zofran®, Lot 
CO99723; GlaxoSmithKline) was purchased from MCVH-Pharmacy. Solutions were 
prepared fresh daily; all drugs were dissolved in 0.9% saline and administered to mice in 
a total volume of 10 ml/kg body weight by intraperitoneal (i.p.) injections. 
  
3. Locomotor Activity Assays 
 Mice, naïve to the test apparatus, were placed in individual Tru-Scan Activity 
System (Coulbourn Instruments, Allentown, PA) photocell activity cages (40 cm3).  Tests 
were conducted between 0800 h and 1730 h. The mice were treated with either saline (0-
min pre-injection time), MD-354 (1.0, 3.0, 6.0, or 10 mg/kg; 0-min pre-injection time or 
30-min pre-injection time), ondansetron (0.1, 0.5, or 1.0 mg/kg; 30-min pre-injection 
time), SR 57227A (1.0, 3.0, or 10 mg/kg; 30-min pre-injection time), alone or in 
combination with (+)amphetamine (2.0 or 3.0 mg/kg; 0-min pre-injection time), 
(+)methamphetamine (1.5 or 3.0; 0-min-preinjection time), cocaine (10 mg/kg; 0-min 
pre-injection time) and DOM (0.3 mg/kg; 0-min pre-injection time).  Other mice were 
treated with (+)amphetamine (0.3, 1.0, 3.0, or 6.0 mg/kg; 0-min pre-injection time), 
(+)methamphetamine (0.3, 1.0, 1.5, 3.0, or 10 mg/kg; 0-min pre-injection time), cocaine 
(1.0, 3.0, 10, or 30 mg/kg; 0-min pre-injection time) or DOM (0.3, 1.0, or 3.0 mg/kg; 0-
min pre-injection time).  The mice were only tested once and each dose of test agent (or 
combination of drugs) was studied in 6-8 mice (n = 6-8 mice/treatment). The behavioral 
analysis examined nine measures of activity: movement episodes, movement time (s), 
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movement distance (cm), vertical entries, margin distance (cm), margin time (s), center 
distance (cm), center time (s), and center entries.  
 
4. Statistical Analysis 
 Data for each measure of activity were analyzed statistically by a one-way 
analysis of variance (ANOVA) followed by a Newman-Keuls post-hoc comparison test.  
t-Tests were also employed in some analysis instead of a one-way ANOVA, when data 
suggested a statistical significance which was not supported by a one-way ANOVA or 
post-hoc comparison. 
   
C.  Molecular Modeling 
 The computational studies were performed on a Silicon Graphics workstation 
using SYBYL (SYBYL Molecular Modeling Package, Version 7.3, 2007; Tripos Inc., St. 
Louis, MO) software.  Compound 42 was built using an arginine fragment in the 
program.  Compound 30 was built from its crystal structure downloaded from the 
Cambridge Database. All of the compounds we constructed using standard bond lengths 
and angles within the Build/Sketch command followed by minimization (MINIMIZE) 
and calculation of charges by the Gasteiger-Hückel algorithm.  The compounds were 
individually superimposed using FIT ATOM on templates 42 and 31 to perform a least 
squares fit.  The linearly independent points (aryl 3-position, aryl 5-position, and the 
carbon atom in the guanidine moiety) were used in FIT ATOM. CoMFA and CoMSIA 
studies were conducted. 
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